Study of Mutagenic Effects of **Sodium Nitrate** (71-7) 7/72

F23

STUDY OF MUTAGENIC EFFECTS OF SODIUM NITRATE
(71-7)

F23

July 1972

Compound Report No. 11

STUDY OF MUTAGENIC EFFECTS OF SODIUM NITRATE (71-7)

Prepared for:

DHEW/PUBLIC HEALTH SERVICE
Food and Drug Administration
Rockville, Maryland

Contract No. FDA 71-267

SRI Project LSU-1348

Submitted by:

G. W. Newell and W. A. Maxwell

Approved:

W. A. Skinner

W. A. Skinner, Executive Director
Life Sciences Division

INTRODUCTION

Under contract to the Food and Drug Administration, Stanford Research Institute is examining the mutagenicity of 14 selected chemical compounds (Contract No. FDA 71-267). This report describes the results of tests conducted on Sodium Nitrate (71-7).

Three methods are used to evaluate the genetic hazards of the test compounds. These are: (1) Host-Mediated Assay, (2) Cytogenetic Assay, and (3) Dominant Lethal Gene test. Methodologies used to conduct these tests are described in detail in "Compound Report No. 1," January 1972. The same procedures were followed in obtaining the information presented in this report.

For the compound under consideration here single and repeated intubations were performed at three concentrations. These amounts were (1) a maximum tolerated dose or 5 g/kg, whichever was lower, (2) a low dose of 30 mg/kg or one near the use level, and (3) a level intermediate between the use level and the maximum tolerated dose.

SUMMARY

Host-Mediated Assay

Sodium nitrate (71-7) did not produce any measureable mutagenic response for *Salmonella typhimurium* or alteration in the recombination frequency for *Saccharomyces cerevisiae* in either the host-mediated assay or the associated *in vitro* tests.

Cytogenetic Assay

Sodium nitrate (Compound 71-7) exhibits no adverse effect on metaphase chromosomes from rat bone marrow cells at any of the time periods or dose levels tested.

It exerts a definite adverse effect on human embryonic lung cells (WI-38) grown in tissue culture, primarily due to increased numbers of acentric fragments.

Dominant Lethal Gene Test

No consistent responses occurred to suggest that sodium nitrate (71-7) is mutagenic to the rat by this experimental procedure. The positive reference compound, TEM, a known mutagen, generally produced mutagenic responses from the first through the fifth weeks of the experiment, as expected. Mathematical treatment of the Dominant Lethal Gene data, according to the statistical program outlined by FDA, failed to show consistent significant differences (which could be attributed to an effect of sodium nitrate) at $P<0.01$, $P<0.05$, $P<0.10$, and $P<0.20$.

As was observed with sodium nitrite (SRI Project 1348, Report No. 12), sodium nitrate was more toxic to heavier, 400 to 500 grams, (and/or older) rats than to lesser weight rats (100 to 150 grams). The LD_{50} for the 400 to 500 gram rat was 4.0 g/kg, for rats weighing 100 to 150 grams the LD_{50} was 6.1 g/kg.

RESULTS AND DISCUSSION

Oral Toxicity

Initially, single and multiple dose LD_{50} data were obtained with male Sprague Dawley derived rats weighing 210 to 225 grams, each. The resultant LD_{50} value for both single and multiple treated rats was 5.2 g/kg. After an evaluation of the data, dosage levels of 3.25 g/kg, 2.0 g/kg, and 30 mg/kg were selected and administered to the rats, weighing 400 to 500 grams each. Within several days 60% of 3.25 g/kg treated rats were dead. The study was abandoned and additional LD_{50} studies initiated.

Subsequently, single dose LD_{50} data were obtained on groups of male Sprague Dawley derived rats, weighing 110 to 140 grams and 410 to 510 grams, each, using a constant concentration (50%) dosing regimen, as employed in the initial study. Data also were obtained using a constant volume (10 ml/kg) regimen with rats weighing 115 to 150 grams each and 435 to 480 grams each.

Evaluation of these additional LD_{50} experiments, showed that sodium nitrate toxicity increased with increasing weight of the rats. As a result of this new information, dosage of 1.6 g/kg, 0.8 g/kg, and 30 mg/kg were established for both single and multiple treated groups. Toxicity data for sodium nitrate is summarized in Table 1. The vehicle for this experiment was water.

Host-Mediated Assay

Table 2 presents a summary of the host-mediated assay results for Sodium nitrate (71-7). Table 3 contains the data obtained on each individual mouse. This table is a computer printout of the calculations made on the data obtained for each mouse. Because of the nature of the computer, it is necessary to exceed its maximum number of significant figures to obtain a value as an exponent. For this reason, 12 significant figures are printed out. However, only three significant figures are used for calculations and reporting the results as summarized in Table 2. Table 4 summarizes the data obtained in the *in vitro* tests.

As can be seen from the results summarized in Table 2, no mutagenic response was observed for the two *Salmonella typhimurium* strains tested when mice were treated with the test compound. There was a slightly higher mutation frequency for the test compound groups in the subacute test with TA-1530 than in the negative control group. It should be pointed out, however, that the negative control group has a lower mutation frequency than is normally observed, whereas the treatment groups have a mutation frequency in the range usually observed for the negative

controls (e.g., 5×10^{-8} to 1×10^{-9}). The mitotic recombination frequency of Saccharomyces cerevisiae was not affected. Similarly, no positive mutagenic response was detected in the in vitro tests.

Cytogenetic Assay

Review of Table 5 indicates that no adverse effect on rat bone marrow chromosomes at any tested dose level or time period may be attributed to Compound 71-7 (sodium nitrate). The very low value for the positive control may be attributed to the fact that the dose was reduced from 0.5 mg/kg administered in previous tests to 0.4 mg/kg in an effort to increase the number of cells available for scoring. Furthermore, TEM treatment, for 6 hours only, results in highly variable percentages of aberrant cells.

Table 6, however, indicates that sodium nitrate causes almost a two-fold increase in the number of aberrant anaphases seen in in vitro tests of WI-38 cells. This is primarily due to an increase in the number of acentric fragments observed, indicating an increased percentage of single breaks in the chromosomes. An increase in the number of cells scored as "other" also contributes to the higher percentage of aberrant cells observed. Cells were scored as other when the two sets of chromosomes were broken up into numerous small clusters with no particular polar orientation. Compound 71-7 thus appears to have a definite adverse effect on anaphase cells obtained from WI-38 cells in culture.

Dominant Lethal Gene Test

Throughout this experiment the biological criteria used to evaluate mutagenic effects in the rat showed no consistent responses which could be attributed to treatment. There were occasional statistical differences between control and sodium nitrate-dosed groups, but these were random occurrences without any suggestion of a time or dose-response effect.

Table 7 presents summary data of the implantations per pregnant female, Table 8 summarizes dead implants per pregnant female, Table 9 summarizes dead implants per total implants, Table 10 summarizes corpora lutea per pregnant female, and Table 11 summarizes pre-implantation loss per pregnant female.

Appendix A contains the statistical analysis procedures for dominant lethal gene tests with a description and explanation of the computer printouts.

Appendix B contains the computer printouts for the raw data and statistical analyses.

Careful review and statistical evaluation of the data do not show sodium nitrate to be a mutagen in the rat by the dominant lethal gene test.

W. A. Maxwell

W. A. Maxwell, Ph.D., Manager
Microbiology Program

G. W. Newell

G. W. Newell, Ph.D., Director
Department of Toxicology

ORAL TOXICITY - RAT

Table 1

Compound: Sodium Nitrate
FDA No: 71-7

Dosage Preparation	Weight Range (grams)	LD_{50} (g/kg)	95% Confidence Limits (g/kg)
Constant Concentration (50%)	110-140	6.1	5.2 to 7.1
Constant Volume (10 ml/kg)	115-150	5.1	4.3 to 6.0
Constant Concentration (50%)	210-225	5.2	4.0 to 6.7
Constant Volume (10 ml/kg)	435-480	4.0	3.4 to 4.7
Constant Concentration (50%)	410-510	4.0	3.1 to 5.2

Table 2

HOST MEDIATED ASSAY
SUMMARY OF DATA

Compound No.: 71-7 (Sodium nitrate)

A. Acute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum	1.57×10^{-8}	0.59	7.64×10^{-8}	1.58	1.27×10^{-4}	1.84
Intermediate	5.71×10^{-8}	2.14	7.47×10^{-8}	1.54	1.09×10^{-4}	1.58
Low Level	1.65×10^{-8}	0.62	9.93×10^{-8}	2.05	9.71×10^{-5}	1.41
Control (+)	2.31×10^{-6}	86.52	1.11×10^{-6}	22.89	9.94×10^{-4}	14.38
Control (-)	2.67×10^{-8}	1.00	4.85×10^{-8}	1.00	6.91×10^{-5}	1.00

B. Subacute

Treatment	Organism					
	Salmonella				Saccharomyces	
	G46		TA 1530		D-3	
	MF	MFt/MFc	MF	MFt/MFc	RF	RFt/RFc
Maximum	7.13×10^{-8}	1.21	4.09×10^{-8}	8.18	8.72×10^{-5}	0.62
Intermediate	5.57×10^{-9}	0.09	6.49×10^{-8}	12.98	1.06×10^{-4}	0.75
Low Level	3.24×10^{-9}	0.06	2.28×10^{-8}	4.56	1.43×10^{-4}	1.01
Control (-)	5.90×10^{-8}	1.00	5.00×10^{-9}	1.00	1.41×10^{-4}	1.00

Table 3

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: G-46

Treatment: (+) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.134000000000ex 04	.538333333330ex 09	.248916408670ex-05
2	.154500000000ex 04	.863333333330ex 09	.178957528958ex-05
3	.712500000000ex 03	.543333333330ex 09	.131134969325ex-05
4	.321666666666ex 03	.933333333330ex 08	.344642857143ex-05
5	.117250000000ex 04	.676666666665ex 09	.173275862069ex-05
6	.127500000000ex 04	.708333333330ex 09	.180000000000ex-05
7	.166000000000ex 04	.385000000000ex 09	.431168831168ex-05
8	.775000000000ex 03	.483333333333ex 09	.160344827586ex-05
			.231055160612ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: G-46

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.833333333330ex 01	.620000000000ex 09	.134408602150ex-07
2	.416666666666ex 01	.306666666666ex 09	.135869565217ex-07
3	.171428571428ex 02	.203333333333ex 09	.843091334893ex-07
4	.666666666665ex 01	.703333333330ex 09	.947867298580ex-08
5	.158333333333ex 02	.123666666666ex 10	.128032345013ex-07
			.267237715424ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.150000000000ex 02	.365000000000ex 09	.410958904109ex-07
2	.216666666666ex 02	.320000000000ex 09	.677083333331ex-07
3	.200000000000ex 02	.463333333333ex 09	.431654676259ex-07
4	.225000000000ex 02	.120666666666ex 10	.186464088398ex-07
5	.100000000000ex 02	.311666666666ex 09	.320855614973ex-07
6	.250000000000ex 02	.263333333333ex 09	.949367088608ex-07
7	.183333333333ex 02	.260000000000ex 09	.705128205126ex-07
8	.591666666665ex 02	.570000000000ex 09	.103801169590ex-06
			.589940450833ex-07

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: G-46

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.583333333330ex 01	.583333333330ex 09	.100000000000ex-07
2	.141666666666ex 02	.104833333333ex 10	.135135135134ex-07
3	.833333333330ex 01	.428333333333ex 09	.194552529182ex-07
4	.600000000000ex 01	.276666666666ex 09	.216867469880ex-07
5	.416666666666ex 01	.631666666665ex 09	.659630606860ex-08
6	.333333333333ex 01	.786666666665ex 09	.423728813559ex-08
7	.100000000000ex 01	.465000000000ex 09	.215053763440ex-08
8	.416666666666ex 01	.776666666665ex 09	.536480686695ex-08
9	.250000000000ex 01	.106000000000ex 10	.235849056603ex-08
10	.833333333330ex 00	.116666666666ex 08	.714285714286ex-07
			.156791514119ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.166666666666ex 01	.216666666666ex 09	.769230769230ex-08
2	.250000000000ex 01	.743333333330ex 09	.336322869956ex-08
3	.166666666666ex 01	.960000000000ex 09	.173611111110ex-08
4	.166666666666ex 01	.850000000000ex 09	.196078431371ex-08
5	.833333333330ex 00	.308333333333ex 09	.270270270269ex-08
6	.166666666666ex 01	.218333333333ex 10	.763358778624ex-09
7	.833333333330ex 01	.500000000000ex 09	.166666666666ex-07
8	.133333333333ex 02	.890000000000ex 09	.149812734082ex-07
			.623330417157ex-08

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: G-46

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.166666666666ex 01	.175000000000ex 09	.952380952377ex-08
2	.125000000000ex 02	.533333333330ex 08	.234375000001ex-06
3	.166666666666ex 02	.102666666666ex 10	.162337662338ex-07
4	.583333333330ex 01	.268333333333ex 09	.217391304346ex-07
5	.500000000000ex 01	.228333333333ex 09	.218978102190ex-07
6	.100000000000ex 02	.600000000000ex 08	.166666666666ex-06
7	.666666666665ex 01	.221666666666ex 09	.300751879699ex-07
8	.833333333330ex 01	.307000000000ex 10	.271444082517ex-08
9	.150000000000ex 02	.140000000000ex 10	.107142857142ex-07
			.571044552871ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.166666666666ex 01	.216666666666ex 09	.769230769230ex-08
2	.250000000000ex 01	.920000000000ex 09	.271739130434ex-08
3	.250000000000ex 01	.995000000000ex 09	.251256281407ex-08
4	.250000000000ex 01	.988333333330ex 09	.252951096122ex-08
5	.166666666666ex 01	.123333333333ex 09	.135135135134ex-07
6	.416666666666ex 01	.105500000000ex 10	.394944707740ex-08
7	.250000000000ex 01	.410000000000ex 09	.609756097560ex-08
			.557318490545ex-08

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: G-46

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.333333333333ex 01	.500000000000ex 08	.666666666666ex-07
2	.333333333333ex 01	.785000000000ex 09	.424628450105ex-08
3	.833333333330ex 01	.993333333330ex 09	.838926174496ex-08
4	.250000000000ex 01	.768333333330ex 09	.325379609545ex-08
5	.191666666666ex 02	.125833333333ex 10	.152317880794ex-07
6	.583333333330ex 01	.808333333330ex 09	.721649484534ex-08
7	.750000000000ex 01	.463333333333ex 09	.161870503597ex-07
8	.108333333333ex 02	.151666666666ex 10	.714285714286ex-08
9	.108333333333ex 02	.101666666666ex 10	.106557377049ex-07
10	.216666666666ex 02	.826666666665ex 09	.262096774193ex-07
			.165199614556ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.166666666666ex 01	.548333333330ex 09	.303951367781ex-08
2	.250000000000ex 01	.431666666666ex 09	.579150579151ex-08
3	.833333333330ex 00	.636666666665ex 09	.130890052355ex-08
4	.166666666666ex 01	.546666666665ex 09	.304878048780ex-08
5	.833333333330ex 00	.843333333330ex 09	.988142292490ex-09
6	.166666666666ex 01	.526666666665ex 09	.316455696202ex-08
7	.166666666666ex 01	.361666666666ex 09	.460829493086ex-08
8	.250000000000ex 01	.108500000000ex 10	.230414746543ex-08
9	.500000000000ex 01	.101500000000ex 10	.492610837438ex-08
			.324221672283ex-08

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: (+) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.223333333333ex 03	.395000000000ex 09	.565400843881ex-06
2	.260000000000ex 03	.421666666666ex 09	.616600790514ex-06
3	.932500000000ex 03	.548333333330ex 09	.170060790274ex-05
4	.865000000000ex 03	.126500000000ex 10	.683794466403ex-06
5	.137500000000ex 04	.713333333330ex 09	.192757009346ex-05
6	.124166666666ex 03	.663333333330ex 09	.187185929648ex-06
7	.530000000000ex 03	.386666666666ex 09	.137068965517ex-05
8	.302000000000ex 03	.300000000000ex 09	.100666666666ex-05
9	.780000000000ex 03	.698333333330ex 09	.111694510740ex-05
10	.222500000000ex 03	.118333333333ex 09	.188028169014ex-05
			.110557431460ex-05

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.833333333330ex 01	.593333333330ex 09	.140449438202ex-07
2	.291666666666ex 02	.333333333333ex 09	.874999999998ex-07
3	.258333333333ex 02	.436666666666ex 09	.591603053435ex-07
4	.416666666666ex 01	.516666666665ex 09	.806451612904ex-08
5	.225000000000ex 02	.668333333330ex 09	.336658354116ex-07
6	.258333333333ex 02	.525000000000ex 09	.492063492062ex-07
7	.191666666666ex 02	.386666666666ex 09	.495689655171ex-07
8	.608333333330ex 02	.700000000000ex 09	.869047619042ex-07
			.485144596662ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.833333333330ex 00	.375000000000ex 09	.222222222221ex-08
2	.833333333330ex 00	.333333333333ex 08	.249999999999ex-07
3	.166666666666ex 01	.119666666666ex 10	.139275766016ex-08
4	.416666666666ex 01	.208333333333ex 10	.200000000000ex-08
5	.250000000000ex 01	.153333333333ex 10	.163043478261ex-08
6	.416666666666ex 01	.139666666666ex 10	.298329355609ex-08
7	.100000000000ex 01	.465000000000ex 09	.215053763440ex-08
8	.250000000000ex 01	.950000000000ex 09	.263157894736ex-08
			.500135310031ex-08

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.833333333330ex 01	.593333333330ex 09	.140449438202ex-07
2	.291666666666ex 02	.333333333333ex 09	.874999999998ex-07
3	.258333333333ex 02	.436666666666ex 09	.591603053435ex-07
4	.416666666666ex 01	.516666666665ex 09	.806451612904ex-08
5	.225000000000ex 02	.668333333330ex 09	.336658354116ex-07
6	.258333333333ex 02	.525000000000ex 09	.492063492062ex-07
7	.191666666666ex 02	.386666666666ex 09	.495689655171ex-07
8	.608333333330ex 02	.700000000000ex 09	.869047619042ex-07
			.485144596662ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.833333333330ex 00	.375000000000ex 09	.222222222221ex-08
2	.833333333330ex 00	.333333333333ex 08	.249999999999ex-07
3	.166666666666ex 01	.119666666666ex 10	.139275766016ex-08
4	.416666666666ex 01	.208333333333ex 10	.200000000000ex-08
5	.250000000000ex 01	.153333333333ex 10	.163043478261ex-08
6	.416666666666ex 01	.139666666666ex 10	.298329355609ex-08
7	.100000000000ex 01	.465000000000ex 09	.215053763440ex-08
8	.250000000000ex 01	.950000000000ex 09	.263157894736ex-08
			.500135310031ex-08

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.633333333330ex 02	.751666666665ex 09	.842572062081ex-07
2	.120000000000ex 02	.285000000000ex 09	.421052631578ex-07
3	.250000000000ex 02	.480000000000ex 09	.520833333333ex-07
4	.408333333333ex 02	.416666666666ex 09	.980000000000ex-07
5	.616666666665ex 02	.761666666665ex 09	.809628008752ex-07
6	.416666666666ex 02	.523333333330ex 09	.796178343952ex-07
7	.558333333330ex 02	.526666666665ex 09	.106012658227ex-06
8	.366666666666ex 02	.668333333330ex 09	.548628428929ex-07
			.747377423858ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.416666666666ex 02	.946666666665ex 09	.440140845070ex-07
2	.733333333330ex 02	.107333333333ex 10	.683229813663ex-07
3	.458333333333ex 02	.100000000000ex 10	.458333333333ex-07
4	.583333333330ex 01	.800000000000ex 08	.729166666662ex-07
5	.275000000000ex 02	.886666666665ex 09	.310150375940ex-07
6	.183333333333ex 02	.175000000000ex 09	.104761904761ex-06
7	.191666666666ex 02	.796666666665ex 09	.240585774058ex-07
8	.916666666665ex 01	.716666666665ex 08	.127906976744ex-06
			.648536952970ex-07

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.633333333330ex 02	.751666666665ex 09	.842572062081ex-07
2	.120000000000ex 02	.285000000000ex 09	.421052631578ex-07
3	.250000000000ex 02	.480000000000ex 09	.520833333333ex-07
4	.408333333333ex 02	.416666666666ex 09	.980000000000ex-07
5	.616666666665ex 02	.761666666665ex 09	.809628008752ex-07
6	.416666666666ex 02	.523333333330ex 09	.796178343952ex-07
7	.558333333330ex 02	.526666666665ex 09	.106012658227ex-06
8	.366666666666ex 02	.668333333330ex 09	.548628428929ex-07
			.747377423858ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.416666666666ex 02	.946666666665ex 09	.440140845070ex-07
2	.733333333330ex 02	.107333333333ex 10	.683229813663ex-07
3	.458333333333ex 02	.100000000000ex 10	.458333333333ex-07
4	.583333333330ex 01	.800000000000ex 08	.729166666662ex-07
5	.275000000000ex 02	.886666666665ex 09	.310150375940ex-07
6	.183333333333ex 02	.175000000000ex 09	.104761904761ex-06
7	.191666666666ex 02	.796666666665ex 09	.240585774058ex-07
8	.916666666665ex 01	.716666666665ex 08	.127906976744ex-06
			.648536952970ex-07

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: TA-1530

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.450000000000ex 02	.110666666666ex 10	.406626506026ex-07
2	.810000000000ex 02	.785000000000ex 09	.103184713375ex-06
3	.191666666666ex 02	.263333333333ex 09	.727848101264ex-07
4	.533333333330ex 02	.268333333333ex 09	.198757763974ex-06
5	.516666666665ex 02	.245000000000ex 09	.210884353740ex-06
6	.291666666666ex 02	.640000000000ex 09	.455729166665ex-07
7	.525000000000ex 02	.748333333330ex 09	.701559020047ex-07
8	.366666666666ex 02	.700000000000ex 09	.523809523808ex-07
			.992980078583ex-07

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.133333333333ex 02	.695000000000ex 09	.191846522781ex-07
2	.125000000000ex 02	.553333333330ex 09	.225903614459ex-07
3	.916666666665ex 01	.743333333330ex 09	.123318385650ex-07
4	.416666666666ex 01	.165000000000ex 09	.252525252524ex-07
5	.583333333330ex 01	.320000000000ex 09	.182291666665ex-07
6	.258333333333ex 02	.620000000000ex 09	.416666666666ex-07
7	.158333333333ex 02	.780000000000ex 09	.202991452991ex-07
			.227934794532ex-07

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: D-3

Treatment: (+) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.305555555555ex 05	.716666666665ex 07	.426356589147ex-02
2	.215000000000ex 05	.465000000000ex 08	.462365591397ex-03
3	.800000000000ex 04	.211666666666ex 08	.377952755906ex-03
4	.125000000000ex 05	.107666666666ex 09	.116099071208ex-03
5	.427777777777ex 05	.352500000000ex 08	.121355397950ex-02
6	.275000000000ex 05	.410000000000ex 08	.670731707317ex-03
7	.206250000000ex 05	.608333333330ex 08	.339041095892ex-03
8	.170000000000ex 05	.335000000000ex 08	.507462686567ex-03
			.993846597402ex-03

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: D-3

Treatment: (-) CONTROL

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.300000000000ex 04	.303333333333ex 08	.989010989012ex-04
2	.200000000000ex 04	.138333333333ex 08	.144578313253ex-03
3	.150000000000ex 04	.288333333333ex 08	.520231213873ex-04
4	.350000000000ex 04	.366666666666ex 08	.954545454547ex-04
5	.100000000000ex 04	.366666666666ex 08	.272727272727ex-04
6	.150000000000ex 04	.350000000000ex 08	.428571428571ex-04
7	.100000000000ex 04	.445000000000ex 08	.224719101123ex-04
			.690798370337ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.300000000000ex 04	.240000000000ex 08	.125000000000ex-03
2	.150000000000ex 04	.421666666666ex 08	.355731225297ex-04
3	.350000000000ex 04	.331666666666ex 08	.105527638191ex-03
4	.200000000000ex 04	.153333333333ex 08	.130434782608ex-03
5	.800000000000ex 04	.293333333333ex 08	.272727272727ex-03
6	.550000000000ex 04	.450000000000ex 08	.122222222222ex-03
7	.600000000000ex 04	.488333333333ex 08	.122866894198ex-03
8	.150000000000ex 04	.930000000000ex 07	.161290322580ex-03
9	.600000000000ex 04	.311666666666ex 08	.192513368984ex-03
			.140906180447ex-03

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7

Organism: D-3

Treatment: MAXIMUM

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.550000000000ex 04	.475000000000ex 08	.115789473684ex-03
2	.500000000000ex 04	.548333333330ex 08	.911854103349ex-04
3	.300000000000ex 04	.210000000000ex 08	.142857142857ex-03
4	.200000000000ex 04	.166666666666ex 08	.120000000000ex-03
5	.300000000000ex 04	.370000000000ex 08	.810810810810ex-04
6	.350000000000ex 04	.210000000000ex 08	.166666666666ex-03
7	.450000000000ex 04	.321666666666ex 08	.139896373057ex-03
8	.450000000000ex 04	.285000000000ex 08	.157894736842ex-03
			.126921360565ex-03

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.300000000000ex 04	.440000000000ex 08	.681818181818ex-04
2	.150000000000ex 04	.433333333333ex 08	.346153846154ex-04
3	.350000000000ex 04	.530000000000ex 08	.660377358490ex-04
4	.300000000000ex 04	.485000000000ex 08	.618556701030ex-04
5	.450000000000ex 04	.578333333330ex 08	.778097982713ex-04
6	.600000000000ex 04	.350000000000ex 08	.171428571428ex-03
7	.150000000000ex 04	.340000000000ex 08	.441176470588ex-04
8	.600000000000ex 04	.855000000000ex 08	.701754385964ex-04
9	.200000000000ex 04	.153333333333ex 08	.130434782608ex-03
10	.150000000000ex 04	.102000000000ex 08	.147058823529ex-03
			.871715670239ex-04

Table 3 (continued)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: D-3

Treatment: INTERMEDIATE

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.400000000000ex 04	.466666666666ex 08	.857142857144ex-04
2	.500000000000ex 03	.433333333333ex 07	.115384615384ex-03
3	.350000000000ex 04	.705000000000ex 08	.496453900709ex-04
4	.250000000000ex 04	.176666666666ex 08	.141509433962ex-03
5	.350000000000ex 04	.143333333333ex 08	.244186046512ex-03
6	.100000000000ex 04	.236666666666ex 08	.422535211268ex-04
7	.350000000000ex 04	.351666666666ex 08	.995260663508ex-04
8	.300000000000ex 04	.321666666666ex 08	.932642487048ex-04
9	.450000000000ex 04	.361666666666ex 08	.124423963133ex-03
10	.250000000000ex 04	.256666666666ex 08	.974025974028ex-04
			.109331016835ex-03

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.450000000000ex 04	.156666666666ex 08	.287234042554ex-03
2	.300000000000ex 04	.460000000000ex 08	.652173913043ex-04
3	.250000000000ex 04	.201666666666ex 08	.123966942149ex-03
4	.100000000000ex 04	.146666666666ex 08	.681818181821ex-04
5	.150000000000ex 04	.183333333333ex 08	.818181818183ex-04
6	.100000000000ex 04	.295000000000ex 08	.338983050847ex-04
7	.300000000000ex 04	.383333333333ex 08	.782608695652ex-04
8	.200000000000ex 04	.161666666666ex 08	.123711340206ex-03
9	.450000000000ex 04	.340000000000ex 08	.132352941176ex-03
10	.200000000000ex 04	.323333333333ex 08	.618556701031ex-04
			.105649750214ex-03

Table 3 (concluded)

HOST MEDIATED ASSAY
INDIVIDUAL MOUSE DATA

Compound No.: 71-7 (Sodium nitrate)

Organism: D-3

Treatment: LOW

A. Acute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.500000000000ex 04	.438333333333ex 08	.114068441064ex-03
2	.300000000000ex 04	.341666666666ex 08	.878048780489ex-04
3	.750000000000ex 04	.568333333330ex 08	.131964809384ex-03
4	.150000000000ex 04	.193333333333ex 08	.775862068966ex-04
5	.150000000000ex 04	.850000000000ex 07	.176470588235ex-03
6	.200000000000ex 04	.245000000000ex 08	.816326530612ex-04
7	.100000000000ex 04	.390000000000ex 08	.256410256410ex-04
8	.300000000000ex 04	.368333333333ex 08	.814479638009ex-04
			.970770707661ex-04

B. Subacute

Mouse No.	Ave. No. Mutant Colonies or Recombinants/ml	Ave. No. Colony Forming Units/ml	Mutation or Recombination Frequency
1	.450000000000ex 04	.506666666665ex 08	.888157894739ex-04
2	.250000000000ex 04	.340000000000ex 08	.735294117647ex-04
3	.650000000000ex 04	.636666666665ex 08	.102094240837ex-03
4	.300000000000ex 04	.508333333330ex 08	.590163934430ex-04
5	.550000000000ex 04	.265000000000ex 08	.207547169811ex-03
6	.500000000000ex 04	.155000000000ex 08	.322580645161ex-03
7	.700000000000ex 04	.301666666666ex 08	.232044198895ex-03
8	.250000000000ex 04	.316666666666ex 08	.789473684212ex-04
9	.250000000000ex 04	.203333333333ex 08	.122950819672ex-03
			.143058448607ex-03

Table 4

HOST-MEDIATED ASSAY
IN VITRO MUTAGENICITY OF COMPOUND 71-7 (Sodium Nitrate)

Salmonella typhimurium G-46	
5% w/v 71-7	EMS
negative	positive

Salmonella typhimurium TA-1530	
5% w/v 71-7	EMS
negative	positive

Saccharomyces cerevisiae D-3

Compound	Concentration	Survival (%)	Recombinants/10 Survivors	RFt/RFc
71-7	5% w/v	128	7.42	1.90
Control (-) for 71-7	--	100	3.90	1.00
EMS	0.1% w/v	86	298.79	74.50
Control (-) for EMS	--	100	3.89	1.00

Table 5

CYTOGENETIC ASSAY
METAPHASE SUMMARY SHEET BY TIME OF SACRIFICE
Sodium Nitrate (71-7)

Dosage	Time*	Mitotic Index (%)	No. of Animals	No. of Cells	Cells with Breaks (%)	Cells with Rearrange-ments (%)	Cells with More than one Type of Aber. (%)	Cells with Aber. (%)
TEM (0.4 mg/kg)	6	1.15	5	250	5.6	0	0	5.6
Negative Control	6	1.95	3	150	2.7	0	0	2.7
30 mg/kg	6	1.40	5	250	1.2	0	0	1.2
800 mg/kg	6	1.10	5	250	0.8	0	0	0.8
1600 mg/kg	6	0.95	5	250	3.6	0	0	3.6
Negative Control	24	1.55	3	150	2.0	0	0	2.0
30 mg/kg	24	1.80	5	250	1.2	0	0	1.2
800 mg/kg	24	1.55	5	250	0	0	0	0
1600 mg/kg	24	2.05	5	247	0	0	0	0
Negative Control	48	1.50	3	150	0.7	0	0	0.7
30 mg/kg	48	2.25	5	250	0	0	0	0
800 mg/kg	48	1.80	5	250	0.8	0	0	0.8
1600 mg/kg	48	1.80	5	250	2.0	0	0	2.0
Negative Control	SA**	1.65	3	150	1.3	0	0	1.3
30 mg/kg	SA	1.70	5	250	1.2	0	0	1.2
800 mg/kg	SA	0.75	5	250	0.4	0	0	0.4
1600 mg/kg	SA	1.85	5	250	0	0	0	0

* Time of sacrifice after treatment (hours).

** SA = Subacute.

Table 6

CYTOGENETIC ASSAY
ANAPHASE SUMMARY SHEET
Sodium Nitrate (71-7)

Dosage	Time*	No. of Cells	Cells with Acentric Fragments (%)	Cells with Bridges (%)	Multipolar Cells (%)	Other (Abnormal) (%)	Cells with More than One Type Aber. (%)	Cells with Aber. (%)
Negative Control	24	263	6.1	2.3	0	2.3	1.9	8.7
10 μg/ml	24	183	12.6	2.2	1.1	4.4	4.4	14.8
100 μg/ml	24	140	12.1	2.9	0.7	2.9	2.9	15.0
1000 μg/ml	24	220	8.6	0.5	0.5	7.3	2.7	14.1
TEM (0.05 μg/ml)	24	121	19.8	5.0	0	5.8	2.5	28.1

* Time of harvest after treatment (hours).

DOMINANT LETHAL GENE-RAT

Table 7

AVERAGE IMPLANTATIONS PER PREGNANT FEMALE

Compound: Sodium Nitrate
FDA No: 71-7

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-7 (30 mg/kg)	71-7 (0.8 g/kg)	71-7 (1.6 g/kg)
Acute-Single Dose					
1	181/15=12.1	241/20=12.1	204/16=12.8	214/16=13.4	140/12=11.7
2	226/20=11.3	136/20= 6.8**	216/19=11.4	166/13=12.8	189/19= 9.9
3	245/20=12.3	167/20= 8.4**	238/20=11.9	216/18=12.0	245/20=12.3
4	258/20=12.9	131/20= 6.6**	256/20=12.8	220/17=12.9	198/16=12.4
5	223/19=11.7	187/19= 9.8*	209/19=11.0	194/16=12.1	232/20=11.6
6	237/20=11.9	229/20=11.5	241/20=12.1	191/16=11.9	188/17=11.1
7	225/20=11.3	250/20=12.5	231/20=11.6	191/16=11.9	228/20=11.4
8	240/20=12.0	230/19=12.1	221/20=11.1	187/17=11.0	220/20=11.0
Subacute-Multiple Dose					
1			162/16=10.1	243/20=12.2	255/20=12.8
2			232/20=11.6	240/20=12.0	229/20=11.5
3			206/16=12.9	223/19=11.7	205/19=10.8
4			234/20=11.7	234/19=12.3	220/19=11.6
5			239/20=12.0	212/20=10.6	242/20=12.1
6			242/20=12.1	229/19=12.1	237/20=11.9
7			227/20=11.4	216/19=11.4	225/20=11.3

* Significant at $P < 0.05$
** Significant at $P < 0.01$

DOMINANT LETHAL GENE-RAT

Table 9

DEAD IMPLANTS/TOTAL IMPLANTS

Compound: Sodium Nitrate
FDA No: 71-7

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-7 (30 mg/kg)	71-7 (0.8 g/kg)	71-7 (1.6 g/kg)
Acute-Single Dose					
1	9/181=0.05	95/241=0.39**	6/204=0.03	9/214=0.04	6/140=0.04
2	15/226=0.07	196/136=0.78**	13/216=0.06	8/166=0.05	15/189=0.08
3	19/225=0.08	147/167=0.88**	18/238=0.08	10/216=0.05	15/245=0.06
4	21/258=0.08	108/131=0.82**	5/256=0.02*D	12/220=0.05	8/198=0.04
5	9/223=0.04	41/187=0.22**	4/209=0.02	16/194=0.08	10/232=0.04
6	13/237=0.05	12/229=0.05	10/241=0.04	7/191=0.04	7/188=0.04
7	25/225=0.11	11/250=0.04	7/231=0.03*D	19/191=0.10	15/228=0.07
8	12/240=0.05	14/230=0.06	8/221=0.04	12/187=0.06	21/220=0.10
Subacute-Multiple Dose					
1			17/162=0.10	15/243=0.06	21/255=0.08
2			27/232=0.12	11/240=0.05	17/229=0.07
3			10/206=0.05	16/223=0.07	11/205=0.05
4			17/234=0.07	8/234=0.03	16/220=0.07
5			18/239=0.08	11/212=0.05	11/242=0.05
6			10/242=0.04	20/229=0.09	29/237=0.12
7			13/227=0.06	11/216=0.05	10/225=0.04*D

* Significant at $P < 0.05$
** Significant at $P < 0.01$
D Decrease below control

DOMINANT LETHAL GENE-RAT

Table 9

DEAD IMPLANTS/TOTAL IMPLANTS

Compound: Sodium Nitrate
FDA No: 71-7

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-7 (30 mg/kg)	71-7 (0.8 g/kg)	71-7 (1.6 g/kg)
Acute-Single Dose					
1	9/181=0.05	95/241=0.39**	6/204=0.03	9/214=0.04	6/140=0.04
2	15/226=0.07	196/136=0.78**	13/216=0.06	8/166=0.05	15/189=0.08
3	19/225=0.08	147/167=0.88**	18/238=0.08	10/216=0.05	15/245=0.06
4	21/258=0.08	108/131=0.82**	5/256=0.02*D	12/220=0.05	8/198=0.04
5	9/223=0.04	41/187=0.22**	4/209=0.02	16/194=0.08	10/232=0.04
6	13/237=0.05	12/229=0.05	10/241=0.04	7/191=0.04	7/188=0.04
7	25/225=0.11	11/250=0.04	7/231=0.03*D	19/191=0.10	15/228=0.07
8	12/240=0.05	14/230=0.06	8/221=0.04	12/187=0.06	21/220=0.10
Subacute-Multiple Dose					
1			17/162=0.10	15/243=0.06	21/255=0.08
2			27/232=0.12	11/240=0.05	17/229=0.07
3			10/206=0.05	16/223=0.07	11/205=0.05
4			17/234=0.07	8/234=0.03	16/220=0.07
5			18/239=0.08	11/212=0.05	11/242=0.05
6			10/242=0.04	20/229=0.09	29/237=0.12
7			13/227=0.06	11/216=0.05	10/225=0.04*D

* Significant at $P < 0.05$
** Significant at $P < 0.01$
D Decrease below control

DOMINANT LETHAL GENE-RAT

Table 11

AVERAGE PREIMPLANTATION LOSS PER PREGNANT FEMALE

Compound: Sodium Nitrate
FDA No: 71-7

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-7 (30 mg/kg)	71-7 (0.8 g/kg)	71-7 (1.6 g/kg)
Acute-Single Dose					
1	27/15=1.80	29/20=1.45	19/16=1.19	4/16=0.25	14/12=1.17
2	36/20=1.80	102/20=5.10**	29/19=1.53	6/13=0.46	52/19=2.74
3	27/20=1.35	93/20=4.65**	36/20=1.80	32/18=1.78	36/20=1.80
4	21/20=1.05	137/20=6.85**	21/20=1.05	14/17=0.82	14/16=0.88
5	25/19=1.32	42/19=2.21	25/19=1.32	14/16=0.88	20/20=1.00
6	21/20=1.05	16/20=0.80	12/20=0.60	23/16=1.44	25/17=1.47
7	33/20=1.65	19/20=0.95	26/20=1.30	26/16=1.63	38/20=1.90
8	19/20=0.95	32/19=1.68	27/20=1.35	18/17=1.06	20/20=1.00
Subacute-Multiple Dose					
1			56/16=3.50	19/20=0.95	33/20=1.65
2			33/20=1.65	25/20=1.25	51/20=2.55
3			10/16=0.63	27/19=1.42	47/19=2.47
4			8/20=0.40	8/19=0.42	40/19=2.11
5			17/20=0.85	39/20=1.95	20/20=1.00
6			20/20=1.00	32/19=1.68	18/20=0.90
7			33/20=1.65	20/19=1.05	34/20=1.70

* Significant at $P < 0.05$
** Significant at $P < 0.01$

DOMINANT LETHAL GENE-RAT

Table 10

AVERAGE CORPORA LUTEA PER PREGNANT FEMALE

Compound: Sodium Nitrate
FDA No: 71-7

Week of Study	Control (10 ml/kg)	TEM (0.2 mg/kg)	71-7 (30 mg/kg)	71-7 (0.8 g/kg)	71-7 (1.6 g/kg)
Acute-Single Dose					
1	208/15=13.9	270/20=13.5	223/16=13.9	218/16=13.6	154/12=12.8*
2	262/20=13.1	238/20=11.9*	245/19=12.9	172/13=13.2	241/19=12.7
3	272/20=13.6	260/20=13.0	274/20=13.7	248/18=13.8	281/20=14.1
4	279/20=14.0	268/20=13.4	277/20=13.9	234/17=13.8	212/16=13.3
5	248/19=13.1	229/19=12.1	234/19=12.3	208/16=13.0	252/20=12.6
6	258/20=12.9	245/20=12.3	253/20=12.7	214/16=13.4	213/17=12.5
7	258/20=12.9	269/20=13.5	257/20=12.9	217/16=13.6	266/20=13.3
8	259/20=13.0	262/19=13.8	248/20=12.4	205/17=12.1	240/20=12.0
Subacute-Multiple Dose					
1			218/16=13.6	262/20=13.1	288/20=14.4
2			265/20=13.3	265/20=13.3	280/20=14.0
3			216/16=13.5	250/19=13.2	252/19=13.3
4			242/20=12.1*	242/19=12.7*	260/19=13.7
5			256/20=12.8	251/20=12.6	262/20=13.1
6			262/20=13.1	261/19=13.7	255/20=12.8
7			260/20=13.0	236/19=12.4	259/20=13.0

* Significant at $P < 0.05$
** Significant at $P < 0.01$

APPENDIX A

Statistical Analysis Procedures for Dominant Lethal Gene Tests With a Description and Explanation of the Computer Printouts

Statistical Analysis Procedures for Dominant Lethal Gene Tests With

A Description and Explanation of the Computer Printouts

The first stage of the analysis of the dominant lethal tests of the mutagenic studies on chemicals is the preparation of punched cards from work sheets. Each sheet contains autopsy data for the female rats that were mated, two per male, to 10 males of the same dosage group in one particular week. There are 9 dosage groups for some of the chemical additives studied, and 8 groups for the others. The 9 groups consist of 5 1-dose groups and 4 5-dose (multiple teatment) groups. The 1-dose groups are for the vehicle control, 3 additive dosage levels, and a positive control (TEM). Each rat in these groups is mated weekly for 8 weeks. The 5-dose groups are for the vehicle control and the 3 additive dosage levels. The rats in these groups are mated weekly for 7 weeks. (There is a deck of 1360 cards for each compound.)

The second stage is the execution of a computer program, KLUTE, which performs the following operations (where each statistical calculation is done once for each week's data):

1. The data cards are read and stored in central memory while a check is made to verify that the number of corpora lutea is greater than or equal to the number of implants. If any data fail this check, the run is aborted and the data are returned for review. The entire set of input data is printed out.

2. The fertility index (the number of pregnant females divided by the number of mated females) is calculated.

3. The chi-square test is done to compare each dosage level to the control on fertility. Let:

N_i = no. of mated females at dose level i,

n_i = no. of pregnant females at dose level i.

Then the chi-square 2 x 2 tables are of the form:

$$\begin{bmatrix} n_o & n_i \\ N_o - n_o & N_i - n_i \end{bmatrix}$$

and chi-squared (with 1 degree of freedom) is:

$$X_i^2 = \frac{(N_o+N_i)(|n_o(N_i-n_i)-n_i(N_o-n_o)|-(N_o+N_i)/2)^2}{(n_o+n_i)(N_o-n_o+N_i-n_i)(N_o)(N_i)} \quad \text{(corrected for continuity)}$$

where the subscript o represents the control group.*

For each dosage group (including the control group and TEM), the following is printed out: the number of pregnant females (N PRG), the number of mated females (N MTD), the fertility index and X^2.

4. Armitage's test for a linear trend in proportions is applied to the fertility index. The formula for this calculation is found on pages 246-248 of "Statistical Calculations" by Snedecor and Cochran, 6th Edition, Iowa State University Press, 1967. Using the notation of (3) above, we have a 2 x 3 contingency table of the form:

	dose 1	dose 2	dose 3	row totals
	n_1	n_2	n_3	t
	N_1-n_1	N_2-n_2	N_3-n_3	T-t
Column Totals	N_1	N_2	N_3	T

Armitage's "chi-square" is given as $X^2_{(C-1)} - X^2_1$, where C=3 and

$$X_1^2 = \frac{T(T\Sigma nx - t\Sigma Nx)^2}{t(T-t)(T\Sigma Nx^2-(\Sigma Nx)^2)}, \quad X^2_{(C-1)} = \frac{T^2(\Sigma\frac{n^2}{N} - \frac{t^2}{T})}{t(T-t)},$$

*In all tests, the single-dose treatment groups are compared with the single-dose control group and the multiple-dose treatment groups compared with the multiple-dose control group.

where Σnx stands for $\sum_{i=1}^{3} n_i x_i$, $\Sigma \frac{n^2}{N}$ for $\sum_{i=1}^{3} \frac{n_i^2}{N_i}$, etc., and the x_i are the dosage levels.

This calculation is then repeated with x replaced by log x. The Armitage test is also applied to the following 2 x 4 contingency table:

Control	dose 1	dose 2	dose 3
n_o	n_1	n_2	n_3
N_o-n_o	N_1-n_1	N_2-n_2	N_3-n_3

In this case, C=4.

The printout for the Armitage tests includes the degrees of freedom, the number pregnant (N PRG) and the number mated (N MTD) for each of the 3 or 4 groups included in the tests, plus $X^2_{(C-1)}$, X^2_1 and their difference (labeled ARMTG CHISQ).

5. The t-test is applied to determine significant differences between the average number of implantations per pregnant female at a dose level, and the average for the control. Let

n_i = no. of pregnant females at dose level i.

u_{ij} = total no. of implantations for pregnant female j of dose i.

Then,

$$\bar{u}_i = \frac{1}{n_i} \sum_{j=1}^{n_i} u_{ij}$$

$$S_i^2 = \sum_{j=1}^{n_i} (u_{ij}-\bar{u}_i)^2$$

The T-statistic for dose i has $n_o + n_i - 2$ degrees of freedom, and is equal to:

$$t_i = \frac{\bar{u}_o - \bar{u}_i}{\left[\frac{S_o^2 + S_i^2}{n_o + n_i - 2}\left(\frac{1}{n_o} + \frac{1}{n_i}\right)\right]^{1/2}}$$

The t-test printout gives, for each group: the number pregnant (N PRG), the mean and standard deviation of the number of implantations. The absolute value of T and the degrees of freedom (DF) are given for each treatment group and for TEM.

6. A regression fit of the average number of implantations, $\bar{u}_i$, is made for both the arithmetic and logarithmic dose $\left(X_i \text{ and } \log X_i\right)$ to see which is better.

These two fits include the data from the three treatment groups only. A third regression using the X_i as independent variables includes data from the three treatment groups and the control group.

The regressions are computed as follows:

Let N = the number of observations, i.e., the total number of pregnant females in the groups used in the regression.

X_i = the value of the independent variable (dose or log dose) for the i-th female.

U_i = the value of the dependent variable (number of implantations) for the i-th female.

Then,

$$\text{XBAR} = \bar{X} = \frac{1}{N} \sum_{i=1}^{N} X_i$$

$$\text{SD X} = \text{standard deviation of the } X_i$$

$$= \left[\frac{1}{N-1} \; SS_X \right]^{1/2},$$

$$\text{where } SS_X = \sum_{i=1}^{N} (X_i - \bar{X})^2$$

$$\text{UBAR} = \bar{U} = \frac{1}{N} \sum_{i=1}^{N} U_i,$$

$$\text{SD U} = \text{standard deviation of the } U_i$$

$$= \left[\frac{1}{N-1} \; SS_U \right]^{1/2},$$

$$\text{where } SS_U = \sum_{i=1}^{N} (U_i - \bar{U})^2,$$

$$\text{and } S_{XU} = \sum_{i=1}^{N} (X_i - \bar{X})(U_i - \bar{U}).$$

From these quantities, we compute:

$$B = \text{estimate of the slope of the regression line}$$
$$= S_{XU}/SS_X,$$

$$A = \text{estimate of the intercept of the regression line}$$
$$= \bar{U} - B\bar{X},$$

Also,

$$\text{VARU.X} = \text{variance of U about the regression line}$$

$$= \frac{SS_U - \left(S_{XU}\right)^2 / SS_X}{N-2}$$

and from this is computed,

$$\text{VARB} = \text{variance of the estimate, B}$$

$$= \frac{\text{VARU.X}}{SS_X}$$

$$\text{VARA} = \text{variance of the estimate, A}$$

$$= \text{VARU.X}\left[\frac{1}{N} + \frac{\bar{X}^2}{SS_X}\right]$$

$$\text{VARUBAR} = \text{variance of } \bar{U},$$

$$= \frac{\text{VARU.X}}{N}$$

and

$$\text{CV U.X} = \text{coefficient of variation of U about X}$$

$$= \frac{(\text{VARU.X})^{1/2}}{\bar{U}}$$

And finally we have:

TB = the t-statistic for testing the hypothesis that the regression slope is zero

$$= \frac{B}{\sqrt{\text{VARB}}}$$

DF = number of degrees of freedom for TB

$$= N - 2$$

7. The preimplantation loss, y_{ij} is calculated for each pregnant female, j, as the number of corpora lutea, v_{ij}, minus the number of implantations, u_{ij}. Then the Freeman-Tukey transformation is applied to y_{ij} as follows:

$$f_{ij} = \sin^{-1}\sqrt{\frac{y_{ij}}{v_{ij}+1}} + \sin^{-1}\sqrt{\frac{y_{ij}+1}{v_{ij}+1}}$$

The t-test is then applied to the f's. Let

$$\bar{f}_i = \frac{1}{n_i}\sum_{j=1}^{n_i} f_{ij}$$

$$S_i^2 = \sum_{j=1}^{n_i} (f_{ij}-\bar{f}_i)^2,$$

where n_i, and n_o are defined above (step 3).

Then
$$t_i = \frac{\bar{f}_o - \bar{f}_i}{\left[\frac{S_o^2 + S_i^2}{n_o + n_i - 2}\left(\frac{1}{n_o} + \frac{1}{n_i}\right)\right]^{1/2}}$$

The printout gives, for each group, the number of pregnant females (N PRG), the mean and standard deviation of the f_{ij}'s. For each treatment group and for TEM, the absolute value of t_i (T), and its degrees of freedom (DF) are given.

8. The number of dead implants, z_{ij}, for each female, j, is the sum of the early and late deaths. The Freeman-Tukey transformation and the subsequent t-test is applied to the dead implants for pregnant females by repeating step 7 above with z_{ij} substituted for y_{ij}.

9. The number of pregnant females with one or more dead implants, m_i, is calculated. In the printout, the m_i are referred to as N WDI (i.e., "number with dead implants").

10. The chi-square test and Armitage's test for a linear trend is calculated for the proportion of pregnant females with one or more dead implants,

$$p_i = \frac{m_i}{n_i}$$

by repeating steps 3 and 4, above, with m_i substituted for n_i, and n_i substituted for N_i.

In the printout, the ratio, p_i, is called the "death index", in analogy with the fertility index.

11. The ratios, p_i, computed above, undergo a probit analysis to determine whether the probit of this proportion is linearly related to the log dose. Computer subroutine PROBT, from the IBM System/360 Scientific Subroutine Package Version III, is used to compute A and B and the X^2 statistic for the regression equation,

$$P_i = A + B*\log x_i$$

where P_i is derived by the program from

$$\int_{-\infty}^{P_i - 5} N_x(0,1)dx = p_i .$$

($N_x(0,1)$ is the normal curve, with a mean of 0 and a standard deviation of 1).

12. The number of dead implants, z_{ij}, and the number of total implants, u_{ij}, are calculated for each pregnant female, j. The Freeman-Tukey transformation and subsequent t-test is applied to this data by repeating step 7, above, as follows:

$$f_{ij} = \sin^{-1}\sqrt{\frac{z_{ij}}{u_{ij}+1}} + \sin^{-1}\sqrt{\frac{z_{ij}+1}{u_{ij}+1}}$$

$$\bar{f}_i = \frac{1}{n_i}\sum_{j=1}^{n_i} f_{ij}$$

$$S_i^2 = \sum_{j=1}^{n_i} (f_{ij} - \bar{f}_i)^2$$

$$t_i = \frac{\bar{f}_o - \bar{f}_i}{\left[\frac{S_o^2 + S_i^2}{n_o + n_i - 2}\left(\frac{1}{n_o} + \frac{1}{n_i}\right)\right]^{1/2}}$$

13. Five one-way analyses of variance are performed on the control groups' data. The five variables analyzed are:

a. Number of pregnant females,

b. Number of implantations per pregnant female,

c. The pre-implantation loss (as defined in Step 7) per pregnant female,

d. The number of dead implants per pregnant female,

e. The ratio of dead implants to the total implants per pregnant female.

In view of the fact that none of the variables on which the one-way analysis of variance have been performed is even approximately normal in distribution, the probability levels associated with these analyses of variances are necessarily approximate.

For case a., R_{kj} equals 1 if female j assigned to male k became pregnant; otherwise R_{kj} equals zero. For cases b. through e. the tabulation is limited to data for pregnant females; i.e., R_{kj} equals the value of the specified variable for female j assigned to male k if the female was pregnant; data for non-pregnant females are excluded.

For case a., L_k equals the number of females assigned to male k. For cases b. through e., L_k equals the number of females assigned to male k that became pregnant.

For each of these variables the ANOVA calculations are as follows:

M is the number of males

$$\bar{R}_k = \frac{1}{L_k} \sum_{j=1}^{L_k} R_{kj}$$

$$\bar{R} = \frac{1}{M} \sum_{k=1}^{M} \bar{R}_k$$

Then, the sum-of-squares-within-males = $SUMSQ_w$

$$= \sum_{k=1}^{M} = \sum_{j=1}^{L_k} (R_{kj} - \bar{R}_k)^2,$$

the degrees-of-freedom-within-males = DF_w

$$= \sum_{k=1}^{M} (L_k - 1),$$

and the mean-square-within-males = $MEANSQ_w = \frac{SUMSQ_w}{DF_w}$.

Similarly, the sum-of-squares-between-males = $SUMSQ_B = \sum_{k=1}^{M} L_k (\bar{R}_k - \bar{R})^2$,

the degrees-of-freedom-between-males = $DF_B = M-1$,

and the mean-square-between-males = $MEANSQ_B = \frac{SUMSQ_B}{DF_B}$.

Finally, the F-ratio is $F = \frac{MEANSQ_B}{MEANSQ_W}$.

In the printout, these quantities are labeled without the subscripts, but the "within" and "between" quantities are identified by the page heading. Also, the total-sum-of-squares = $SUMSQ_W + SUMSQ_B$

and its degrees-of-freedom

$$= \sum_{k=1}^{M} L_k - 1,$$

are printed.

14. The t-test is applied to determine significant differences between the average number of corpora lutea per pregnant female at a dose level, and the average for the control. Let

n_i = no. of pregnant females at dose level i.

C_{ij} = total no. of corpora lutea for pregnant female j of dose i.

Then,

$$\bar{C}_i = \frac{1}{n_i} \sum_{j=1}^{n_i} C_{ij}$$

$$S_i^2 = \sum_{j=1}^{n_i} (C_{ij} - \bar{C}_i)^2$$

The T-statistic for dose i has $n_o + n_1 - 2$ degrees of freedom, and is equal to:

$$t_i = \frac{\bar{C}_o - \bar{C}_i}{\left[\frac{S_o^2 + S_i^2}{n_o + n_i - 2}\left(\frac{1}{n_o} + \frac{1}{n_i}\right)\right]^{1/2}}$$

The t-test printout gives, for each group: the number pregnant (N PRG), the mean and standard deviation of the number of corpora lutea. The <u>absolute value</u> of T and the degrees of freedom (DF) are given for each treatment group and for TEM.

APPENDIX B

Raw Data and Statistical Analyses

CONTENTS

Item	Page
1. Raw Data	
Week 1	1 - 5
Week 2	6 - 10
Week 3	11 - 15
Week 4	16 - 20
Week 5	21 - 25
Week 6	26 - 30
Week 7	31 - 35
Week 8	36 - 38
2. Chi-square test of the Fertility Index	39
3. Armitage test for a Linear Trend in Proportions for the Fertility Index - Dose Levels	40
4. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Log of Dose Levels.	41
5. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Dose Levels and Controls	42
6. T-Test of number of Implantations	43
7. Regression Fits of the Number, U, of Implantations Dose and Log Dose - Control Exluded	44
8. Regression Fits of the Number, U, of Implantations Dose - Control Group Included	45
9. T-Test of the (Transformed) Pre-Implantation Loses	46
10. T-Test of the (Transformed) Number of Dead Implants	47
11. Chi-square Test of the Death Index	48
12. Armitage Test for a Linear Trend in Proportions for the Death Index - Dose Levels	49
13. Armitage Test for a Linear Trend in Proportions for the Death Index - Log of Dose Levels	50
14. Armitage Test for a Linear Trend in Proportions for the Fertility Index - Dose Levels including Control	51
15. Probit Analysis of the Proportions of Females with one or more Dead Implants	52
16. T-Test of the (transformed) Number of Dead Implants over Total Implants	53
17. Control Group ANOVA for the Number of Pregnant Females	54
18. Control Group ANOVA for the Number of Implantations Per Pregnant Females	55
19. Control Group ANOVA for the Pre-Implantation Loss per Pregnant Female	56
20. Control Group ANOVA for the Number of Dead Implants per Female	57
21. Control Group ANOVA for the Ratio of Dead Implants to Total Implants per Female	58
22. T-Test of the Number of Corpora Lutea in Pregnant Females	59

TEST				MALE	FEMALE		IMPLANTS		EARLY DEATHS		LATE DEATHS		CORPORA LUTEA	
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
CNTRL7	1	S	0.0000	2	3	Y	9	3	0	0	0	0	9	3
CNTRL7	1	S	0.0000	2	4	Y	4	8	0	0	0	0	5	10
CNTRL7	1	S	0.0000	3	5	Y	4	9	0	0	0	1	4	9
CNTRL7	1	S	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	S	0.0000	4	7	Y	9	5	0	0	0	0	9	5
CNTRL7	1	S	0.0000	4	8	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	S	0.0000	5	9	Y	5	10	0	0	0	2	5	10
CNTRL7	1	S	0.0000	5	10	Y	4	3	1	0	0	0	9	6
CNTRL7	1	S	0.0000	6	11	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	S	0.0000	6	12	Y	1	0	0	0	0	0	4	8
CNTRL7	1	S	0.0000	7	13	Y	8	7	0	0	1	0	8	7
CNTRL7	1	S	0.0000	7	14	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	S	0.0000	8	15	Y	9	5	0	0	0	0	9	5
CNTRL7	1	S	0.0000	8	16	Y	5	7	0	0	0	0	5	7
CNTRL7	1	S	0.0000	9	17	Y	7	6	0	0	0	0	7	6
CNTRL7	1	S	0.0000	9	18	Y	3	10	0	1	0	0	3	10
CNTRL7	1	S	0.0000	10	19	Y	7	7	2	0	1	0	8	8
CNTRL7	1	S	0.0000	10	20	Y	5	9	0	0	0	0	5	9
71-7	1	S	.0300	21	41	Y	7	6	0	0	0	0	7	6
71-7	1	S	.0300	21	42	Y	8	6	0	0	0	0	8	6
71-7	1	S	.0300	22	43	Y	8	7	0	0	0	0	8	7
71-7	1	S	.0300	22	44	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.0300	23	45	Y	6	6	0	0	0	0	6	6
71-7	1	S	.0300	23	46	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.0300	24	47	Y	5	8	0	0	0	0	5	8
71-7	1	S	.0300	24	48	Y	7	7	0	0	0	0	8	8
71-7	1	S	.0300	25	49	Y	5	7	0	0	0	0	7	9
71-7	1	S	.0300	25	50	Y	8	5	0	0	0	0	8	5
71-7	1	S	.0300	26	51	Y	5	7	0	0	0	0	5	7
71-7	1	S	.0300	26	52	Y	8	4	2	0	0	0	10	6
71-7	1	S	.0300	27	53	Y	9	5	0	0	2	1	9	5
71-7	1	S	.0300	27	54	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.0300	28	55	Y	3	7	0	0	0	0	3	11
71-7	1	S	.0300	28	56	Y	6	7	0	0	0	0	8	7
71-7	1	S	.0300	29	57	Y	4	6	0	0	1	0	6	7
71-7	1	S	.0300	29	58	Y	6	7	0	0	0	0	6	7
71-7	1	S	.0300	30	59	Y	11	3	0	0	0	0	11	3
71-7	1	S	.0300	30	60	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	1	S	.8000	31	61	Y	7	7	0	0	0	0	7	7
71-7	1	S	.8000	31	62	Y	5	6	0	0	0	0	5	6
71-7	1	S	.8000	32	63	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.8000	32	64	Y	7	3	0	0	0	0	7	3
71-7	1	S	.8000	33	65	Y	2	8	0	0	0	0	2	9
71-7	1	S	.8000	33	66	Y	5	7	0	0	0	0	5	7
71-7	1	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.8000	35	69	Y	8	8	0	0	1	0	8	9
71-7	1	S	.8000	35	70	Y	5	8	0	0	0	0	5	8
71-7	1	S	.8000	36	71	Y	6	9	0	0	2	2	7	9
71-7	1	S	.8000	36	72	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	.8000	37	73	Y	7	7	0	0	0	0	7	7
71-7	1	S	.8000	37	74	Y	6	8	1	1	0	0	6	8
71-7	1	S	.8000	38	75	Y	5	8	0	0	0	0	5	8
71-7	1	S	.8000	38	76	Y	5	8	0	0	0	0	5	8
71-7	1	S	.8000	39	77	Y	7	9	0	0	0	0	8	9
71-7	1	S	.8000	39	78	Y	5	10	0	0	0	1	5	10
71-7	1	S	.8000	40	79	Y	8	6	0	0	0	0	8	6
71-7	1	S	.8000	40	80	Y	6	8	0	0	0	1	6	8
71-7	1	S	1.6000	41	81	Y	8	4	0	0	0	2	8	6
71-7	1	S	1.6000	41	82	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	42	83	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	42	84	Y	7	6	0	0	0	1	8	6
71-7	1	S	1.6000	43	85	Y	5	7	0	0	0	0	5	8
71-7	1	S	1.6000	43	86	Y	7	3	1	0	0	0	8	3
71-7	1	S	1.6000	44	87	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	44	88	Y	5	6	0	0	0	0	7	6
71-7	1	S	1.6000	45	89	Y	4	8	0	0	0	0	4	8
71-7	1	S	1.6000	45	90	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	46	91	Y	4	9	0	0	0	0	4	10
71-7	1	S	1.6000	46	92	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	47	93	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	47	94	Y	8	4	0	0	0	0	8	4
71-7	1	S	1.6000	48	95	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	48	96	Y	7	2	0	0	0	0	8	7
71-7	1	S	1.6000	49	97	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	S	1.6000	49	98	Y	8	5	0	0	0	0	8	5
71-7	1	S	1.6000	50	99	Y	5	6	0	0	0	2	5	6
71-7	1	S	1.6000	50	100	Y	0	7	0	0	0	0	4	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	1	S	.0002	11	21	Y	4	7	1	1	0	0	4	7
TEM7	1	S	.0002	11	22	Y	7	6	5	5	0	0	7	6
TEM7	1	S	.0002	12	23	Y	5	8	1	0	0	0	5	8
TEM7	1	S	.0002	12	24	Y	3	5	2	3	0	0	4	8
TEM7	1	S	.0002	13	25	Y	5	7	0	0	3	0	6	7
TEM7	1	S	.0002	13	26	Y	4	8	3	4	0	1	4	9
TEM7	1	S	.0002	14	27	Y	7	9	2	4	1	1	7	9
TEM7	1	S	.0002	14	28	Y	5	4	1	1	0	0	6	7
TEM7	1	S	.0002	15	29	Y	6	4	0	0	0	2	8	5
TEM7	1	S	.0002	15	30	Y	5	7	0	3	3	0	5	7
TEM7	1	S	.0002	16	31	Y	6	7	0	0	5	2	6	7
TEM7	1	S	.0002	16	32	Y	3	7	3	4	0	0	6	7
TEM7	1	S	.0002	17	33	Y	8	5	0	2	0	0	9	5
TEM7	1	S	.0002	17	34	Y	5	8	3	3	0	2	5	8
TEM7	1	S	.0002	18	35	Y	8	7	0	0	0	0	9	8
TEM7	1	S	.0002	18	36	Y	7	6	2	3	1	0	9	6
TEM7	1	S	.0002	19	37	Y	8	5	3	0	0	0	9	5
TEM7	1	S	.0002	19	38	Y	6	5	5	4	0	0	9	5
TEM7	1	S	.0002	20	39	Y	7	6	0	1	0	0	7	6
TEM7	1	S	.0002	20	40	Y	5	6	3	2	0	0	8	7
CNTRL7	1	M	0.0000	1	1	Y	3	9	0	0	0	0	5	10
CNTRL7	1	M	0.0000	1	2	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	M	0.0000	2	3	Y	9	3	0	0	0	0	9	3
CNTRL7	1	M	0.0000	2	4	Y	4	8	0	0	0	0	5	10
CNTRL7	1	M	0.0000	3	5	Y	4	9	0	0	0	1	4	9
CNTRL7	1	M	0.0000	3	6	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	M	0.0000	4	7	Y	9	5	0	0	0	0	9	5
CNTRL7	1	M	0.0000	4	8	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	M	0.0000	5	9	Y	5	10	0	0	0	2	5	10
CNTRL7	1	M	0.0000	5	10	Y	4	3	1	0	0	0	9	6
CNTRL7	1	M	0.0000	6	11	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	M	0.0000	6	12	Y	1	0	0	0	0	0	4	8
CNTRL7	1	M	0.0000	7	13	Y	8	7	0	0	1	0	8	7
CNTRL7	1	M	0.0000	7	14	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	1	M	0.0000	8	15	Y	9	5	0	0	0	0	9	5
CNTRL7	1	M	0.0000	8	16	Y	5	7	0	0	0	0	5	7
CNTRL7	1	M	0.0000	9	17	Y	7	6	0	0	0	0	7	6
CNTRL7	1	M	0.0000	9	18	Y	3	10	0	1	0	0	3	10
CNTRL7	1	M	0.0000	10	19	Y	7	7	2	0	1	0	8	8
CNTRL7	1	M	0.0000	10	20	Y	5	9	0	0	0	0	5	9

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	1	M	.0300	11	21	Y	4	5	0	0	0	2	4	8
71-7	1	M	.0300	11	22	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	M	.0300	12	23	Y	0	2	0	0	0	0	3	8
71-7	1	M	.0300	12	24	Y	6	7	0	0	0	0	6	8
71-7	1	M	.0300	13	25	Y	8	4	0	0	0	0	8	4
71-7	1	M	.0300	13	26	Y	1	0	1	0	0	0	8	8
71-7	1	M	.0300	14	27	Y	9	5	1	0	0	1	11	6
71-7	1	M	.0300	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	M	.0300	15	29	Y	7	5	0	0	0	0	7	6
71-7	1	M	.0300	15	30	Y	5	6	0	0	0	2	8	7
71-7	1	M	.0300	16	31	Y	7	6	0	0	0	0	9	7
71-7	1	M	.0300	16	32	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	M	.0300	17	33	Y	2	0	0	0	0	0	2	7
71-7	1	M	.0300	17	34	Y	3	9	0	0	0	0	4	9
71-7	1	M	.0300	18	35	Y	9	2	2	0	0	0	11	2
71-7	1	M	.0300	18	36	Y	2	7	0	2	0	0	6	8
71-7	1	M	.0300	19	37	Y	9	6	0	1	4	0	9	6
71-7	1	M	.0300	19	38	Y	4	8	0	0	0	0	4	8
71-7	1	M	.0300	20	39	Y	7	7	1	0	0	0	8	8
71-7	1	M	.0300	20	40	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	1	M	.8000	21	41	Y	5	2	0	0	2	0	5	8
71-7	1	M	.8000	21	42	Y	5	8	0	0	0	0	5	8
71-7	1	M	.8000	22	43	Y	5	6	0	0	0	0	6	9
71-7	1	M	.8000	22	44	Y	3	9	1	0	0	0	3	9
71-7	1	M	.8000	23	45	Y	6	8	0	0	0	0	6	9
71-7	1	M	.8000	23	46	Y	5	7	0	0	0	0	5	7
71-7	1	M	.8000	24	47	Y	6	5	0	0	0	0	7	5
71-7	1	M	.8000	24	48	Y	7	6	0	0	0	1	8	6
71-7	1	M	.8000	25	49	Y	7	6	0	0	0	1	8	6
71-7	1	M	.8000	25	50	Y	6	6	0	1	0	1	6	6
71-7	1	M	.8000	25	51	Y	7	5	0	0	1	3	7	5
71-7	1	M	.8000	24	52	Y	7	3	0	0	0	0	9	3
71-7	1	M	.8000	26	53	Y	2	12	0	0	0	0	2	12
71-7	1	M	.8000	26	54	Y	4	9	1	1	0	1	6	9
71-7	1	M	.8000	27	55	Y	9	6	0	0	0	0	9	6
71-7	1	M	.8000	27	56	Y	6	7	0	0	0	0	6	7
71-7	1	M	.8000	28	57	Y	2	11	0	0	0	0	2	11
71-7	1	M	.8000	28	58	Y	7	6	0	0	0	0	7	6
71-7	1	M	.8000	30	59	Y	8	3	0	0	0	0	8	3
71-7	1	M	.8000	30	60	Y	5	6	0	0	0	1	6	6

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-7 SODIUM NITRATE

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	1	M	1.6000	31	61	Y	9	5	1	1	0	1	9	5
71-7	1	M	1.6000	31	62	Y	7	8	1	1	0	0	7	8
71-7	1	M	1.6000	32	63	Y	5	5	0	0	0	0	7	5
71-7	1	M	1.6000	32	64	Y	8	5	0	0	0	0	8	5
71-7	1	M	1.6000	33	65	Y	8	7	1	0	1	0	8	7
71-7	1	M	1.6000	33	66	Y	6	5	0	0	0	0	8	6
71-7	1	M	1.6000	34	67	Y	5	9	1	0	0	0	5	9
71-7	1	M	1.6000	34	68	Y	7	8	0	0	0	0	7	8
71-7	1	M	1.6000	35	69	Y	6	9	0	0	0	3	6	10
71-7	1	M	1.6000	35	70	Y	0	2	0	0	0	0	7	7
71-7	1	M	1.6000	36	71	Y	6	9	0	0	0	0	8	10
71-7	1	M	1.6000	36	72	Y	4	8	0	0	0	0	4	8
71-7	1	M	1.6000	37	73	Y	0	9	0	0	0	2	3	9
71-7	1	M	1.6000	37	74	Y	9	9	0	0	1	1	12	10
71-7	1	M	1.6000	38	75	Y	5	8	0	0	0	0	5	9
71-7	1	M	1.6000	38	76	Y	6	8	0	1	0	0	6	8
71-7	1	M	1.6000	39	77	Y	6	6	0	0	0	0	7	7
71-7	1	M	1.6000	39	78	Y	5	8	0	1	0	0	5	8
71-7	1	M	1.6000	40	79	Y	4	8	0	0	0	1	4	8
71-7	1	M	1.6000	40	80	Y	6	7	1	0	1	1	7	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	2	S	0.0000	1	1	Y	9	7	0	0	0	0	9	9
CNTRL7	2	S	0.0000	1	2	Y	5	8	1	1	0	0	5	8
CNTRL7	2	S	0.0000	2	3	Y	5	0	0	0	0	0	5	7
CNTRL7	2	S	0.0000	2	4	Y	6	9	0	0	1	0	6	9
CNTRL7	2	S	0.0000	3	5	Y	5	9	0	0	0	3	5	9
CNTRL7	2	S	0.0000	3	6	Y	6	7	0	0	0	0	6	7
CNTRL7	2	S	0.0000	4	7	Y	5	8	0	0	0	0	5	8
CNTRL7	2	S	0.0000	4	8	Y	5	6	0	0	0	0	6	6
CNTRL7	2	S	0.0000	5	9	Y	6	7	0	0	0	0	7	8
CNTRL7	2	S	0.0000	5	10	Y	1	1	0	0	0	1	8	4
CNTRL7	2	S	0.0000	6	11	Y	7	8	0	0	0	0	7	8
CNTRL7	2	S	0.0000	6	12	Y	6	6	0	0	0	0	6	6
CNTRL7	2	S	0.0000	7	13	Y	7	6	0	0	1	0	7	6
CNTRL7	2	S	0.0000	7	14	Y	2	6	1	1	1	3	3	9
CNTRL7	2	S	0.0000	8	15	Y	0	7	0	0	0	0	0	7
CNTRL7	2	S	0.0000	8	16	Y	8	3	0	0	0	0	12	3
CNTRL7	2	S	0.0000	9	17	Y	2	7	0	0	0	0	7	7
CNTRL7	2	S	0.0000	9	18	Y	6	5	0	0	0	0	7	5
CNTRL7	2	S	0.0000	10	19	Y	7	6	0	0	0	0	7	6
CNTRL7	2	S	0.0000	10	20	Y	6	6	1	0	0	0	6	6
71-7	2	S	.0300	21	41	Y	4	8	0	0	0	1	4	9
71-7	2	S	.0300	21	42	Y	2	7	0	0	0	0	2	9
71-7	2	S	.0300	22	43	Y	7	7	0	0	0	0	7	7
71-7	2	S	.0300	22	44	Y	7	6	2	0	0	0	7	6
71-7	2	S	.0300	23	45	Y	4	6	0	0	0	0	4	7
71-7	2	S	.0300	23	46	Y	4	7	1	2	0	0	5	7
71-7	2	S	.0300	24	47	Y	6	7	0	0	0	0	6	7
71-7	2	S	.0300	24	48	Y	4	7	0	0	0	0	4	7
71-7	2	S	.0300	25	49	Y	0	8	0	2	0	0	4	9
71-7	2	S	.0300	25	50	Y	2	7	0	0	0	0	3	8
71-7	2	S	.0300	26	51	Y	6	8	0	0	1	0	7	9
71-7	2	S	.0300	26	52	Y	6	8	0	0	0	0	6	9
71-7	2	S	.0300	27	53	Y	6	6	0	0	2	1	6	6
71-7	2	S	.0300	27	54	Y	7	5	0	0	0	0	8	5
71-7	2	S	.0300	28	55	Y	6	6	0	0	0	0	7	9
71-7	2	S	.0300	28	56	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.0300	29	57	Y	2	7	0	0	0	0	2	10
71-7	2	S	.0300	29	58	Y	4	7	0	0	0	0	5	7
71-7	2	S	.0300	30	59	Y	4	5	0	0	1	0	5	9
71-7	2	S	.0300	30	60	Y	7	6	0	0	0	0	7	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	2	S	.8000	31	61	Y	7	9	0	0	0	0	7	9
71-7	2	S	.8000	31	62	Y	7	6	0	0	0	0	7	6
71-7	2	S	.8000	32	63	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	32	64	Y	9	4	0	0	0	0	9	4
71-7	2	S	.8000	33	65	Y	4	9	0	0	0	0	4	9
71-7	2	S	.8000	33	66	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	35	69	Y	7	4	0	0	2	0	7	4
71-7	2	S	.8000	35	70	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	36	71	Y	5	7	0	0	1	0	5	8
71-7	2	S	.8000	36	72	Y	2	8	0	0	1	2	2	10
71-7	2	S	.8000	37	73	Y	2	12	0	0	0	0	2	12
71-7	2	S	.8000	37	74	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	38	75	Y	7	6	0	0	0	1	7	6
71-7	2	S	.8000	38	76	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	.8000	39	77	Y	8	6	0	0	0	0	10	6
71-7	2	S	.8000	39	78	Y	4	7	0	1	0	0	4	8
71-7	2	S	.8000	40	79	Y	4	8	0	0	0	0	4	8
71-7	2	S	.8000	40	80	Y	7	7	0	0	0	0	7	7
71-7	2	S	1.6000	41	81	Y	7	5	0	0	0	0	7	6
71-7	2	S	1.6000	41	82	Y	6	4	3	1	0	0	7	5
71-7	2	S	1.6000	42	83	Y	6	6	2	0	0	0	6	6
71-7	2	S	1.6000	42	84	Y	6	5	0	0	0	0	6	5
71-7	2	S	1.6000	43	85	Y	3	8	0	0	0	0	5	8
71-7	2	S	1.6000	43	86	Y	2	0	0	0	0	0	5	7
71-7	2	S	1.6000	44	87	Y	2	0	0	0	0	0	8	5
71-7	2	S	1.6000	44	88	Y	2	5	0	0	0	0	8	5
71-7	2	S	1.6000	45	89	Y	2	8	0	0	0	0	2	8
71-7	2	S	1.6000	45	90	Y	8	5	0	0	0	0	8	5
71-7	2	S	1.6000	46	91	Y	2	7	0	0	0	0	5	8
71-7	2	S	1.6000	46	92	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	2	S	1.6000	47	93	Y	5	8	0	0	0	2	5	9
71-7	2	S	1.6000	47	94	Y	7	4	0	0	0	0	7	5
71-7	2	S	1.6000	48	95	Y	4	7	0	0	0	0	5	7
71-7	2	S	1.6000	48	96	Y	5	3	1	0	2	0	7	6
71-7	2	S	1.6000	49	97	Y	5	8	0	0	0	0	5	8
71-7	2	S	1.6000	49	98	Y	8	8	0	0	1	0	8	9
71-7	2	S	1.6000	50	99	Y	4	10	0	0	0	1	4	10
71-7	2	S	1.6000	50	100	Y	1	3	1	1	0	0	5	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	2	S	.0002	11	21	Y	3	0	0	0	0	0	5	5
TEM7	2	S	.0002	11	22	Y	3	2	0	0	3	2	10	3
TEM7	2	S	.0002	12	23	Y	3	6	3	5	0	0	5	6
TEM7	2	S	.0002	12	24	Y	2	5	2	4	0	0	2	10
TEM7	2	S	.0002	13	25	Y	3	6	3	5	0	1	5	8
TEM7	2	S	.0002	13	26	Y	2	3	0	0	0	0	4	7
TEM7	2	S	.0002	14	27	Y	2	7	2	7	0	0	5	8
TEM7	2	S	.0002	14	28	Y	5	6	4	6	0	0	5	7
TEM7	2	S	.0002	15	29	Y	7	2	0	0	7	2	8	5
TEM7	2	S	.0002	15	30	Y	2	5	2	5	0	0	4	7
TEM7	2	S	.0002	16	31	Y	5	4	5	3	0	0	5	5
TEM7	2	S	.0002	16	32	Y	4	0	3	0	0	0	7	4
TEM7	2	S	.0002	17	33	Y	1	3	0	2	0	0	2	8
TEM7	2	S	.0002	17	34	Y	4	0	0	0	4	0	8	6
TEM7	2	S	.0002	18	35	Y	6	6	0	4	1	0	7	6
TEM7	2	S	.0002	18	36	Y	5	5	3	0	2	5	5	8
TEM7	2	S	.0002	19	37	Y	0	1	0	0	0	1	6	4
TEM7	2	S	.0002	19	38	Y	6	3	0	0	0	0	8	5
TEM7	2	S	.0002	20	39	Y	4	0	4	0	0	0	5	5
TEM7	2	S	.0002	20	40	Y	3	5	1	3	1	1	8	7
CNTRL7	2	M	0.0000	1	1	Y	9	7	0	0	0	0	9	9
CNTRL7	2	M	0.0000	1	2	Y	5	8	1	1	0	0	5	8
CNTRL7	2	M	0.0000	2	3	Y	5	0	0	0	0	0	5	7
CNTRL7	2	M	0.0000	2	4	Y	6	9	0	0	1	0	6	9
CNTRL7	2	M	0.0000	3	5	Y	5	9	0	0	0	3	5	9
CNTRL7	2	M	0.0000	3	6	Y	6	7	0	0	0	0	6	7
CNTRL7	2	M	0.0000	4	7	Y	5	8	0	0	0	0	5	8
CNTRL7	2	M	0.0000	4	8	Y	5	6	0	0	0	0	6	6
CNTRL7	2	M	0.0000	5	9	Y	6	7	0	0	0	0	7	8
CNTRL7	2	M	0.0000	5	10	Y	1	1	0	0	0	1	8	4
CNTRL7	2	M	0.0000	6	11	Y	7	8	0	0	0	0	7	8
CNTRL7	2	M	0.0000	6	12	Y	6	6	0	0	0	0	6	6
CNTRL7	2	M	0.0000	7	13	Y	7	6	0	0	1	0	7	6
CNTRL7	2	M	0.0000	7	14	Y	2	6	1	1	1	3	3	9
CNTRL7	2	M	0.0000	8	15	Y	0	7	0	0	0	0	0	7
CNTRL7	2	M	0.0000	8	16	Y	8	3	0	0	0	0	12	3
CNTRL7	2	M	0.0000	9	17	Y	2	7	0	0	0	0	7	7
CNTRL7	2	M	0.0000	9	18	Y	6	5	0	0	0	0	7	5
CNTRL7	2	M	0.0000	10	19	Y	7	6	0	0	0	0	7	6
CNTRL7	2	M	0.0000	10	20	Y	6	6	1	0	0	0	6	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	2	M	.0300	11	21	Y	5	10	0	0	0	0	5	10
71-7	2	M	.0300	11	22	Y	6	8	0	0	2	5	6	8
71-7	2	M	.0300	12	23	Y	9	5	0	0	3	0	9	5
71-7	2	M	.0300	12	24	Y	8	5	0	2	2	0	8	8
71-7	2	M	.0300	13	25	Y	4	7	0	0	0	0	5	7
71-7	2	M	.0300	13	26	Y	2	1	2	1	0	0	9	3
71-7	2	M	.0300	14	27	Y	2	0	0	0	0	0	8	6
71-7	2	M	.0300	14	28	Y	5	9	0	0	0	0	5	9
71-7	2	M	.0300	15	29	Y	10	4	0	0	0	0	10	4
71-7	2	M	.0300	15	30	Y	4	7	0	2	0	0	5	7
71-7	2	M	.0300	16	31	Y	6	4	0	0	0	0	7	4
71-7	2	M	.0300	16	32	Y	7	8	0	0	0	0	8	8
71-7	2	M	.0300	17	33	Y	7	2	0	1	0	0	7	3
71-7	2	M	.0300	17	34	Y	7	6	0	0	0	0	7	6
71-7	2	M	.0300	16	35	Y	5	9	0	0	0	0	5	9
71-7	2	M	.0300	18	36	Y	8	4	1	0	0	0	8	4
71-7	2	M	.0300	19	37	Y	6	6	0	0	0	0	7	7
71-7	2	M	.0300	19	38	Y	6	6	0	0	1	1	6	7
71-7	2	M	.0300	20	39	Y	7	4	0	0	0	0	7	4
71-7	2	M	.0300	20	40	Y	7	6	0	0	1	3	8	6
71-7	2	M	.8000	21	41	Y	4	3	1	0	0	0	4	7
71-7	2	M	.8000	21	42	Y	4	8	0	0	0	0	4	8
71-7	2	M	.8000	22	43	Y	2	3	0	0	0	0	3	10
71-7	2	M	.8000	22	44	Y	4	9	0	0	0	0	4	9
71-7	2	M	.8000	23	45	Y	6	6	0	0	0	0	6	6
71-7	2	M	.8000	23	46	Y	7	7	1	1	0	0	7	8
71-7	2	M	.8000	24	47	Y	3	10	0	0	0	0	3	11
71-7	2	M	.8000	24	48	Y	6	7	0	1	0	0	6	8
71-7	2	M	.8000	25	49	Y	4	8	0	0	0	0	4	8
71-7	2	M	.8000	25	50	Y	3	10	0	0	0	1	3	10
71-7	2	M	.8000	25	51	Y	6	7	0	0	0	0	6	7
71-7	2	M	.8000	24	52	Y	3	9	0	0	0	0	3	9
71-7	2	M	.8000	27	53	Y	6	7	0	0	0	0	8	8
71-7	2	M	.8000	27	54	Y	2	10	0	1	0	0	2	10
71-7	2	M	.8000	28	55	Y	5	8	0	0	0	0	6	8
71-7	2	M	.8000	28	56	Y	6	8	0	2	0	0	8	9
71-7	2	M	.8000	29	57	Y	7	4	0	0	0	0	8	5
71-7	2	M	.8000	29	58	Y	7	5	0	0	0	0	7	6
71-7	2	M	.8000	30	59	Y	5	6	1	0	0	0	5	6
71-7	2	M	.8000	30	60	Y	6	9	1	1	0	0	6	9

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-7 SODIUM NITRATE

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	2	M	1.6000	31	61	Y	9	7	0	0	0	0	9	7
71-7	2	M	1.6000	31	62	Y	6	7	1	0	0	0	6	7
71-7	2	M	1.6000	32	63	Y	5	8	0	0	0	0	6	8
71-7	2	M	1.6000	32	64	Y	7	7	0	0	1	0	7	7
71-7	2	M	1.6000	33	65	Y	2	0	0	0	0	0	7	5
71-7	2	M	1.6000	33	66	Y	4	10	0	0	0	0	4	11
71-7	2	M	1.6000	34	67	Y	4	6	0	1	0	0	8	6
71-7	2	M	1.6000	34	68	Y	7	7	0	0	0	0	7	7
71-7	2	M	1.6000	35	69	Y	4	1	0	0	0	0	4	8
71-7	2	M	1.6000	35	70	Y	4	9	0	0	0	1	6	9
71-7	2	M	1.6000	36	71	Y	7	6	0	0	0	0	7	7
71-7	2	M	1.6000	36	72	Y	5	10	0	0	0	0	7	10
71-7	2	M	1.6000	37	73	Y	1	1	0	1	0	0	6	5
71-7	2	M	1.6000	37	74	Y	8	6	0	0	0	0	8	7
71-7	2	M	1.6000	38	75	Y	9	4	2	0	1	1	9	5
71-7	2	M	1.6000	38	76	Y	10	7	2	0	2	1	10	7
71-7	2	M	1.6000	39	77	Y	0	3	0	2	0	0	6	7
71-7	2	M	1.6000	39	78	Y	6	7	0	0	0	0	6	8
71-7	2	M	1.6000	40	79	Y	6	7	0	1	0	0	7	7
71-7	2	M	1.6000	40	80	Y	5	7	0	0	0	0	6	7

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	3	S	0.0000	1	1	Y	7	3	0	0	1	0	8	3
CNTRL7	3	S	0.0000	1	2	Y	0	11	0	0	0	0	3	11
CNTRL7	3	S	0.0000	2	3	Y	7	7	1	1	0	0	7	7
CNTRL7	3	S	0.0000	2	4	Y	8	6	1	0	0	0	8	6
CNTRL7	3	S	0.0000	3	5	Y	7	7	0	0	1	0	7	9
CNTRL7	3	S	0.0000	3	6	Y	4	8	0	0	1	2	5	9
CNTRL7	3	S	0.0000	4	7	Y	6	8	0	0	0	0	6	9
CNTRL7	3	S	0.0000	4	8	Y	5	8	0	0	0	1	5	10
CNTRL7	3	S	0.0000	5	9	Y	4	8	0	0	0	0	5	8
CNTRL7	3	S	0.0000	5	10	Y	7	5	0	7	0	0	7	5
CNTRL7	3	S	0.0000	6	11	Y	2	9	0	0	0	0	2	11
CNTRL7	3	S	0.0000	6	12	Y	8	7	0	0	0	0	8	7
CNTRL7	3	S	0.0000	7	13	Y	5	7	0	0	0	2	6	8
CNTRL7	3	S	0.0000	7	14	Y	8	3	0	0	0	1	9	4
CNTRL7	3	S	0.0000	8	15	Y	6	5	0	0	1	0	6	5
CNTRL7	3	S	0.0000	8	16	Y	3	7	1	0	0	1	4	9
CNTRL7	3	S	0.0000	9	17	Y	8	6	0	1	0	0	8	6
CNTRL7	3	S	0.0000	9	18	Y	8	4	1	0	0	0	9	4
CNTRL7	3	S	0.0000	10	19	Y	1	7	0	0	0	0	5	7
CNTRL7	3	S	0.0000	10	20	Y	6	9	0	0	0	1	7	9
71-7	3	S	.0300	21	41	Y	3	8	0	0	0	0	3	9
71-7	3	S	.0300	21	42	Y	5	5	0	0	0	0	6	5
71-7	3	S	.0300	22	43	Y	6	3	0	0	1	0	6	7
71-7	3	S	.0300	22	44	Y	8	5	0	0	1	1	8	6
71-7	3	S	.0300	23	45	Y	9	4	1	0	1	0	9	6
71-7	3	S	.0300	23	46	Y	8	5	0	0	0	0	9	6
71-7	3	S	.0300	24	47	Y	6	5	0	0	0	0	9	5
71-7	3	S	.0300	24	48	Y	4	7	0	0	0	0	5	9
71-7	3	S	.0300	25	49	Y	6	7	0	0	0	0	6	7
71-7	3	S	.0300	25	50	Y	5	9	0	0	1	0	5	9
71-7	3	S	.0300	26	51	Y	4	10	0	0	0	0	4	10
71-7	3	S	.0300	26	52	Y	0	6	0	0	0	2	7	11
71-7	3	S	.0300	27	53	Y	9	5	0	0	0	0	9	6
71-7	3	S	.0300	27	54	Y	3	8	0	0	0	0	3	8
71-7	3	S	.0300	28	55	Y	7	6	0	0	0	1	7	6
71-7	3	S	.0300	28	56	Y	7	8	0	0	0	1	7	9
71-7	3	S	.0300	29	57	Y	5	6	1	0	1	1	6	8
71-7	3	S	.0300	29	58	Y	3	8	1	0	0	0	3	8
71-7	3	S	.0300	30	59	Y	3	9	0	0	0	0	3	11
71-7	3	S	.0300	30	60	Y	5	8	2	2	0	0	5	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	3	S	.8000	31	61	Y	5	7	0	1	0	0	5	8
71-7	3	S	.8000	31	62	Y	7	7	0	0	0	0	8	7
71-7	3	S	.8000	32	63	Y	7	3	0	0	0	0	7	6
71-7	3	S	.8000	32	64	Y	8	3	0	0	0	0	8	6
71-7	3	S	.8000	33	65	Y	4	6	0	0	0	0	5	7
71-7	3	S	.8000	33	66	Y	6	8	0	2	0	0	6	8
71-7	3	S	.8000	34	67	Y	1	0	1	0	0	0	6	5
71-7	3	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	S	.8000	35	69	Y	6	8	0	0	0	0	6	9
71-7	3	S	.8000	35	70	Y	2	10	0	0	0	0	2	12
71-7	3	S	.8000	36	71	Y	5	9	0	0	0	1	5	11
71-7	3	S	.8000	36	72	Y	5	6	0	0	0	0	5	7
71-7	3	S	.8000	37	73	Y	9	5	0	0	0	0	9	7
71-7	3	S	.8000	37	74	Y	7	6	0	0	0	0	7	6
71-7	3	S	.8000	38	75	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	S	.8000	38	76	Y	5	7	0	0	0	1	5	7
71-7	3	S	.8000	39	77	Y	8	5	0	0	0	0	8	5
71-7	3	S	.8000	39	78	Y	9	6	0	0	0	0	10	6
71-7	3	S	.8000	40	79	Y	4	10	0	1	0	0	4	11
71-7	3	S	.8000	40	80	Y	5	7	0	1	0	2	7	7
71-7	3	S	1.6000	41	81	Y	5	4	1	0	0	0	5	6
71-7	3	S	1.6000	41	82	Y	6	8	0	1	0	0	6	8
71-7	3	S	1.6000	42	83	Y	5	10	0	3	0	0	6	10
71-7	3	S	1.6000	42	84	Y	6	7	0	0	0	0	7	8
71-7	3	S	1.6000	43	85	Y	8	4	0	1	0	0	10	4
71-7	3	S	1.6000	43	86	Y	7	1	0	0	0	0	7	6
71-7	3	S	1.6000	44	87	Y	7	7	0	0	0	0	7	7
71-7	3	S	1.6000	44	88	Y	9	5	0	0	0	0	9	5
71-7	3	S	1.6000	45	89	Y	5	7	0	0	0	0	6	9
71-7	3	S	1.6000	45	90	Y	4	9	0	0	0	0	4	9
71-7	3	S	1.6000	46	91	Y	7	6	0	0	0	0	7	6
71-7	3	S	1.6000	46	92	Y	3	5	0	0	0	0	10	6
71-7	3	S	1.6000	47	93	Y	5	5	0	1	1	1	7	6
71-7	3	S	1.6000	47	94	Y	9	8	1	0	0	0	9	8
71-7	3	S	1.6000	48	95	Y	9	6	3	0	0	0	9	6
71-7	3	S	1.6000	48	96	Y	4	6	0	0	1	0	6	8
71-7	3	S	1.6000	49	97	Y	7	6	0	0	0	0	8	7
71-7	3	S	1.6000	49	98	Y	8	6	0	0	0	0	8	6
71-7	3	S	1.6000	50	99	Y	3	7	0	0	0	0	4	10
71-7	3	S	1.6000	50	100	Y	8	3	1	0	0	0	8	3

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	3	S	.0002	11	21	Y	3	1	3	1	0	0	6	6
TEM7	3	S	.0002	11	22	Y	1	3	1	3	0	0	3	8
TEM7	3	S	.0002	12	23	Y	4	4	4	4	0	0	6	5
TEM7	3	S	.0002	12	24	Y	3	5	3	5	0	0	4	8
TEM7	3	S	.0002	13	25	Y	1	2	1	2	0	0	8	4
TEM7	3	S	.0002	13	26	Y	2	6	2	4	0	0	4	10
TEM7	3	S	.0002	14	27	Y	3	4	2	4	0	0	6	8
TEM7	3	S	.0002	14	28	Y	6	5	4	3	0	1	6	6
TEM7	3	S	.0002	15	29	Y	8	4	8	0	0	3	9	6
TEM7	3	S	.0002	15	30	Y	2	4	1	4	0	0	3	8
TEM7	3	S	.0002	16	31	Y	4	7	4	7	0	0	6	8
TEM7	3	S	.0002	16	32	Y	0	4	0	3	0	0	6	7
TEM7	3	S	.0002	17	33	Y	5	4	0	0	5	4	6	6
TEM7	3	S	.0002	17	34	Y	7	8	7	6	0	0	7	10
TEM7	3	S	.0002	18	35	Y	3	6	2	5	0	0	9	6
TEM7	3	S	.0002	18	36	Y	6	6	6	5	0	0	8	7
TEM7	3	S	.0002	19	37	Y	6	5	6	5	0	0	7	5
TEM7	3	S	.0002	19	38	Y	3	2	0	0	0	0	6	7
TEM7	3	S	.0002	20	39	Y	4	4	4	4	0	0	6	7
TEM7	3	S	.0002	20	40	Y	7	5	7	4	0	0	7	5
CNTRL7	3	M	0.0000	1	1	Y	7	3	0	0	1	0	8	3
CNTRL7	3	M	0.0000	1	2	Y	0	11	0	0	0	0	3	11
CNTRL7	3	M	0.0000	2	3	Y	7	7	1	1	0	0	7	7
CNTRL7	3	M	0.0000	2	4	Y	8	6	1	0	0	0	8	6
CNTRL7	3	M	0.0000	3	5	Y	7	7	0	0	1	0	7	9
CNTRL7	3	M	0.0000	3	6	Y	4	8	0	0	1	2	5	9
CNTRL7	3	M	0.0000	4	7	Y	6	8	0	0	0	0	6	9
CNTRL7	3	M	0.0000	4	8	Y	5	8	0	0	0	1	5	10
CNTRL7	3	M	0.0000	5	9	Y	4	8	0	0	0	0	5	8
CNTRL7	3	M	0.0000	5	10	Y	7	5	0	7	0	0	7	5
CNTRL7	3	M	0.0000	6	11	Y	2	9	0	0	0	0	2	11
CNTRL7	3	M	0.0000	6	12	Y	8	7	0	0	0	0	8	7
CNTRL7	3	M	0.0000	7	13	Y	5	7	0	0	0	2	6	8
CNTRL7	3	M	0.0000	7	14	Y	8	3	0	0	0	1	9	4
CNTRL7	3	M	0.0000	8	15	Y	6	5	0	0	1	0	6	5
CNTRL7	3	M	0.0000	8	16	Y	3	7	1	0	0	1	4	9
CNTRL7	3	M	0.0000	9	17	Y	8	6	0	1	0	0	8	6
CNTRL7	3	M	0.0000	9	18	Y	8	4	1	0	0	0	9	4
CNTRL7	3	M	0.0000	10	19	Y	1	7	0	0	0	0	5	7
CNTRL7	3	M	0.0000	10	20	Y	6	9	0	0	0	1	7	9

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	3	M	.0300	11	21	Y	4	8	0	0	0	0	5	10
71-7	3	M	.0300	11	22	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	.0300	12	23	Y	5	8	0	0	0	0	5	9
71-7	3	M	.0300	12	24	Y	9	6	0	0	2	1	9	6
71-7	3	M	.0300	13	25	Y	8	4	0	0	1	0	9	4
71-7	3	M	.0300	13	26	Y	4	6	0	1	0	0	4	6
71-7	3	M	.0300	14	27	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	.0300	14	28	Y	9	6	0	0	0	0	9	6
71-7	3	M	.0300	15	29	Y	5	2	0	0	2	0	6	4
71-7	3	M	.0300	15	30	Y	4	8	0	0	0	0	5	8
71-7	3	M	.0300	16	31	Y	6	6	0	0	0	0	6	6
71-7	3	M	.0300	16	32	Y	4	9	0	0	0	1	4	9
71-7	3	M	.0300	17	33	Y	7	6	0	0	0	0	7	6
71-7	3	M	.0300	17	34	Y	5	8	0	0	0	0	5	8
71-7	3	M	.0300	18	35	Y	5	8	0	0	0	0	6	8
71-7	3	M	.0300	18	36	Y	10	6	0	0	0	0	10	6
71-7	3	M	.0300	19	37	Y	8	6	0	0	0	0	8	6
71-7	3	M	.0300	19	38	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	.0300	20	39	Y	8	8	0	0	0	2	8	8
71-7	3	M	.0300	20	40	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	.8000	21	41	Y	7	5	0	0	1	0	8	5
71-7	3	M	.8000	21	42	Y	6	6	0	0	0	0	6	8
71-7	3	M	.8000	22	43	Y	6	3	0	1	0	0	7	7
71-7	3	M	.8000	22	44	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	.8000	23	45	Y	6	8	1	0	0	0	6	8
71-7	3	M	.8000	23	46	Y	9	4	0	0	1	1	9	4
71-7	3	M	.8000	24	47	Y	8	8	1	0	0	0	8	8
71-7	3	M	.8000	24	48	Y	4	9	0	0	0	0	4	9
71-7	3	M	.8000	25	49	Y	7	5	0	0	0	1	7	5
71-7	3	M	.8000	25	50	Y	5	7	0	0	1	1	9	7
71-7	3	M	.8000	25	51	Y	7	5	0	0	0	0	7	6
71-7	3	M	.8000	24	52	Y	5	5	1	0	0	0	5	5
71-7	3	M	.8000	27	53	Y	6	6	0	0	1	1	6	8
71-7	3	M	.8000	27	54	Y	5	2	0	1	0	0	5	6
71-7	3	M	.8000	28	55	Y	6	7	0	0	0	0	6	7
71-7	3	M	.8000	28	56	Y	8	4	0	0	0	0	8	4
71-7	3	M	.8000	29	57	Y	5	7	0	0	1	0	5	7
71-7	3	M	.8000	29	58	Y	7	5	0	0	0	0	8	5
71-7	3	M	.8000	30	59	Y	6	6	0	1	0	0	7	7
71-7	3	M	.8000	30	60	Y	0	8	0	0	0	1	5	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	3	M	1.6000	31	61	Y	8	4	0	0	0	0	9	4
71-7	3	M	1.6000	31	62	Y	5	9	0	0	0	0	5	9
71-7	3	M	1.6000	32	63	Y	3	9	0	0	0	0	3	9
71-7	3	M	1.6000	32	64	Y	5	8	0	0	0	0	5	9
71-7	3	M	1.6000	33	65	Y	7	5	0	0	2	0	8	6
71-7	3	M	1.6000	33	66	Y	5	7	0	1	0	0	5	9
71-7	3	M	1.6000	34	67	Y	7	6	0	0	0	0	7	6
71-7	3	M	1.6000	34	68	Y	5	6	0	0	1	0	6	10
71-7	3	M	1.6000	35	69	Y	7	6	0	0	1	1	7	6
71-7	3	M	1.6000	35	70	Y	1	7	0	0	0	1	5	12
71-7	3	M	1.6000	36	71	Y	10	3	0	0	0	0	10	3
71-7	3	M	1.6000	36	72	Y	6	8	0	0	0	0	6	8
71-7	3	M	1.6000	37	73	Y	5	7	0	0	0	0	5	8
71-7	3	M	1.6000	37	74	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	3	M	1.6000	38	75	Y	3	7	0	0	0	0	3	10
71-7	3	M	1.6000	38	76	Y	1	0	1	0	0	0	2	6
71-7	3	M	1.6000	39	77	Y	4	6	1	0	0	0	5	8
71-7	3	M	1.6000	39	78	Y	4	6	0	0	0	0	4	6
71-7	3	M	1.6000	40	79	Y	4	7	0	0	0	0	5	8
71-7	3	M	1.6000	40	80	Y	3	1	2	0	0	0	9	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	4	S	0.0000	1	1	Y	5	8	0	0	0	0	5	8
CNTRL7	4	S	0.0000	1	2	Y	4	8	0	0	0	1	4	8
CNTRL7	4	S	0.0000	2	3	Y	8	6	0	0	2	3	8	6
CNTRL7	4	S	0.0000	2	4	Y	5	6	0	0	0	0	5	10
CNTRL7	4	S	0.0000	3	5	Y	8	7	0	0	0	0	8	7
CNTRL7	4	S	0.0000	3	6	Y	4	7	0	0	0	0	4	9
CNTRL7	4	S	0.0000	4	7	Y	8	9	0	0	0	0	8	9
CNTRL7	4	S	0.0000	4	8	Y	4	11	0	0	0	1	4	11
CNTRL7	4	S	0.0000	5	9	Y	5	7	0	0	1	0	5	7
CNTRL7	4	S	0.0000	5	10	Y	6	7	0	0	1	3	6	7
CNTRL7	4	S	0.0000	6	11	Y	2	7	1	1	0	2	6	10
CNTRL7	4	S	0.0000	6	12	Y	5	8	0	0	0	0	5	8
CNTRL7	4	S	0.0000	7	13	Y	5	9	0	0	1	1	5	9
CNTRL7	4	S	0.0000	7	14	Y	5	7	0	1	0	0	6	10
CNTRL7	4	S	0.0000	8	15	Y	8	6	0	0	0	0	8	6
CNTRL7	4	S	0.0000	8	16	Y	3	8	1	1	0	0	4	9
CNTRL7	4	S	0.0000	9	17	Y	5	7	0	0	0	0	6	7
CNTRL7	4	S	0.0000	9	18	Y	5	4	0	0	0	0	5	6
CNTRL7	4	S	0.0000	10	19	Y	6	10	0	0	0	0	7	10
CNTRL7	4	S	0.0000	10	20	Y	5	8	0	0	0	0	5	8
71-7	4	S	.0300	21	41	Y	11	2	0	0	0	0	11	2
71-7	4	S	.0300	21	42	Y	6	6	0	0	0	0	7	8
71-7	4	S	.0300	22	43	Y	7	5	0	0	0	0	8	5
71-7	4	S	.0300	22	44	Y	9	5	0	0	0	0	10	6
71-7	4	S	.0300	23	45	Y	7	4	0	0	0	0	8	5
71-7	4	S	.0300	23	46	Y	5	11	0	0	0	0	5	12
71-7	4	S	.0300	24	47	Y	5	6	0	0	0	0	6	7
71-7	4	S	.0300	24	48	Y	5	8	0	2	0	0	6	8
71-7	4	S	.0300	25	49	Y	10	2	0	0	1	0	11	2
71-7	4	S	.0300	25	50	Y	8	7	1	0	0	0	8	7
71-7	4	S	.0300	26	51	Y	5	7	0	1	0	0	5	7
71-7	4	S	.0300	26	52	Y	4	9	0	0	0	0	5	11
71-7	4	S	.0300	27	53	Y	4	8	0	0	0	0	5	8
71-7	4	S	.0300	27	54	Y	3	11	0	0	0	0	3	11
71-7	4	S	.0300	28	55	Y	4	7	0	0	0	0	7	7
71-7	4	S	.0300	28	56	Y	9	5	0	0	0	0	9	5
71-7	4	S	.0300	29	57	Y	5	7	0	0	0	0	6	7
71-7	4	S	.0300	29	58	Y	7	6	0	0	0	0	7	6
71-7	4	S	.0300	30	59	Y	7	5	0	0	0	0	7	5
71-7	4	S	.0300	30	60	Y	8	6	0	0	0	0	8	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	4	S	.8000	31	61	Y	8	7	0	0	1	0	8	7
71-7	4	S	.8000	31	62	Y	4	9	0	0	0	0	5	9
71-7	4	S	.8000	32	63	Y	8	4	0	0	0	0	8	4
71-7	4	S	.8000	32	64	Y	5	7	0	0	0	0	5	7
71-7	4	S	.8000	33	65	Y	6	7	0	0	0	1	9	7
71-7	4	S	.8000	33	66	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	.8000	35	69	Y	3	10	0	0	0	0	3	10
71-7	4	S	.8000	35	70	Y	7	6	1	0	0	0	8	6
71-7	4	S	.8000	36	71	Y	7	7	0	0	0	0	7	7
71-7	4	S	.8000	36	72	Y	9	5	0	1	0	0	9	5
71-7	4	S	.8000	37	73	Y	10	7	0	0	0	0	10	7
71-7	4	S	.8000	37	74	Y	5	8	0	0	0	0	5	8
71-7	4	S	.8000	38	75	Y	9	1	0	0	4	0	9	5
71-7	4	S	.8000	38	76	Y	7	5	0	0	0	0	7	5
71-7	4	S	.8000	39	77	Y	8	5	0	0	0	0	9	6
71-7	4	S	.8000	39	78	Y	5	7	0	0	0	1	5	7
71-7	4	S	.8000	40	79	Y	5	7	0	0	0	0	6	7
71-7	4	S	.8000	40	80	Y	7	5	0	0	0	3	9	6
71-7	4	S	1.6000	41	81	Y	8	4	0	0	0	0	8	4
71-7	4	S	1.6000	41	82	Y	8	5	0	0	0	0	9	6
71-7	4	S	1.6000	42	83	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	1.6000	42	84	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	1.6000	43	85	Y	6	4	0	0	0	0	7	4
71-7	4	S	1.6000	43	86	Y	6	6	0	0	0	0	6	7
71-7	4	S	1.6000	44	87	Y	7	4	0	0	0	0	7	4
71-7	4	S	1.6000	44	88	Y	7	2	0	0	0	0	7	2
71-7	4	S	1.6000	45	89	Y	7	4	0	0	0	0	7	4
71-7	4	S	1.6000	45	90	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	1.6000	46	91	Y	7	7	0	0	1	1	7	8
71-7	4	S	1.6000	46	92	Y	7	8	0	0	0	1	7	8
71-7	4	S	1.6000	47	93	Y	4	5	0	0	0	0	4	9
71-7	4	S	1.6000	47	94	Y	8	7	1	0	0	0	8	7
71-7	4	S	1.6000	48	95	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	S	1.6000	48	96	Y	7	8	0	0	0	0	7	8
71-7	4	S	1.6000	49	97	Y	6	5	0	0	0	0	8	5
71-7	4	S	1.6000	49	98	Y	6	7	0	0	0	2	8	7
71-7	4	S	1.6000	50	99	Y	5	9	0	0	0	0	5	10
71-7	4	S	1.6000	50	100	Y	9	5	0	0	0	2	9	5

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	4	S	.0002	11	21	Y	5	2	0	0	3	2	10	8
TEM7	4	S	.0002	11	22	Y	2	1	2	1	0	0	8	3
TEM7	4	S	.0002	12	23	Y	4	7	1	1	0	0	4	8
TEM7	4	S	.0002	12	24	Y	1	5	1	5	0	0	7	6
TEM7	4	S	.0002	13	25	Y	5	2	0	0	5	2	7	4
TEM7	4	S	.0002	13	26	Y	4	5	4	5	0	0	5	7
TEM7	4	S	.0002	14	27	Y	4	4	4	4	0	0	4	7
TEM7	4	S	.0002	14	28	Y	4	4	4	4	0	0	5	6
TEM7	4	S	.0002	15	29	Y	2	3	0	2	2	1	7	5
TEM7	4	S	.0002	15	30	Y	2	4	0	0	0	0	6	7
TEM7	4	S	.0002	16	31	Y	3	3	3	3	0	0	7	9
TEM7	4	S	.0002	16	32	Y	2	4	2	4	0	0	7	6
TEM7	4	S	.0002	17	33	Y	3	3	0	0	3	3	7	7
TEM7	4	S	.0002	17	34	Y	3	4	0	0	3	4	5	8
TEM7	4	S	.0002	18	35	Y	1	4	1	4	0	0	5	9
TEM7	4	S	.0002	18	36	Y	2	7	2	6	0	0	3	11
TEM7	4	S	.0002	19	37	Y	6	5	0	0	3	3	6	5
TEM7	4	S	.0002	19	38	Y	2	0	2	0	0	0	8	7
TEM7	4	S	.0002	20	39	Y	1	0	0	0	1	0	9	12
TEM7	4	S	.0002	20	40	Y	6	2	1	0	5	2	6	7
CNTRL7	4	M	0.0000	1	1	Y	5	8	0	0	0	0	5	8
CNTRL7	4	M	0.0000	1	2	Y	4	8	0	0	0	1	4	8
CNTRL7	4	M	0.0000	2	3	Y	8	6	0	0	2	3	8	6
CNTRL7	4	M	0.0000	2	4	Y	5	6	0	0	0	0	5	10
CNTRL7	4	M	0.0000	3	5	Y	8	7	0	0	0	0	8	7
CNTRL7	4	M	0.0000	3	6	Y	4	7	0	0	0	0	4	9
CNTRL7	4	M	0.0000	4	7	Y	8	9	0	0	0	0	8	9
CNTRL7	4	M	0.0000	4	8	Y	4	11	0	0	0	1	4	11
CNTRL7	4	M	0.0000	5	9	Y	5	7	0	0	1	0	5	7
CNTRL7	4	M	0.0000	5	10	Y	6	7	0	0	1	3	6	7
CNTRL7	4	M	0.0000	6	11	Y	2	7	1	1	0	2	6	10
CNTRL7	4	M	0.0000	6	12	Y	5	8	0	0	0	0	5	8
CNTRL7	4	M	0.0000	7	13	Y	5	9	0	0	1	1	5	9
CNTRL7	4	M	0.0000	7	14	Y	5	7	0	1	0	0	6	10
CNTRL7	4	M	0.0000	8	15	Y	8	6	0	0	0	0	8	6
CNTRL7	4	M	0.0000	8	16	Y	3	8	1	1	0	0	4	9
CNTRL7	4	M	0.0000	9	17	Y	5	7	0	0	0	0	6	7
CNTRL7	4	M	0.0000	9	18	Y	5	4	0	0	0	0	5	6
CNTRL7	4	M	0.0000	10	19	Y	6	10	0	0	0	0	7	10
CNTRL7	4	M	0.0000	10	20	Y	5	8	0	0	0	0	5	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	4	M	.0300	11	21	Y	6	4	0	0	1	1	7	4
71-7	4	M	.0300	11	22	Y	8	6	0	0	1	0	8	6
71-7	4	M	.0300	12	23	Y	5	5	0	0	0	0	6	5
71-7	4	M	.0300	12	24	Y	6	6	1	0	0	0	6	6
71-7	4	M	.0300	13	25	Y	8	6	0	0	0	0	8	6
71-7	4	M	.0300	13	26	Y	5	8	1	0	0	0	5	8
71-7	4	M	.0300	14	27	Y	2	11	0	0	0	0	2	11
71-7	4	M	.0300	14	28	Y	5	9	0	0	0	0	5	9
71-7	4	M	.0300	15	29	Y	1	0	0	0	0	0	2	0
71-7	4	M	.0300	15	30	Y	3	5	3	3	0	0	4	7
71-7	4	M	.0300	16	31	Y	4	8	1	1	0	0	4	8
71-7	4	M	.0300	16	32	Y	6	6	1	0	0	0	6	6
71-7	4	M	.0300	17	33	Y	12	2	0	0	1	0	12	2
71-7	4	M	.0300	17	34	Y	5	8	0	0	0	0	5	8
71-7	4	M	.0300	18	35	Y	4	8	0	0	0	0	4	9
71-7	4	M	.0300	18	36	Y	6	5	1	0	0	0	6	5
71-7	4	M	.0300	19	37	Y	8	5	0	0	0	0	8	5
71-7	4	M	.0300	19	38	Y	6	6	0	0	0	0	6	6
71-7	4	M	.0300	20	39	Y	6	8	0	1	0	0	7	8
71-7	4	M	.0300	20	40	Y	6	6	0	0	0	0	6	6
71-7	4	M	.8000	21	41	Y	6	9	0	0	0	0	6	9
71-7	4	M	.8000	21	42	Y	8	5	0	0	1	0	8	5
71-7	4	M	.8000	22	43	Y	8	5	0	0	0	0	8	6
71-7	4	M	.8000	22	44	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	M	.8000	23	45	Y	7	4	0	0	1	2	7	4
71-7	4	M	.8000	23	46	Y	6	7	0	0	0	0	6	8
71-7	4	M	.8000	24	47	Y	4	9	0	0	0	0	5	9
71-7	4	M	.8000	24	48	Y	6	6	0	0	0	0	6	8
71-7	4	M	.8000	25	49	Y	6	7	0	0	0	0	6	7
71-7	4	M	.8000	25	50	Y	6	4	0	0	0	0	6	4
71-7	4	M	.8000	25	51	Y	4	10	0	1	0	0	4	11
71-7	4	M	.8000	24	52	Y	4	8	0	0	0	1	5	8
71-7	4	M	.8000	27	53	Y	6	7	0	0	0	0	6	7
71-7	4	M	.8000	27	54	Y	8	6	0	0	0	1	6	8
71-7	4	M	.8000	28	55	Y	3	7	0	0	0	0	3	7
71-7	4	M	.8000	28	56	Y	6	5	0	0	0	0	6	5
71-7	4	M	.8000	29	57	Y	9	2	0	0	0	0	9	2
71-7	4	M	.8000	29	58	Y	8	5	0	0	0	1	8	5
71-7	4	M	.8000	30	59	Y	6	5	0	0	0	0	7	5
71-7	4	M	.8000	30	60	Y	5	7	0	0	0	0	5	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	4	M	1.6000	31	61	Y	1	0	0	0	0	0	7	7
71-7	4	M	1.6000	31	62	Y	3	9	0	0	0	0	3	9
71-7	4	M	1.6000	32	63	Y	8	5	2	0	0	0	8	6
71-7	4	M	1.6000	32	64	Y	4	7	0	0	0	0	5	7
71-7	4	M	1.6000	33	65	Y	8	6	0	0	0	0	9	6
71-7	4	M	1.6000	33	66	Y	5	10	0	0	0	0	5	10
71-7	4	M	1.6000	34	67	Y	6	8	0	0	2	3	6	9
71-7	4	M	1.6000	34	68	Y	7	5	0	0	0	0	7	5
71-7	4	M	1.6000	35	69	Y	6	3	0	0	0	0	6	3
71-7	4	M	1.6000	35	70	Y	0	5	0	0	0	0	6	9
71-7	4	M	1.6000	36	71	Y	6	5	0	0	0	0	7	5
71-7	4	M	1.6000	36	72	Y	7	5	0	1	0	0	7	5
71-7	4	M	1.6000	37	73	Y	10	3	0	0	0	0	10	3
71-7	4	M	1.6000	37	74	Y	5	8	0	0	0	0	5	8
71-7	4	M	1.6000	38	75	Y	5	8	0	1	0	0	5	9
71-7	4	M	1.6000	38	76	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	4	M	1.6000	39	77	Y	12	2	0	0	4	1	12	2
71-7	4	M	1.6000	39	78	Y	5	9	0	0	0	1	5	9
71-7	4	M	1.6000	40	79	Y	7	5	0	0	1	0	7	5
71-7	4	M	1.6000	40	80	Y	10	2	0	0	0	0	12	11

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	5	S	0.0000	1	1	Y	5	3	0	0	0	0	7	4
CNTRL7	5	S	0.0000	1	2	Y	4	8	0	0	0	0	4	8
CNTRL7	5	S	0.0000	2	3	Y	4	8	0	0	0	0	4	8
CNTRL7	5	S	0.0000	2	4	Y	7	4	0	0	0	0	12	8
CNTRL7	5	S	0.0000	3	5	Y	9	3	0	0	0	0	9	3
CNTRL7	5	S	0.0000	3	6	Y	3	11	0	0	0	2	3	12
CNTRL7	5	S	0.0000	4	7	Y	6	4	0	0	1	0	7	4
CNTRL7	5	S	0.0000	4	8	Y	5	5	0	0	0	0	5	5
CNTRL7	5	S	0.0000	5	9	Y	6	8	0	0	0	0	7	13
CNTRL7	5	S	0.0000	5	10	Y	5	7	1	0	1	0	5	7
CNTRL7	5	S	0.0000	6	11	Y	4	7	0	1	0	0	4	7
CNTRL7	5	S	0.0000	6	12	Y	7	6	0	0	0	0	7	6
CNTRL7	5	S	0.0000	7	13	Y	5	5	0	0	0	1	5	7
CNTRL7	5	S	0.0000	7	14	Y	6	6	0	0	0	0	6	6
CNTRL7	5	S	0.0000	8	15	Y	6	5	1	0	0	0	6	7
CNTRL7	5	S	0.0000	8	16	Y	5	8	1	0	0	0	5	8
CNTRL7	5	S	0.0000	9	17	Y	3	7	0	0	0	0	3	7
CNTRL7	5	S	0.0000	9	18	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	5	S	0.0000	10	19	Y	9	4	0	0	0	0	10	4
CNTRL7	5	S	0.0000	10	20	Y	7	8	0	0	0	0	7	8
71-7	5	S	.0300	21	41	Y	5	6	1	0	0	0	5	6
71-7	5	S	.0300	21	42	Y	2	11	0	0	0	0	2	11
71-7	5	S	.0300	22	43	Y	2	3	0	0	0	0	9	6
71-7	5	S	.0300	22	44	Y	5	6	0	0	0	0	5	6
71-7	5	S	.0300	23	45	Y	7	4	0	0	0	0	7	6
71-7	5	S	.0300	23	46	Y	8	4	0	0	0	0	8	5
71-7	5	S	.0300	24	47	Y	3	10	0	0	0	0	3	11
71-7	5	S	.0300	24	48	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	5	S	.0300	25	49	Y	9	1	1	0	0	0	9	1
71-7	5	S	.0300	25	50	Y	4	8	0	0	0	0	4	8
71-7	5	S	.0300	26	51	Y	6	6	0	0	0	0	6	7
71-7	5	S	.0300	26	52	Y	6	6	0	0	0	0	6	7
71-7	5	S	.0300	27	53	Y	1	0	0	0	0	0	2	6
71-7	5	S	.0300	27	54	Y	8	4	1	0	0	0	8	4
71-7	5	S	.0300	28	55	Y	7	8	0	0	0	0	7	8
71-7	5	S	.0300	28	56	Y	5	5	0	0	0	0	7	5
71-7	5	S	.0300	29	57	Y	7	5	0	0	0	0	7	5
71-7	5	S	.0300	29	58	Y	4	10	0	0	0	0	4	10
71-7	5	S	.0300	30	59	Y	6	6	1	0	0	0	6	6
71-7	5	S	.0300	30	60	Y	4	7	0	0	0	0	4	7

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	5	S	.8000	31	61	Y	9	4	0	0	0	0	9	4
71-7	5	S	.8000	31	62	Y	8	5	1	0	0	0	8	5
71-7	5	S	.8000	32	63	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	5	S	.8000	32	64	Y	10	4	0	0	0	0	10	4
71-7	5	S	.8000	33	65	Y	9	6	0	0	0	0	9	6
71-7	5	S	.8000	33	66	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	5	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	5	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	5	S	.8000	35	69	Y	4	6	0	2	0	0	4	7
71-7	5	S	.8000	35	70	Y	3	9	0	0	0	1	3	9
71-7	5	S	.8000	36	71	Y	1	8	0	0	0	1	4	8
71-7	5	S	.8000	36	72	Y	6	5	0	0	3	1	7	6
71-7	5	S	.8000	37	73	Y	7	6	1	0	0	0	7	6
71-7	5	S	.8000	37	74	Y	4	6	0	0	0	0	5	6
71-7	5	S	.8000	38	75	Y	6	6	0	0	0	0	6	6
71-7	5	S	.8000	38	76	Y	2	8	0	0	2	1	4	8
71-7	5	S	.8000	39	77	Y	7	7	0	0	0	0	8	7
71-7	5	S	.8000	39	78	Y	5	7	0	0	0	0	6	7
71-7	5	S	.8000	40	79	Y	5	6	0	0	3	0	7	7
71-7	5	S	.8000	40	80	Y	6	9	0	0	0	0	6	9
71-7	5	S	1.6000	41	81	Y	7	6	1	0	0	0	7	6
71-7	5	S	1.6000	41	82	Y	6	7	0	0	0	0	6	7
71-7	5	S	1.6000	42	83	Y	6	6	1	0	0	0	8	6
71-7	5	S	1.6000	42	84	Y	4	9	0	0	0	0	4	9
71-7	5	S	1.6000	43	85	Y	6	6	0	0	0	0	9	11
71-7	5	S	1.6000	43	86	Y	5	6	0	0	0	0	5	6
71-7	5	S	1.6000	44	87	Y	7	6	0	0	0	0	8	6
71-7	5	S	1.6000	44	88	Y	6	6	0	0	0	0	7	7
71-7	5	S	1.6000	45	89	Y	4	6	0	0	0	1	5	6
71-7	5	S	1.6000	45	90	Y	5	7	0	2	0	0	5	8
71-7	5	S	1.6000	46	91	Y	8	4	0	0	0	0	8	4
71-7	5	S	1.6000	46	92	Y	4	5	0	1	0	0	4	5
71-7	5	S	1.6000	47	93	Y	5	6	0	0	0	0	5	6
71-7	5	S	1.6000	47	94	Y	1	1	1	1	0	0	5	3
71-7	5	S	1.6000	48	95	Y	2	7	0	0	0	0	2	8
71-7	5	S	1.6000	48	96	Y	10	3	0	0	0	1	10	3
71-7	5	S	1.6000	49	97	Y	4	10	0	0	0	0	4	10
71-7	5	S	1.6000	49	98	Y	8	6	1	0	0	0	8	6
71-7	5	S	1.6000	50	99	Y	6	6	0	0	0	0	7	6
71-7	5	S	1.6000	50	100	Y	3	9	0	0	0	0	3	9

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	5	S	.0002	11	21	Y	2	7	0	0	0	3	3	8
TEM7	5	S	.0002	11	22	Y	4	4	1	1	0	3	4	4
TEM7	5	S	.0002	12	23	Y	3	8	0	0	0	0	3	9
TEM7	5	S	.0002	12	24	Y	2	3	2	3	0	0	9	10
TEM7	5	S	.0002	13	25	Y	5	5	2	2	0	0	6	5
TEM7	5	S	.0002	13	26	Y	5	8	0	0	1	0	5	8
TEM7	5	S	.0002	14	27	Y	6	5	2	1	0	7	6	6
TEM7	5	S	.0002	14	28	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM7	5	S	.0002	15	29	Y	7	4	0	0	1	1	7	4
TEM7	5	S	.0002	15	30	Y	6	5	0	0	1	0	6	5
TEM7	5	S	.0002	16	31	Y	4	6	1	3	0	0	4	7
TEM7	5	S	.0002	16	32	Y	6	8	0	2	0	0	6	8
TEM7	5	S	.0002	17	33	Y	3	6	0	2	0	0	3	7
TEM7	5	S	.0002	17	34	Y	5	8	0	0	0	1	5	8
TEM7	5	S	.0002	18	35	Y	6	0	1	0	0	0	6	5
TEM7	5	S	.0002	18	36	Y	0	4	0	0	0	0	8	4
TEM7	5	S	.0002	19	37	Y	8	4	0	0	0	0	8	7
TEM7	5	S	.0002	19	38	Y	5	5	0	0	1	2	5	6
TEM7	5	S	.0002	20	39	Y	0	9	0	0	0	2	3	9
TEM7	5	S	.0002	20	40	Y	3	8	1	0	0	0	3	9
CNTRL7	5	M	0.0000	1	1	Y	5	3	0	0	0	0	7	4
CNTRL7	5	M	0.0000	1	2	Y	4	8	0	0	0	0	4	8
CNTRL7	5	M	0.0000	2	3	Y	4	8	0	0	0	0	4	8
CNTRL7	5	M	0.0000	2	4	Y	7	4	0	0	0	0	12	8
CNTRL7	5	M	0.0000	3	5	Y	9	3	0	0	0	0	9	3
CNTRL7	5	M	0.0000	3	6	Y	3	11	0	0	0	2	3	12
CNTRL7	5	M	0.0000	4	7	Y	6	4	0	0	1	0	7	4
CNTRL7	5	M	0.0000	4	8	Y	5	5	0	0	0	0	5	5
CNTRL7	5	M	0.0000	5	9	Y	6	8	0	0	0	0	7	13
CNTRL7	5	M	0.0000	5	10	Y	5	7	1	0	1	0	5	7
CNTRL7	5	M	0.0000	6	11	Y	4	7	0	1	0	0	4	7
CNTRL7	5	M	0.0000	6	12	Y	7	6	0	0	0	0	7	6
CNTRL7	5	M	0.0000	7	13	Y	5	5	0	0	0	1	5	7
CNTRL7	5	M	0.0000	7	14	Y	6	6	0	0	0	0	6	6
CNTRL7	5	M	0.0000	8	15	Y	6	5	1	0	0	0	6	7
CNTRL7	5	M	0.0000	8	16	Y	5	8	1	0	0	0	5	8
CNTRL7	5	M	0.0000	9	17	Y	3	7	0	0	0	0	3	7
CNTRL7	5	M	0.0000	9	18	N	-0	-0	-0	-0	-0	-0	-0	-0
CNTRL7	5	M	0.0000	10	19	Y	9	4	0	0	0	0	10	4
CNTRL7	5	M	0.0000	10	20	Y	7	8	0	0	0	0	7	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	5	M	.0300	11	21	Y	7	5	0	0	0	0	7	5
71-7	5	M	.0300	11	22	Y	4	6	0	0	1	1	5	6
71-7	5	M	.0300	12	23	Y	8	5	1	0	0	0	8	5
71-7	5	M	.0300	12	24	Y	3	4	1	0	0	0	4	6
71-7	5	M	.0300	13	25	Y	5	8	0	0	0	0	5	8
71-7	5	M	.0300	13	26	Y	6	8	0	0	0	2	6	8
71-7	5	M	.0300	14	27	Y	7	5	0	1	0	0	7	7
71-7	5	M	.0300	14	28	Y	3	6	0	0	0	0	4	6
71-7	5	M	.0300	15	29	Y	5	10	0	0	0	1	5	10
71-7	5	M	.0300	15	30	Y	6	5	0	0	0	0	7	5
71-7	5	M	.0300	16	31	Y	3	6	0	1	0	0	3	8
71-7	5	M	.0300	16	32	Y	6	6	1	0	0	0	6	6
71-7	5	M	.0300	17	33	Y	10	4	0	0	0	1	10	4
71-7	5	M	.0300	17	34	Y	4	6	0	0	0	0	4	6
71-7	5	M	.0300	18	35	Y	8	6	2	0	0	0	9	6
71-7	5	M	.0300	18	36	Y	3	12	0	0	0	0	3	13
71-7	5	M	.0300	19	37	Y	8	6	0	0	0	1	8	6
71-7	5	M	.0300	19	38	Y	5	4	0	0	0	0	7	6
71-7	5	M	.0300	20	39	Y	8	6	0	2	0	0	8	6
71-7	5	M	.0300	20	40	Y	4	8	0	1	1	0	4	9
71-7	5	M	.8000	21	41	Y	0	12	0	0	0	5	2	12
71-7	5	M	.8000	21	42	Y	6	6	0	0	0	1	6	6
71-7	5	M	.8000	22	43	Y	1	0	0	0	0	0	8	5
71-7	5	M	.8000	22	44	Y	5	7	0	1	0	0	5	9
71-7	5	M	.8000	23	45	Y	4	8	0	0	0	0	4	8
71-7	5	M	.8000	23	46	Y	6	8	0	0	0	0	6	8
71-7	5	M	.8000	24	47	Y	8	6	0	0	0	1	9	7
71-7	5	M	.8000	24	48	Y	6	6	0	0	0	0	6	8
71-7	5	M	.8000	25	49	Y	4	4	0	0	0	0	4	6
71-7	5	M	.8000	25	50	Y	0	3	0	0	0	0	9	7
71-7	5	M	.8000	26	51	Y	4	8	1	1	0	0	4	8
71-7	5	M	.8000	26	52	Y	4	9	0	0	0	0	4	9
71-7	5	M	.8000	27	53	Y	5	3	0	0	0	0	5	3
71-7	5	M	.8000	27	54	Y	5	4	0	0	0	0	6	4
71-7	5	M	.8000	28	55	Y	6	4	0	0	0	0	7	4
71-7	5	M	.8000	28	56	Y	5	8	0	0	0	0	5	8
71-7	5	M	.8000	29	57	Y	5	7	0	0	0	0	6	8
71-7	5	M	.8000	29	58	Y	4	8	0	0	0	0	4	8
71-7	5	M	.8000	30	59	Y	4	9	0	0	0	0	4	9
71-7	5	M	.8000	30	60	Y	6	4	0	1	0	0	6	4

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	5	M	1.6000	31	61	Y	2	8	0	0	0	0	2	8
71-7	5	M	1.6000	31	62	Y	4	7	0	0	0	0	4	7
71-7	5	M	1.6000	32	63	Y	6	7	0	0	0	0	6	7
71-7	5	M	1.6000	32	64	Y	5	7	0	0	0	0	6	7
71-7	5	M	1.6000	33	65	Y	7	6	0	0	0	0	7	6
71-7	5	M	1.6000	33	66	Y	5	8	0	0	1	0	5	8
71-7	5	M	1.6000	34	67	Y	8	8	0	0	1	1	9	8
71-7	5	M	1.6000	34	68	Y	3	8	0	0	0	0	3	8
71-7	5	M	1.6000	35	69	Y	3	6	0	0	0	0	7	6
71-7	5	M	1.6000	35	70	Y	5	7	0	0	0	0	5	8
71-7	5	M	1.6000	36	71	Y	6	6	2	0	0	0	8	8
71-7	5	M	1.6000	36	72	Y	3	10	1	0	1	0	3	12
71-7	5	M	1.6000	37	73	Y	9	5	0	1	0	1	9	5
71-7	5	M	1.6000	37	74	Y	6	5	0	0	0	0	6	7
71-7	5	M	1.6000	38	75	Y	6	7	0	0	0	1	8	7
71-7	5	M	1.6000	38	76	Y	4	7	0	0	0	1	4	9
71-7	5	M	1.6000	39	77	Y	4	6	0	0	0	0	4	6
71-7	5	M	1.6000	39	78	Y	4	8	0	0	0	0	4	8
71-7	5	M	1.6000	40	79	Y	9	4	0	0	0	0	9	4
71-7	5	M	1.6000	40	80	Y	5	8	0	0	0	0	6	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	6	S	0.0000	1	1	Y	7	2	0	0	0	0	7	2
CNTRL7	6	S	0.0000	1	2	Y	5	7	0	0	0	0	5	7
CNTRL7	6	S	0.0000	2	3	Y	12	4	0	0	1	0	12	4
CNTRL7	6	S	0.0000	2	4	Y	0	6	0	0	0	0	8	6
CNTRL7	6	S	0.0000	3	5	Y	5	8	0	0	0	0	7	8
CNTRL7	6	S	0.0000	3	6	Y	4	7	0	0	1	1	4	8
CNTRL7	6	S	0.0000	4	7	Y	8	5	0	0	0	0	8	5
CNTRL7	6	S	0.0000	4	3	Y	5	7	0	0	0	0	5	7
CNTRL7	6	S	0.0000	5	9	Y	0	7	0	0	0	1	6	7
CNTRL7	6	S	0.0000	5	10	Y	9	3	0	0	0	0	10	3
CNTRL7	6	S	0.0000	6	11	Y	7	5	0	0	0	0	7	5
CNTRL7	6	S	0.0000	6	12	Y	5	7	0	0	0	0	5	7
CNTRL7	6	S	0.0000	7	13	Y	7	6	0	0	5	0	7	6
CNTRL7	6	S	0.0000	7	14	Y	3	6	0	0	0	3	4	6
CNTRL7	6	S	0.0000	8	15	Y	6	8	0	0	0	0	6	8
CNTRL7	6	S	0.0000	8	16	Y	5	7	0	0	0	0	5	7
CNTRL7	6	S	0.0000	9	17	Y	5	7	0	0	0	0	5	8
CNTRL7	6	S	0.0000	9	18	Y	11	5	0	0	0	0	11	5
CNTRL7	6	S	0.0000	10	19	Y	6	8	1	0	0	0	6	9
CNTRL7	6	S	0.0000	10	20	Y	7	5	0	0	0	0	7	5
71-7	6	S	.0300	21	41	Y	6	4	0	0	0	0	7	4
71-7	6	S	.0300	21	42	Y	6	7	0	0	0	0	6	7
71-7	6	S	.0300	22	43	Y	5	7	0	0	0	0	5	7
71-7	6	S	.0300	22	44	Y	6	7	0	0	1	0	6	9
71-7	6	S	.0300	23	45	Y	7	6	0	0	0	0	7	7
71-7	6	S	.0300	23	46	Y	5	5	1	0	0	0	5	6
71-7	6	S	.0300	24	47	Y	3	6	0	1	0	1	5	9
71-7	6	S	.0300	24	48	Y	6	6	0	0	0	0	6	6
71-7	6	S	.0300	25	49	Y	6	6	0	0	0	0	6	6
71-7	6	S	.0300	25	50	Y	6	6	0	0	0	0	6	6
71-7	6	S	.0300	26	51	Y	4	9	0	0	0	0	4	9
71-7	6	S	.0300	26	52	Y	6	5	0	0	0	0	6	5
71-7	6	S	.0300	27	53	Y	5	5	0	0	0	0	5	6
71-7	6	S	.0300	27	54	Y	5	6	0	0	0	0	5	6
71-7	6	S	.0300	28	55	Y	8	7	0	0	1	2	8	7
71-7	6	S	.0300	28	56	Y	5	7	0	0	0	0	5	7
71-7	6	S	.0300	29	57	Y	6	8	0	0	0	0	6	8
71-7	6	S	.0300	29	58	Y	9	5	0	1	0	0	9	6
71-7	6	S	.0300	30	59	Y	9	5	0	1	0	0	9	5
71-7	6	S	.0300	30	60	Y	6	5	0	0	0	1	6	5

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	6	S	.8000	31	61	Y	9	3	0	0	0	0	9	3
71-7	6	S	.8000	31	62	Y	8	6	1	1	0	0	9	6
71-7	6	S	.8000	32	63	Y	5	8	1	0	0	0	8	11
71-7	6	S	.8000	32	64	Y	3	6	0	1	0	0	4	9
71-7	6	S	.8000	33	65	Y	6	5	0	0	0	0	6	5
71-7	6	S	.8000	33	66	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	.8000	35	69	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	.8000	35	70	Y	5	8	0	0	0	0	5	8
71-7	6	S	.8000	36	71	Y	7	5	0	0	0	0	8	5
71-7	6	S	.8000	36	72	Y	6	6	0	0	0	0	7	8
71-7	6	S	.8000	37	73	Y	6	7	0	0	0	0	6	7
71-7	6	S	.8000	37	74	Y	6	6	0	1	0	0	6	6
71-7	6	S	.8000	38	75	Y	9	5	1	0	0	0	9	6
71-7	6	S	.8000	38	76	Y	6	5	0	0	0	0	6	6
71-7	6	S	.8000	39	77	Y	7	4	0	0	0	0	8	4
71-7	6	S	.8000	39	78	Y	3	6	0	0	0	0	3	9
71-7	6	S	.8000	40	79	Y	7	7	0	0	0	0	7	7
71-7	6	S	.8000	40	80	Y	6	5	0	1	0	0	7	6
71-7	6	S	1.6000	41	81	Y	6	4	0	0	1	0	6	5
71-7	6	S	1.6000	41	82	Y	9	5	0	0	0	0	9	5
71-7	6	S	1.6000	42	83	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	1.6000	42	84	Y	4	6	0	0	0	0	4	6
71-7	6	S	1.6000	43	85	Y	2	2	0	0	0	0	5	8
71-7	6	S	1.6000	43	86	Y	0	5	0	0	0	0	5	5
71-7	6	S	1.6000	44	87	Y	9	5	0	0	0	0	9	5
71-7	6	S	1.6000	44	88	Y	7	6	0	0	1	0	8	6
71-7	6	S	1.6000	45	89	Y	5	7	0	0	0	0	5	7
71-7	6	S	1.6000	45	90	Y	6	8	0	0	0	0	7	8
71-7	6	S	1.6000	46	91	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	6	S	1.6000	46	92	Y	5	9	0	0	0	0	5	10
71-7	6	S	1.6000	47	93	Y	9	3	0	0	0	0	9	4
71-7	6	S	1.6000	47	94	Y	3	8	0	1	0	0	4	8
71-7	6	S	1.6000	48	95	Y	6	5	0	0	0	0	6	5
71-7	6	S	1.6000	48	96	Y	4	7	0	0	0	0	5	7
71-7	6	S	1.6000	49	97	Y	1	9	0	0	0	0	3	9
71-7	6	S	1.6000	49	98	Y	6	6	0	0	0	0	6	7
71-7	6	S	1.6000	50	99	Y	4	7	0	1	3	0	5	7
71-7	6	S	1.6000	50	100	N	-0	-0	-0	-0	-0	-0	-0	-0

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	6	S	.0002	11	21	Y	4	10	0	0	1	1	5	10
TEM7	6	S	.0002	11	22	Y	2	9	0	0	0	0	2	9
TEM7	6	S	.0002	12	23	Y	6	5	1	0	0	0	7	6
TEM7	6	S	.0002	12	24	Y	7	5	0	1	0	0	7	5
TEM7	6	S	.0002	13	25	Y	6	5	0	0	0	0	6	5
TEM7	6	S	.0002	13	26	Y	5	5	0	0	0	0	5	6
TEM7	6	S	.0002	14	27	Y	5	7	0	1	0	0	5	7
TEM7	6	S	.0002	14	28	Y	8	3	0	0	0	0	8	4
TEM7	6	S	.0002	15	29	Y	4	8	0	0	0	1	4	8
TEM7	6	S	.0002	15	30	Y	6	4	0	0	0	0	7	4
TEM7	6	S	.0002	16	31	Y	2	10	2	0	0	0	2	12
TEM7	6	S	.0002	16	32	Y	6	5	0	0	0	0	6	5
TEM7	6	S	.0002	17	33	Y	5	6	0	0	0	0	5	6
TEM7	6	S	.0002	17	34	Y	6	4	0	0	1	0	6	5
TEM7	6	S	.0002	18	35	Y	7	5	0	0	0	1	7	8
TEM7	6	S	.0002	18	36	Y	6	7	0	0	0	0	6	7
TEM7	6	S	.0002	19	37	Y	6	6	0	0	0	0	6	6
TEM7	6	S	.0002	19	38	Y	5	5	0	0	0	1	7	6
TEM7	6	S	.0002	20	39	Y	10	2	0	0	0	0	10	2
TEM7	6	S	.0002	20	40	Y	6	6	0	0	0	1	6	7
CNTRL7	6	M	0.0000	1	1	Y	7	2	0	0	0	0	7	2
CNTRL7	6	M	0.0000	1	2	Y	5	7	0	0	0	0	5	7
CNTRL7	6	M	0.0000	2	3	Y	12	4	0	0	1	0	12	4
CNTRL7	6	M	0.0000	2	4	Y	0	6	0	0	0	0	8	6
CNTRL7	6	M	0.0000	3	5	Y	5	8	0	0	0	0	7	8
CNTRL7	6	M	0.0000	3	6	Y	4	7	0	0	1	1	4	8
CNTRL7	6	M	0.0000	4	7	Y	8	5	0	0	0	0	8	5
CNTRL7	6	M	0.0000	4	8	Y	5	7	0	0	0	0	5	7
CNTRL7	6	M	0.0000	5	9	Y	0	7	0	0	0	1	6	7
CNTRL7	6	M	0.0000	5	10	Y	9	3	0	0	0	0	10	3
CNTRL7	6	M	0.0000	6	11	Y	7	5	0	0	0	0	7	5
CNTRL7	6	M	0.0000	6	12	Y	5	7	0	0	0	0	5	7
CNTRL7	6	M	0.0000	7	13	Y	7	6	0	0	5	0	7	6
CNTRL7	6	M	0.0000	7	14	Y	3	6	0	0	0	3	4	6
CNTRL7	6	M	0.0000	8	15	Y	6	8	0	0	0	0	6	8
CNTRL7	6	M	0.0000	8	16	Y	5	7	0	0	0	0	5	7
CNTRL7	6	M	0.0000	9	17	Y	5	7	0	0	0	0	5	8
CNTRL7	6	M	0.0000	9	18	Y	11	5	0	0	0	0	11	5
CNTRL7	6	M	0.0000	10	19	Y	6	8	1	0	0	0	6	9
CNTRL7	6	M	0.0000	10	20	Y	7	5	0	0	0	0	7	5

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	6	M	.0300	11	21	Y	7	4	0	1	0	0	7	5
71-7	6	M	.0300	11	22	Y	5	7	0	0	0	1	5	7
71-7	6	M	.0300	12	23	Y	8	6	0	0	0	0	8	6
71-7	6	M	.0300	12	24	Y	5	6	0	0	0	0	5	6
71-7	6	M	.0300	13	25	Y	7	6	1	0	0	0	8	6
71-7	6	M	.0300	13	26	Y	8	3	0	0	0	0	9	3
71-7	6	M	.0300	14	27	Y	7	4	0	0	0	0	8	4
71-7	6	M	.0300	14	28	Y	4	7	0	0	0	0	4	7
71-7	6	M	.0300	15	29	Y	7	5	0	0	0	0	7	6
71-7	6	M	.0300	15	30	Y	9	3	0	0	0	0	9	3
71-7	6	M	.0300	16	31	Y	5	7	0	1	1	0	6	7
71-7	6	M	.0300	16	32	Y	7	6	0	0	0	0	9	6
71-7	6	M	.0300	17	33	Y	7	3	0	0	0	0	9	4
71-7	6	M	.0300	17	34	Y	5	8	0	0	0	0	6	8
71-7	6	M	.0300	18	35	Y	4	11	0	0	0	0	5	11
71-7	6	M	.0300	18	36	Y	3	9	0	0	0	0	3	10
71-7	6	M	.0300	19	37	Y	4	5	1	0	0	0	5	9
71-7	6	M	.0300	19	38	Y	6	6	0	0	0	0	6	6
71-7	6	M	.0300	20	39	Y	5	9	0	1	0	0	5	9
71-7	6	M	.0300	20	40	Y	5	9	0	0	0	3	6	9
71-7	6	M	.8000	21	41	Y	4	9	0	0	0	0	4	9
71-7	6	M	.8000	21	42	Y	5	7	1	0	2	0	5	8
71-7	6	M	.8000	22	43	Y	6	7	0	0	0	0	6	7
71-7	6	M	.8000	22	44	Y	6	7	0	0	0	0	7	8
71-7	6	M	.8000	23	45	Y	6	8	1	1	0	0	8	9
71-7	6	M	.8000	23	46	Y	8	4	1	0	0	0	9	5
71-7	6	M	.8000	24	47	N	-0	-0	0	0	0	0	-0	-0
71-7	6	M	.8000	24	48	Y	4	8	0	0	0	0	4	8
71-7	6	M	.8000	25	49	Y	1	10	0	1	0	0	6	13
71-7	6	M	.8000	25	50	Y	5	7	1	0	0	0	5	9
71-7	6	M	.8000	26	51	Y	5	6	2	2	1	0	6	6
71-7	6	M	.8000	26	52	Y	8	5	0	0	0	0	9	5
71-7	6	M	.8000	27	53	Y	6	6	2	0	0	0	6	7
71-7	6	M	.8000	27	54	Y	9	5	0	0	0	0	10	5
71-7	6	M	.8000	28	55	Y	6	6	0	1	0	0	7	6
71-7	6	M	.8000	28	56	Y	4	9	0	0	0	0	6	9
71-7	6	M	.8000	29	57	Y	3	7	0	1	0	1	4	8
71-7	6	M	.8000	29	58	Y	8	4	0	0	0	0	9	5
71-7	6	M	.8000	30	59	Y	7	2	0	1	0	0	7	4
71-7	6	M	.8000	30	60	Y	4	7	0	0	0	1	4	8

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	6	M	1.6000	31	61	Y	5	5	0	0	0	0	5	5
71-7	6	M	1.6000	31	62	Y	6	6	1	1	2	2	7	6
71-7	6	M	1.6000	32	63	Y	5	7	0	2	0	0	5	7
71-7	6	M	1.6000	32	64	Y	2	3	0	0	0	0	3	5
71-7	6	M	1.6000	33	65	Y	7	2	0	0	2	0	9	2
71-7	6	M	1.6000	33	66	Y	7	7	0	0	0	0	7	8
71-7	6	M	1.6000	34	67	Y	5	5	1	0	0	1	5	6
71-7	6	M	1.6000	34	68	Y	6	5	0	1	2	2	6	5
71-7	6	M	1.6000	35	69	Y	5	8	0	0	0	0	6	8
71-7	6	M	1.6000	35	70	Y	9	7	0	0	0	0	9	7
71-7	6	M	1.6000	36	71	Y	5	8	0	0	0	0	5	8
71-7	6	M	1.6000	36	72	Y	7	3	1	0	0	0	9	5
71-7	6	M	1.6000	37	73	Y	4	7	0	0	0	3	4	7
71-7	6	M	1.6000	37	74	Y	3	7	0	0	0	0	5	8
71-7	6	M	1.6000	38	75	Y	10	4	1	0	0	0	10	4
71-7	6	M	1.6000	38	76	Y	8	7	0	0	3	0	8	7
71-7	6	M	1.6000	39	77	Y	6	9	0	0	1	0	6	10
71-7	6	M	1.6000	39	78	Y	8	4	1	0	0	0	8	4
71-7	6	M	1.6000	40	79	Y	4	9	0	1	0	0	4	9
71-7	6	M	1.6000	40	80	Y	5	7	0	1	0	0	5	8

DOMINANT LETHAL GENE STUDY OF COMPOUND 71-7 SODIUM NITRATE

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
CNTRL7	7	S	0.0000	1	1	Y	4	7	1	0	0	0	5	7
CNTRL7	7	S	0.0000	1	2	Y	3	6	0	0	0	0	6	7
CNTRL7	7	S	0.0000	2	3	Y	6	2	0	0	0	0	7	6
CNTRL7	7	S	0.0000	2	4	Y	3	7	0	0	0	0	3	8
CNTRL7	7	S	0.0000	3	5	Y	5	7	0	1	1	2	5	7
CNTRL7	7	S	0.0000	3	6	Y	4	7	0	0	0	1	4	8
CNTRL7	7	S	0.0000	4	7	Y	6	5	0	1	0	0	6	5
CNTRL7	7	S	0.0000	4	8	Y	2	8	1	0	0	1	2	8
CNTRL7	7	S	0.0000	5	9	Y	5	6	0	2	3	2	10	6
CNTRL7	7	S	0.0000	5	10	Y	7	5	0	0	0	2	7	6
CNTRL7	7	S	0.0000	6	11	Y	4	12	0	0	0	0	4	12
CNTRL7	7	S	0.0000	6	12	Y	4	9	0	1	0	0	4	10
CNTRL7	7	S	0.0000	7	13	Y	8	6	0	1	0	1	8	6
CNTRL7	7	S	0.0000	7	14	Y	5	8	0	0	0	0	5	9
CNTRL7	7	S	0.0000	8	15	Y	5	6	0	0	0	0	5	6
CNTRL7	7	S	0.0000	8	16	Y	4	3	0	0	0	1	9	5
CNTRL7	7	S	0.0000	9	17	Y	4	8	0	2	0	0	4	9
CNTRL7	7	S	0.0000	9	18	Y	4	8	0	0	0	1	5	8
CNTRL7	7	S	0.0000	10	19	Y	6	7	0	0	0	0	8	8
CNTRL7	7	S	0.0000	10	20	Y	4	5	0	0	0	0	4	6
71-7	7	S	.0300	21	41	Y	1	10	0	0	0	0	1	10
71-7	7	S	.0300	21	42	Y	4	5	0	0	0	0	7	5
71-7	7	S	.0300	22	43	Y	9	4	0	0	0	0	10	4
71-7	7	S	.0300	22	44	Y	8	5	0	0	0	0	8	5
71-7	7	S	.0300	23	45	Y	4	10	0	0	0	0	4	10
71-7	7	S	.0300	23	46	Y	9	3	0	0	0	0	11	4
71-7	7	S	.0300	24	47	Y	3	9	1	0	0	0	3	9
71-7	7	S	.0300	24	48	Y	2	0	0	0	0	0	8	6
71-7	7	S	.0300	25	49	Y	7	6	0	1	0	1	7	6
71-7	7	S	.0300	25	50	Y	8	5	0	0	0	0	8	5
71-7	7	S	.0300	26	51	Y	10	5	0	1	0	0	10	5
71-7	7	S	.0300	26	52	Y	7	6	0	0	0	0	8	7
71-7	7	S	.0300	27	53	Y	3	9	0	0	0	0	3	10
71-7	7	S	.0300	27	54	Y	5	5	1	0	0	0	5	7
71-7	7	S	.0300	28	55	Y	3	8	0	0	0	0	3	8
71-7	7	S	.0300	28	56	Y	7	4	0	1	0	0	8	4
71-7	7	S	.0300	29	57	Y	5	7	0	0	0	1	6	7
71-7	7	S	.0300	29	58	Y	6	5	0	0	0	0	6	5
71-7	7	S	.0300	30	59	Y	5	6	0	0	0	0	5	6
71-7	7	S	.0300	30	60	Y	7	6	0	0	0	0	7	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	7	S	.8000	31	61	Y	4	10	0	0	0	0	4	10
71-7	7	S	.8000	31	62	Y	5	9	0	0	0	0	5	9
71-7	7	S	.8000	32	63	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	7	S	.8000	32	64	Y	9	4	0	0	0	0	9	4
71-7	7	S	.8000	33	65	Y	4	6	0	0	0	0	5	8
71-7	7	S	.8000	33	66	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	7	S	.8000	34	67	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	7	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	7	S	.8000	35	69	Y	6	6	3	3	0	1	7	6
71-7	7	S	.8000	35	70	Y	6	4	0	0	0	0	6	4
71-7	7	S	.8000	36	71	Y	6	7	0	1	0	0	6	7
71-7	7	S	.8000	36	72	Y	2	6	1	0	0	0	3	12
71-7	7	S	.8000	37	73	Y	1	8	0	0	0	0	2	11
71-7	7	S	.8000	37	74	Y	6	7	1	0	0	1	6	7
71-7	7	S	.8000	38	75	Y	6	6	0	2	0	0	7	7
71-7	7	S	.8000	38	76	Y	8	5	0	0	0	0	11	5
71-7	7	S	.8000	39	77	Y	9	4	0	0	1	0	11	4
71-7	7	S	.8000	39	78	Y	4	9	0	0	0	0	4	9
71-7	7	S	.8000	40	79	Y	4	7	2	1	0	0	5	9
71-7	7	S	.8000	40	80	Y	7	6	0	0	1	1	7	7
71-7	7	S	1.6000	41	81	Y	4	8	0	0	0	0	4	8
71-7	7	S	1.6000	41	82	Y	1	9	0	0	0	0	1	10
71-7	7	S	1.6000	42	83	Y	6	9	0	1	0	0	6	9
71-7	7	S	1.6000	42	84	Y	9	6	1	0	0	0	9	7
71-7	7	S	1.6000	43	85	Y	5	7	0	2	0	0	8	7
71-7	7	S	1.6000	43	86	Y	7	8	0	0	1	0	7	8
71-7	7	S	1.6000	44	87	Y	6	8	1	1	0	0	6	8
71-7	7	S	1.6000	44	88	Y	5	7	0	0	0	0	5	8
71-7	7	S	1.6000	45	89	Y	5	7	0	0	0	1	5	7
71-7	7	S	1.6000	45	90	Y	6	8	0	0	0	0	6	9
71-7	7	S	1.6000	46	91	Y	7	4	0	0	0	0	7	5
71-7	7	S	1.6000	46	92	Y	1	3	0	0	0	0	7	6
71-7	7	S	1.6000	47	93	Y	1	1	0	0	0	0	4	7
71-7	7	S	1.6000	47	94	Y	8	7	0	0	0	0	8	7
71-7	7	S	1.6000	48	95	Y	7	5	0	0	0	0	7	6
71-7	7	S	1.6000	48	96	Y	6	8	0	1	0	0	6	8
71-7	7	S	1.6000	49	97	Y	6	4	1	0	0	0	6	4
71-7	7	S	1.6000	49	98	Y	2	0	0	0	0	0	6	7
71-7	7	S	1.6000	50	99	Y	7	6	1	2	2	0	7	6
71-7	7	S	1.6000	50	100	Y	8	6	0	0	0	0	8	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	7	S	.0002	11	21	Y	6	7	0	0	0	0	6	8
TEM7	7	S	.0002	11	22	Y	8	5	0	0	0	0	8	5
TEM7	7	S	.0002	12	23	Y	5	9	0	0	0	1	5	10
TEM7	7	S	.0002	12	24	Y	6	6	0	0	1	0	6	6
TEM7	7	S	.0002	13	25	Y	5	9	0	0	3	0	5	10
TEM7	7	S	.0002	13	26	Y	3	8	0	1	0	0	3	9
TEM7	7	S	.0002	14	27	Y	6	6	0	0	0	0	6	6
TEM7	7	S	.0002	14	28	Y	6	8	0	0	1	0	6	8
TEM7	7	S	.0002	15	29	Y	8	6	1	0	0	0	8	6
TEM7	7	S	.0002	15	30	Y	8	8	0	0	0	1	8	8
TEM7	7	S	.0002	16	31	Y	6	4	0	0	0	0	8	4
TEM7	7	S	.0002	16	32	Y	5	7	1	1	0	0	5	7
TEM7	7	S	.0002	17	33	Y	4	2	0	0	0	0	7	6
TEM7	7	S	.0002	17	34	Y	4	8	0	0	0	0	4	8
TEM7	7	S	.0002	18	35	Y	6	6	0	0	0	0	7	6
TEM7	7	S	.0002	18	36	Y	3	7	0	0	0	0	4	8
TEM7	7	S	.0002	19	37	Y	6	8	0	0	0	0	6	8
TEM7	7	S	.0002	19	38	Y	6	6	0	0	0	0	6	7
TEM7	7	S	.0002	20	39	Y	8	5	0	0	0	0	8	7
TEM7	7	S	.0002	20	40	Y	8	8	0	0	0	0	8	8
CNTRL7	7	M	0.0000	1	1	Y	4	7	1	0	0	0	5	7
CNTRL7	7	M	0.0000	1	2	Y	3	6	0	0	0	0	6	7
CNTRL7	7	M	0.0000	2	3	Y	6	2	0	0	0	0	7	6
CNTRL7	7	M	0.0000	2	4	Y	3	7	0	0	0	0	3	8
CNTRL7	7	M	0.0000	3	5	Y	5	7	0	1	1	2	5	7
CNTRL7	7	M	0.0000	3	6	Y	4	7	0	0	0	1	4	8
CNTRL7	7	M	0.0000	4	7	Y	6	5	0	1	0	0	6	5
CNTRL7	7	M	0.0000	4	8	Y	2	8	1	0	0	1	2	8
CNTRL7	7	M	0.0000	5	9	Y	5	6	0	2	3	2	10	6
CNTRL7	7	M	0.0000	5	10	Y	7	5	0	0	0	2	7	6
CNTRL7	7	M	0.0000	6	11	Y	4	12	0	0	0	0	4	12
CNTRL7	7	M	0.0000	6	12	Y	4	9	0	1	0	0	4	10
CNTRL7	7	M	0.0000	7	13	Y	8	6	0	1	0	1	8	6
CNTRL7	7	M	0.0000	7	14	Y	5	8	0	0	0	0	5	9
CNTRL7	7	M	0.0000	8	15	Y	5	6	0	0	0	0	5	6
CNTRL7	7	M	0.0000	8	16	Y	4	3	0	0	0	1	9	5
CNTRL7	7	M	0.0000	9	17	Y	4	8	0	2	0	0	4	9
CNTRL7	7	M	0.0000	9	18	Y	4	8	0	0	0	1	5	8
CNTRL7	7	M	0.0000	10	19	Y	6	7	0	0	0	0	8	8
CNTRL7	7	M	0.0000	10	20	Y	4	5	0	0	0	0	4	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	7	M	.0300	11	21	Y	6	8	0	0	0	0	6	8
71-7	7	M	.0300	11	22	Y	1	1	0	0	0	0	4	5
71-7	7	M	.0300	12	23	Y	7	7	0	0	0	4	7	7
71-7	7	M	.0300	12	24	Y	7	6	0	0	2	1	8	6
71-7	7	M	.0300	13	25	Y	7	4	0	0	0	0	7	4
71-7	7	M	.0300	13	26	Y	5	6	0	0	0	0	5	6
71-7	7	M	.0300	14	27	Y	4	8	0	0	0	0	5	8
71-7	7	M	.0300	14	28	Y	7	2	1	0	0	0	7	5
71-7	7	M	.0300	15	29	Y	7	4	0	0	0	0	7	4
71-7	7	M	.0300	15	30	Y	6	6	0	1	0	0	6	7
71-7	7	M	.0300	16	31	Y	8	5	0	0	0	0	9	7
71-7	7	M	.0300	16	32	Y	5	5	0	0	0	1	8	5
71-7	7	M	.0300	17	33	Y	6	7	0	0	0	0	6	7
71-7	7	M	.0300	17	34	Y	5	7	0	0	0	0	5	7
71-7	7	M	.0300	18	35	Y	6	5	0	0	0	0	6	6
71-7	7	M	.0300	18	36	Y	6	6	0	0	0	2	9	11
71-7	7	M	.0300	19	37	Y	7	7	0	0	0	0	7	7
71-7	7	M	.0300	19	38	Y	4	8	0	0	0	0	4	8
71-7	7	M	.0300	20	39	Y	7	6	0	0	0	0	9	6
71-7	7	M	.0300	20	40	Y	3	5	0	1	0	0	6	5
71-7	7	M	.8000	21	41	Y	3	6	0	0	1	1	3	7
71-7	7	M	.8000	21	42	Y	6	5	0	0	0	0	6	6
71-7	7	M	.8000	22	43	Y	3	10	1	0	0	0	3	10
71-7	7	M	.8000	22	44	Y	10	3	1	0	0	0	10	3
71-7	7	M	.8000	23	45	Y	7	6	0	1	0	0	7	6
71-7	7	M	.8000	23	46	Y	5	8	0	0	0	1	5	8
71-7	7	M	.8000	24	47	Y	7	5	0	0	0	0	7	5
71-7	7	M	.8000	24	48	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	7	M	.8000	25	49	Y	4	7	0	0	0	0	5	8
71-7	7	M	.8000	25	50	Y	5	5	0	0	0	0	7	5
71-7	7	M	.8000	26	51	Y	6	0	0	0	1	0	6	7
71-7	7	M	.8000	26	52	Y	4	9	0	1	1	0	4	10
71-7	7	M	.8000	27	53	Y	3	5	0	0	0	0	4	6
71-7	7	M	.8000	27	54	Y	5	6	0	0	0	0	5	6
71-7	7	M	.8000	28	55	Y	7	6	0	0	0	0	7	6
71-7	7	M	.8000	28	56	Y	6	5	0	0	1	0	7	5
71-7	7	M	.8000	29	57	Y	6	6	0	0	0	0	6	7
71-7	7	M	.8000	29	58	Y	2	8	0	0	0	1	2	8
71-7	7	M	.8000	30	59	Y	7	8	0	0	0	0	8	8
71-7	7	M	.8000	30	60	Y	6	6	0	0	0	0	7	6

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	7	M	1.6000	31	61	Y	3	9	0	1	0	0	6	10
71-7	7	M	1.6000	31	62	Y	6	4	0	0	0	0	6	5
71-7	7	M	1.6000	32	63	Y	7	6	0	0	0	0	7	6
71-7	7	M	1.6000	32	64	Y	3	8	0	0	0	0	3	10
71-7	7	M	1.6000	33	65	Y	4	10	0	0	1	2	5	10
71-7	7	M	1.6000	33	66	Y	7	7	0	1	0	0	7	7
71-7	7	M	1.6000	34	67	Y	10	2	0	0	0	0	11	3
71-7	7	M	1.6000	34	68	Y	0	3	0	0	0	0	6	6
71-7	7	M	1.6000	35	69	Y	4	3	0	0	0	0	5	9
71-7	7	M	1.6000	35	70	Y	4	5	0	0	0	0	5	6
71-7	7	M	1.6000	36	71	Y	3	9	0	0	0	0	3	10
71-7	7	M	1.6000	36	72	Y	7	7	0	0	0	0	7	7
71-7	7	M	1.6000	37	73	Y	6	8	0	0	0	0	6	8
71-7	7	M	1.6000	37	74	Y	9	3	0	0	1	0	9	3
71-7	7	M	1.6000	38	75	Y	5	5	0	0	0	0	5	5
71-7	7	M	1.6000	38	76	Y	7	6	0	0	0	0	8	6
71-7	7	M	1.6000	39	77	Y	6	6	0	0	0	0	6	6
71-7	7	M	1.6000	39	78	Y	3	6	0	1	0	0	3	7
71-7	7	M	1.6000	40	79	Y	7	3	0	0	0	0	9	3
71-7	7	M	1.6000	40	80	Y	7	7	0	1	1	1	7	8

[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
CNTRL7	8	S	0.0000	8	16	Y	7	9	0	1	0	0	7	9
CNTRL7	8	S	0.0000	9	17	Y	3	8	0	0	0	1	4	8
CNTRL7	8	S	0.0000	9	18	Y	5	6	0	0	0	0	5	7
CNTRL7	8	S	0.0000	10	19	Y	6	5	0	1	0	0	6	6
CNTRL7	8	S	0.0000	10	20	Y	3	8	0	0	0	0	3	10
71-7	8	S	.0300	21	41	Y	5	7	0	0	0	0	5	8
71-7	8	S	.0300	21	42	Y	4	6	0	1	0	0	4	6
71-7	8	S	.0300	22	43	Y	4	7	0	0	0	0	5	7
71-7	8	S	.0300	22	44	Y	8	4	0	0	0	0	9	4
71-7	8	S	.0300	23	45	Y	5	5	0	0	1	0	6	6
71-7	8	S	.0300	23	46	Y	6	5	0	0	0	0	6	6
71-7	8	S	.0300	24	47	Y	2	1	0	0	0	0	5	5
71-7	8	S	.0300	24	48	Y	8	4	0	0	0	0	10	4
71-7	8	S	.0300	25	49	Y	3	9	0	0	0	1	3	9
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
71-7	8	S	.0300	29	57	Y	5	7	0	0	0	0	5	7
71-7	8	S	.0300	29	58	Y	4	5	0	0	0	1	5	6
71-7	8	S	.0300	30	59	Y	9	4	0	0	2	0	9	7
[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
71-7	8	S	.8000	31	61	Y	4	5	0	0	0	0	4	9
71-7	8	S	.8000	31	62	Y	4	7	0	0	0	0	4	8
71-7	8	S	.8000	32	63	Y	5	2	0	0	1	0	6	4
71-7	8	S	.8000	32	64	Y	8	5	2	0	0	0	8	5
71-7	8	S	.8000	33	65	Y	5	4	0	0	1	2	5	4
71-7	8	S	.8000	33	66	Y	7	4	0	0	0	0	7	4
71-7	8	S	.8000	34	67	Y	2	12	0	0	0	0	3	12
71-7	8	S	.8000	34	68	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	8	S	.8000	35	69	Y	6	6	0	0	0	0	6	6
71-7	8	S	.8000	35	70	Y	5	5	0	0	0	0	5	5
71-7	8	S	.8000	36	71	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	8	S	.8000	36	72	N	-0	-0	-0	-0	-0	-0	-0	-0
71-7	8	S	.8000	37	73	Y	6	7	0	0	0	0	6	7
71-7	8	S	.8000	37	74	Y	6	1	3	0	0	0	6	4
71-7	8	S	.8000	38	75	Y	8	5	0	0	0	0	8	5
71-7	8	S	.8000	38	76	Y	4	6	0	2	0	0	7	6
71-7	8	S	.8000	39	77	Y	5	7	0	0	0	0	5	7
71-7	8	S	.8000	39	78	Y	5	8	0	0	0	0	5	9
71-7	8	S	.8000	40	79	Y	7	2	0	0	1	0	9	2
71-7	8	S	.8000	40	80	Y	6	8	0	0	0	0	6	8
71-7	8	S	1.6000	41	81	Y	5	6	0	0	0	0	5	6
71-7	8	S	1.6000	41	82	Y	6	9	0	0	0	0	6	9
71-7	8	S	1.6000	42	83	Y	3	7	0	0	0	0	3	8
71-7	8	S	1.6000	42	84	Y	5	7	0	1	0	0	5	8
71-7	8	S	1.6000	43	85	Y	5	6	0	0	0	0	6	7
71-7	8	S	1.6000	43	86	Y	4	5	1	0	0	0	5	7
71-7	8	S	1.6000	44	87	Y	8	5	1	0	0	0	9	6
71-7	8	S	1.6000	44	88	Y	4	7	0	0	0	0	4	7
71-7	8	S	1.6000	45	89	Y	8	3	0	0	0	0	8	4
71-7	8	S	1.6000	45	90	Y	5	5	1	2	1	3	5	6
71-7	8	S	1.6000	46	91	Y	7	2	2	0	0	0	9	2
71-7	8	S	1.6000	46	92	Y	1	5	0	0	0	0	1	5
71-7	8	S	1.6000	47	93	Y	3	7	0	0	0	0	4	8
71-7	8	S	1.6000	47	94	Y	5	3	0	0	0	0	6	3
71-7	8	S	1.6000	48	95	Y	8	5	1	0	0	0	8	5
71-7	8	S	1.6000	48	96	Y	4	9	0	0	0	1	4	9
71-7	8	S	1.6000	49	97	Y	6	5	0	0	0	0	6	5
71-7	8	S	1.6000	49	98	Y	5	8	0	0	0	0	6	9
71-7	8	S	1.6000	50	99	Y	6	7	0	2	1	1	6	7
71-7	8	S	1.6000	50	100	Y	3	8	0	0	0	3	3	10

TEST MATERIAL	WEEK	S/M	DOSE	MALE NO.	FEMALE NO.	PREG.	IMPLANTS L	IMPLANTS R	EARLY DEATHS L	EARLY DEATHS R	LATE DEATHS L	LATE DEATHS R	CORPORA LUTEA L	CORPORA LUTEA R
TEM7	8	S	.0002	11	21	Y	6	9	0	0	0	0	6	12
TEM7	8	S	.0002	11	22	Y	7	5	0	0	0	0	7	5
TEM7	8	S	.0002	12	23	Y	8	4	0	0	0	0	8	4
TEM7	8	S	.0002	12	24	Y	7	6	0	1	0	0	7	6
TEM7	8	S	.0002	13	25	Y	7	5	0	2	3	1	9	7
TEM7	8	S	.0002	13	26	Y	7	5	0	0	0	0	8	5
TEM7	8	S	.0002	14	27	Y	8	9	1	0	0	1	8	9
TEM7	8	S	.0002	14	28	Y	5	6	0	0	0	0	6	6
TEM7	8	S	.0002	15	29	Y	7	5	0	0	0	0	9	5
TEM7	8	S	.0002	15	30	Y	6	6	0	0	1	0	6	6
TEM7	8	S	.0002	16	31	Y	8	5	0	0	0	0	8	5
TEM7	8	S	.0002	16	32	Y	0	1	0	0	0	0	7	5
TEM7	8	S	.0002	17	33	Y	4	8	0	0	0	0	5	9
TEM7	8	S	.0002	17	34	Y	9	3	0	0	0	0	12	4
TEM7	8	S	.0002	18	35	Y	8	5	0	0	0	0	9	6
TEM7	8	S	.0002	18	36	Y	11	3	0	0	0	0	11	3
TEM7	8	S	.0002	19	37	Y	4	8	0	0	0	0	4	9
TEM7	8	S	.0002	19	38	Y	7	6	0	0	1	0	7	6
TEM7	8	S	.0002	20	39	N	-0	-0	-0	-0	-0	-0	-0	-0
TEM7	8	S	.0002	20	40	Y	8	4	1	1	1	0	9	4

CHI-SQUARE TEST OF THE FERTILITY INDEX (1 DEGREE OF FREEDOM)

WEEK	VEHICLE CONTROL				71-7 .03 G/KG				71-7 .8 G/KG				71-7 1.6 G/KG				TEM .2 MG/KG			
	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ	N PRG	N MTD	FERT. INDEX	CHISQ
SINGLE TREATMENT																				
1	15	20	.75	0.00	16	20	.80	0.00	16	20	.80	0.00	12	20	.60	.46	20	20	1.00	3.66
2	20	20	1.00	0.00	19	20	.95	0.00	13	20	.65	6.23	19	20	.95	0.00	20	20	1.00	0.00
3	20	20	1.00	0.00	20	20	1.00	0.00	18	20	.90	.53	20	20	1.00	0.00	20	20	1.00	0.00
4	20	20	1.00	0.00	20	20	1.00	0.00	17	20	.85	1.44	16	20	.80	2.50	20	20	1.00	0.00
5	19	20	.95	0.00	19	20	.95	.53	16	20	.80	.91	20	20	1.00	0.00	19	20	.95	.53
6	20	20	1.00	0.00	20	20	1.00	0.00	16	20	.80	2.50	17	20	.85	1.44	20	20	1.00	0.00
7	20	20	1.00	0.00	20	20	1.00	0.00	16	20	.80	2.50	20	20	1.00	0.00	20	20	1.00	0.00
8	20	20	1.00	0.00	20	20	1.00	0.00	17	20	.85	1.44	20	20	1.00	0.00	19	20	.95	0.00
MULTIPLE TREATMENT																				
1	15	20	.75	0.00	16	20	.80	0.00	20	20	1.00	3.66	20	20	1.00	3.66				
2	20	20	1.00	0.00	20	20	1.00	0.00	20	20	1.00	0.00	20	20	1.00	0.00				
3	20	20	1.00	0.00	16	20	.80	2.50	19	20	.95	0.00	19	20	.95	0.00				
4	20	20	1.00	0.00	20	20	1.00	0.00	19	20	.95	0.00	19	20	.95	0.00				
5	19	20	.95	0.00	20	20	1.00	0.00	20	20	1.00	0.00	20	20	1.00	0.00				
6	20	20	1.00	0.00	20	20	1.00	0.00	19	20	.95	0.00	20	20	1.00	0.00				
7	20	20	1.00	0.00	20	20	1.00	0.00	19	20	.95	0.00	20	20	1.00	0.00				

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(1 DEGREE OF FREEDOM) BASED ON THE DOSE LEVELS

	.03 G/KG		.8 G/KG		1.6 G/KG				
WEEK	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	16	20	16	20	12	20	2.73	2.07	.66
2	19	20	13	20	19	20	9.41	.00	9.41
3	20	20	18	20	20	20	4.14	.00	4.14
4	20	20	17	20	16	20	4.20	3.86	.35
5	19	20	16	20	20	20	5.67	.36	5.32
6	20	20	16	20	17	20	4.20	2.14	2.07
7	20	20	16	20	20	20	8.57	.00	8.57
8	20	20	17	20	20	20	6.32	.00	6.32
								MULTIPLE TREATMENT	
1	16	20	20	20	20	20	8.57	6.35	2.23
2	20	20	20	20	20	20	0.00	0.00	0.00
3	16	20	19	20	19	20	3.33	2.47	.87
4	20	20	19	20	19	20	1.03	.77	.27
5	20	20	20	20	20	20	0.00	0.00	0.00
6	20	20	19	20	20	20	2.03	.00	2.03
7	20	20	19	20	20	20	2.03	.00	2.03

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(1 DEGREE OF FREEDOM) BASED ON THE LOGARITHMS OF THE DOSE LEVELS

	.03 G/KG		.8 G/KG		1.6 G/KG				
WEEK	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	16	20	16	20	12	20	2.73	1.10	1.63
2	19	20	13	20	19	20	9.41	1.17	8.25
3	20	20	18	20	20	20	4.14	.51	3.63
4	20	20	17	20	16	20	4.20	4.18	.03
5	19	20	16	20	20	20	5.67	.08	5.60
6	20	20	16	20	17	20	4.20	3.55	.66
7	20	20	16	20	20	20	8.57	1.06	7.51
8	20	20	17	20	20	20	6.32	.78	5.53
								MULTIPLE TREATMENT	
1	16	20	20	20	20	20	8.57	8.34	.23
2	20	20	20	20	20	20	0.00	0.00	0.00
3	16	20	19	20	19	20	3.33	3.24	.09
4	20	20	19	20	19	20	1.03	1.01	.03
5	20	20	20	20	20	20	0.00	0.00	0.00
6	20	20	19	20	20	20	2.03	.25	1.78
7	20	20	19	20	20	20	2.03	.25	1.78

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE FERTILITY INDEX
(2 DEGREES OF FREEDOM) BASED ON THE DOSE LEVELS AND INCLUDING THE CONTROL GROUP

	CONTROL		.03 G/KG		.8 G/KG		1.6 G/KG				
WEEK	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	N PRG	N MTD	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
						SINGLE TREATMENT					
1	15	20	16	20	16	20	12	20	2.78	1.69	1.08
2	20	20	19	20	13	20	19	20	15.40	.90	14.50
3	20	20	20	20	18	20	20	20	6.15	.18	5.98
4	20	20	20	20	17	20	16	20	7.99	7.51	.48
5	19	20	19	20	16	20	20	20	6.49	.07	6.41
6	20	20	20	20	16	20	17	20	7.98	5.10	2.89
7	20	20	20	20	16	20	20	20	12.63	.36	12.27
8	20	20	20	20	17	20	20	20	9.35	.27	9.08
						MULTIPLE TREATMENT					
1	15	20	16	20	20	20	20	20	10.39	8.30	2.09
2	20	20	20	20	20	20	20	20	0.00	0.00	0.00
3	20	20	16	20	19	20	19	20	6.49	.53	5.96
4	20	20	20	20	19	20	19	20	2.05	1.67	.38
5	19	20	20	20	20	20	20	20	3.04	.87	2.17
6	20	20	20	20	19	20	20	20	3.04	.09	2.95
7	20	20	20	20	19	20	20	20	3.04	.09	2.95

T-TEST OF THE NUMBER OF IMPLANTATIONS IN PREGNANT FEMALES.

WEEK	CONTROL			71-7 .03 G/KG					71-7 .8 G/KG					71-7 1.6 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	15	12.07	3.61	16	12.75	1.39	29	.703	16	13.37	1.86	29	1.280	12	11.25	1.82	25	.712	20	12.05	1.90	33	.018
2	20	11.30	3.53	19	11.37	1.92	37	.075	13	12.77	1.59	31	1.407	19	9.95	3.87	37	1.143	20	6.95	3.00	38	4.202
3	20	12.25	1.86	20	11.90	2.07	38	.562	18	12.00	3.12	36	.303	20	12.25	2.47	38	0.000	20	8.35	3.33	38	4.574
4	20	12.80	2.09	20	12.80	1.36	38	0.000	17	12.94	1.52	35	.231	16	12.37	2.06	34	.609	20	6.55	2.61	38	8.305
5	19	11.74	1.73	19	11.00	3.14	36	.895	16	12.12	1.86	33	.640	20	11.45	2.63	37	.401	19	9.84	2.65	36	2.610
6	20	11.85	2.54	20	12.05	1.61	38	.298	16	11.94	1.57	34	.120	17	11.06	2.86	35	.891	20	11.45	1.05	38	.651
7	20	11.25	2.10	20	11.55	2.65	38	.397	16	11.94	1.81	34	1.038	20	11.40	4.10	38	.146	20	12.50	2.24	38	1.863
8	20	12.00	2.43	20	11.05	2.16	38	1.306	17	11.00	2.26	35	1.288	20	11.00	2.08	38	1.400	19	12.11	3.02	37	.120
MULTIPLE TREATMENT																							
1	15	12.07	3.61	16	10.12	4.50	29	1.319	20	12.15	1.73	33	.091	20	12.75	3.24	33	.587					
2	20	11.30	3.53	20	11.60	3.52	38	.269	20	12.00	2.29	38	.744	20	11.45	4.59	38	.116					
3	20	12.25	1.86	16	12.87	2.25	34	.913	19	11.74	2.05	37	.819	19	10.79	3.33	37	1.704					
4	20	12.80	2.09	20	11.70	2.98	38	1.352	19	12.32	1.38	37	.849	19	11.58	3.39	37	1.362					
5	19	11.74	1.73	20	11.95	2.31	37	.325	20	10.60	3.42	37	1.298	20	12.10	1.59	37	.684					
6	20	11.85	2.54	20	12.10	1.48	38	.380	19	12.05	1.27	37	.313	20	11.85	2.52	38	0.000					
7	20	11.25	2.10	20	11.35	2.72	38	.130	19	11.37	2.11	37	.175	20	11.25	2.79	38	0.000					

REGRESSION FITS OF THE NUMBER, U, OF IMPLANTATIONS ON 1) DOSE, AND 2) LOG DOSE.
(PREDICTED U = A + B*X) CONTROL GROUP EXCLUDED

WEEK	X	N	XBAR	SD X	UBAR	SD U	B	A	TB	DF	VARU.X	CV U	VARB	VARA	VARUBAR
							SINGLE TREATMENT								
1	DOSE	44	.74	.63	12.57	1.86	-.876	13.215	-2.010	42	3.2320	.1430	.1901	.1771	.0735
	LOG DOSE	44	-1.23	1.76	12.57	1.86	-.153	12.380	-.952	42	3.4679	.1482	.0259	.1179	.0788
2	DOSE	51	.81	.68	11.20	2.93	-.918	11.941	-1.539	49	8.3326	.2578	.3558	.3975	.1634
	LOG DOSE	51	-1.19	1.82	11.20	2.93	-.163	11.002	-.717	49	8.6448	.2626	.0519	.2428	.1695
3	DOSE	58	.81	.66	12.05	2.53	.223	11.871	.435	56	6.4931	.2114	.2634	.2849	.1120
	LOG DOSE	58	-1.12	1.77	12.05	2.53	.071	12.131	.373	56	6.4990	.2115	.0363	.1573	.1121
4	DOSE	53	.75	.65	12.72	1.63	-.257	12.910	-.735	51	2.6921	.1290	.1225	.1199	.0508
	LOG DOSE	53	-1.25	1.79	12.72	1.63	-.055	12.648	-.434	51	2.7107	.1295	.0162	.0766	.0511
5	DOSE	55	.82	.67	11.49	2.62	.272	11.267	.504	53	6.9806	.2299	.2905	.3246	.1269
	LOG DOSE	55	-1.11	1.78	11.49	2.62	.175	11.684	.873	53	6.9147	.2288	.0403	.1749	.1257
6	DOSE	53	.77	.66	11.70	2.09	-.622	12.175	-1.432	51	4.2821	.1769	.1888	.1916	.0808
	LOG DOSE	53	-1.24	1.80	11.70	2.09	-.181	11.473	-1.131	51	4.3454	.1782	.0257	.1215	.0820
7	DOSE	56	.81	.67	11.61	3.03	-.099	11.687	-.161	54	9.3170	.2630	.3779	.4148	.1664
	LOG DOSE	56	-1.15	1.80	11.61	3.03	.005	11.613	.022	54	9.3213	.2630	.0526	.2358	.1665
8	DOSE	57	.81	.66	11.02	2.13	-.032	11.043	-.073	55	4.5992	.1947	.1866	.2033	.0807
	LOG DOSE	57	-1.13	1.78	11.02	2.13	-.013	11.002	-.083	55	4.5991	.1946	.0258	.1138	.0807
							MULTIPLE TREATMENTS								
1	DOSE	56	.87	.63	11.79	3.37	1.628	10.376	2.359	54	10.5000	.2749	.4763	.5445	.1875
	LOG DOSE	56	-.91	1.68	11.79	3.37	.647	12.377	2.506	54	10.3757	.2733	.0668	.2410	.1853
2	DOSE	60	.81	.65	11.68	3.54	-.099	11.764	-.138	58	12.7369	.3055	.5167	.5513	.2123
	LOG DOSE	60	-1.09	1.75	11.68	3.54	.012	11.697	.047	58	12.7406	.3055	.0706	.2957	.2123
3	DOSE	54	.85	.64	11.74	2.71	-1.323	12.870	-2.361	52	6.7453	.2212	.3138	.3534	.1249
	LOG DOSE	54	-.95	1.70	11.74	2.71	-.472	11.292	-2.234	52	6.8147	.2223	.0446	.1666	.1262
4	DOSE	58	.80	.65	11.86	2.70	-.075	11.922	-.136	56	7.4064	.2294	.3084	.3234	.1277
	LOG DOSE	58	-1.13	1.76	11.86	2.70	.039	11.906	.191	56	7.4041	.2294	.0418	.1808	.1277
5	DOSE	60	.81	.65	11.55	2.60	.107	11.463	.203	58	6.8718	.2270	.2788	.2974	.1145
	LOG DOSE	60	-1.09	1.75	11.55	2.60	-.103	11.438	-.530	58	6.8435	.2265	.0379	.1588	.1141
6	DOSE	59	.81	.65	12.00	1.82	-.160	12.129	-.433	57	3.3574	.1527	.1362	.1463	.0569
	LOG DOSE	59	-1.10	1.76	12.00	1.82	-.048	11.947	-.352	57	3.3611	.1528	.0187	.0796	.0570
7	DOSE	59	.81	.65	11.32	2.52	-.064	11.374	-.125	57	6.4698	.2247	.2624	.2819	.1097
	LOG DOSE	59	-1.10	1.76	11.32	2.52	-.016	11.305	-.083	57	6.4708	.2247	.0360	.1533	.1097

REGRESSION FITS OF THE NUMBER, U, OF IMPLANTATIONS ON DOSE.
(PREDICTED U = A + B*X) CONTROL GROUP INCLUDED

WEEK	X	N	XBAR	SD X	UBAR	SD U	B	A	TB	DF	VARU.X	CV U	VARB	VARA	VARUBAR
							SINGLE TREATMENT								
1	DOSE	59	.55	.63	12.44	2.40	-.466	12.697	-.931	57	5.7813	.1933	.2503	.1739	.0980
2	DOSE	71	.58	.69	11.23	3.08	-.691	11.628	-1.292	69	9.4015	.2731	.2860	.2295	.1324
3	DOSE	78	.60	.67	12.10	2.37	.091	12.048	.223	76	5.6697	.1967	.1647	.1325	.0727
4	DOSE	73	.55	.65	12.74	1.76	-.218	12.858	-.678	71	3.1074	.1384	.1030	.0732	.0426
5	DOSE	74	.61	.68	11.55	2.42	.109	11.487	.260	72	5.9151	.2105	.1758	.1460	.0799
6	DOSE	73	.56	.66	11.74	2.20	-.507	12.021	-1.289	71	4.8176	.1870	.1544	.1138	.0660
7	DOSE	76	.60	.68	11.51	2.80	.053	11.481	.111	74	7.9580	.2450	.2318	.1874	.1047
8	DOSE	77	.60	.67	11.27	2.23	-.366	11.492	-.959	75	4.9957	.1983	.1453	.1172	.0649
							MULTIPLE TREATMENTS								
1	DOSE	71	.68	.66	11.85	3.40	1.068	11.116	1.773	69	11.2180	.2828	.3629	.3272	.1580
2	DOSE	80	.61	.66	11.59	3.52	.064	11.549	.106	78	12.5288	.3055	.3632	.2907	.1566
3	DOSE	74	.62	.66	11.88	2.50	-1.083	12.553	-2.540	72	5.8369	.2034	.1817	.1493	.0789
4	DOSE	78	.59	.66	12.10	2.58	-.386	12.331	-.865	76	6.6604	.2132	.1991	.1552	.0854
5	DOSE	79	.62	.66	11.59	2.41	.013	11.587	.032	77	5.8835	.2092	.1724	.1397	.0745
6	DOSE	79	.61	.66	11.96	2.01	-.062	11.999	-.179	77	4.0877	.1690	.1186	.0952	.0517
7	DOSE	79	.61	.66	11.30	2.41	-.021	11.316	-.050	77	5.8791	.2145	.1706	.1369	.0744

T-TEST TEST OF THE (TRANSFORMED) PRE-IMPLANTATION LOSSES IN PREGNANT FEMALES.
(LOSSES TAKEN AS A SUBSET OF THE SET OF CORPORA LUTEA)

WEEK	CONTROL			71-7 .03 G/KG					71-7 .8 G/KG					71-7 1.6 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
											SINGLE TREATMENT												
1	15	.63	.65	16	.54	.37	29	.488	16	.36	.16	29	1.641	12	.69	.40	25	.267	20	.65	.36	33	.105
2	20	.68	.57	19	.69	.36	37	.081	13	.42	.24	31	1.544	19	.90	.66	37	1.111	20	1.41	.47	38	4.401
3	20	.66	.30	20	.69	.42	38	.248	18	.75	.49	36	.702	20	.68	.44	38	.193	20	1.28	.48	38	4.869
4	20	.54	.38	20	.57	.28	38	.324	17	.50	.31	35	.326	16	.53	.30	34	.049	20	1.53	.53	38	6.813
5	19	.56	.38	19	.61	.57	36	.347	16	.54	.31	33	.129	20	.58	.46	37	.141	19	.79	.52	36	1.569
6	20	.53	.42	20	.45	.28	38	.701	16	.64	.35	34	.827	17	.69	.45	35	1.109	20	.53	.27	38	.004
7	20	.70	.39	20	.59	.49	38	.812	16	.66	.41	34	.316	20	.70	.66	38	.014	20	.54	.35	38	1.384
8	20	.56	.35	20	.67	.41	38	.948	17	.59	.38	35	.308	20	.61	.28	38	.527	19	.67	.52	37	.830
											MULTIPLE TREATMENT												
1	15	.63	.65	16	1.04	.69	29	1.685	20	.53	.35	33	.600	20	.63	.50	33	.004					
2	20	.68	.57	20	.66	.57	38	.095	20	.59	.41	38	.579	20	.87	.66	38	.952					
3	20	.66	.30	16	.46	.30	34	1.936	19	.63	.40	37	.231	19	.83	.61	37	1.088					
4	20	.54	.38	20	.46	.35	38	.647	19	.44	.20	37	.938	19	.66	.63	37	.746					
5	19	.56	.38	20	.55	.32	37	.129	20	.71	.62	37	.877	20	.55	.31	37	.091					
6	20	.53	.42	20	.58	.28	38	.418	19	.72	.27	37	1.672	20	.56	.34	38	.185					
7	20	.70	.39	20	.68	.49	38	.144	19	.59	.36	37	.897	20	.71	.47	38	.048					

T-TEST OF THE (TRANSFORMED) NUMBER OF DEAD IMPLANTS.

WEEK	CONTROL			71-7 .03 G/KG					71-7 .8 G/KG					71-7 1.6 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	15	.45	.24	16	.37	.23	29	.935	16	.42	.25	29	.276	12	.44	.26	25	.050	20	1.26	.49	33	5.660
2	20	.48	.35	19	.48	.30	37	.022	13	.47	.30	31	.081	19	.50	.33	37	.186	20	1.40	.63	38	5.703
3	20	.63	.35	20	.53	.30	38	1.046	18	.44	.25	36	1.909	20	.49	.28	38	1.478	20	1.68	.53	38	7.365
4	20	.54	.36	20	.35	.18	38	2.101	17	.47	.28	35	.650	16	.42	.23	34	1.138	20	1.40	.49	38	6.364
5	19	.44	.24	19	.37	.18	36	1.090	16	.57	.34	33	1.263	20	.47	.26	37	.307	19	.95	.50	36	3.974
6	20	.46	.33	20	.44	.23	38	.233	16	.42	.20	34	.407	17	.40	.27	35	.530	20	.49	.22	38	.399
7	20	.62	.35	20	.40	.21	38	2.427	16	.58	.39	34	.371	20	.49	.30	38	1.251	20	.45	.24	38	1.836
8	20	.48	.25	20	.43	.21	38	.686	17	.51	.35	35	.358	20	.58	.41	38	.927	19	.45	.32	37	.295
MULTIPLE TREATMENT																							
1	15	.45	.24	16	.55	.32	29	1.046	20	.49	.31	33	.490	20	.55	.29	33	1.166					
2	20	.48	.35	20	.60	.42	38	.993	20	.45	.23	38	.324	20	.50	.31	38	.154					
3	20	.63	.35	16	.46	.28	34	1.574	19	.57	.22	37	.725	19	.46	.24	37	1.766					
4	20	.54	.36	20	.56	.35	38	.200	19	.42	.24	37	1.220	19	.49	.34	37	.462					
5	19	.44	.24	20	.58	.24	37	1.791	20	.44	.28	37	.032	20	.44	.23	37	.055					
6	20	.46	.33	20	.43	.24	38	.277	19	.58	.33	37	1.119	20	.69	.39	38	1.965					
7	20	.62	.35	20	.46	.28	38	1.628	19	.49	.24	37	1.357	20	.42	.25	38	2.076					

CHI-SQUARE TEST OF THE DEATH INDEX (1 DEGREE OF FREEDOM)

WEEK	VEHICLE CONTROL				71-7 .03 G/KG				71-7 .8 G/KG				71-7 1.6 G/KG				TEM .2 MG/KG			
	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ	N WDI	N PRG	DEATH INDEX	CHISQ
SINGLE TREATMENT																				
1	6	15	.40	0.00	3	16	.19	.82	5	16	.31	.02	4	12	.33	.00	19	20	.95	10.15
2	7	20	.35	0.00	7	19	.37	.05	5	13	.38	.03	7	19	.37	.05	17	20	.85	8.44
3	14	20	.70	0.00	10	20	.50	.94	7	18	.39	2.56	9	20	.45	1.64	19	20	.95	2.77
4	9	20	.45	0.00	4	20	.20	1.82	7	17	.41	.01	5	16	.31	.25	19	20	.95	9.64
5	7	19	.37	0.00	4	19	.21	.51	8	16	.50	.19	8	20	.40	.02	16	19	.84	7.05
6	6	20	.30	0.00	7	20	.35	0.00	6	16	.38	.01	4	17	.24	.00	10	20	.50	.94
7	12	20	.60	0.00	6	20	.30	2.53	8	16	.50	.07	9	20	.45	.40	8	20	.40	.90
8	9	20	.45	0.00	7	20	.35	.10	6	17	.35	.07	9	20	.45	.10	6	19	.32	.28
MULTIPLE TREATMENT																				
1	6	15	.40	0.00	8	16	.50	.04	8	20	.40	.12	11	20	.55	.29				
2	7	20	.35	0.00	9	20	.45	.10	8	20	.40	0.00	9	20	.45	.10				
3	14	20	.70	0.00	6	16	.38	2.60	13	19	.68	.06	8	19	.42	2.05				
4	9	20	.45	0.00	10	20	.50	0.00	6	19	.32	.28	7	19	.37	.04				
5	7	19	.37	0.00	13	20	.65	2.07	6	20	.30	.01	7	20	.35	.05				
6	6	20	.30	0.00	7	20	.35	0.00	11	19	.58	2.05	13	20	.65	3.61				
7	12	20	.60	0.00	7	20	.35	1.60	9	19	.47	.22	6	20	.30	2.53				

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(1 DEGREE OF FREEDOM) BASED ON THE DOSE LEVELS

WEEK	.03 G/KG N WDI	.03 G/KG N PRG	.8 G/KG N WDI	.8 G/KG N PRG	1.6 G/KG N WDI	1.6 G/KG N PRG	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	3	16	5	16	4	12	.94	.79	.15
2	7	19	5	13	7	19	.01	.00	.01
3	10	20	7	18	9	20	.47	.10	.38
4	4	20	7	17	5	16	1.97	.63	1.34
5	4	19	8	16	8	20	3.32	1.43	1.89
6	7	20	6	16	4	17	.86	.53	.34
7	6	20	8	16	9	20	1.67	.91	.75
8	7	20	6	17	9	20	.53	.43	.11
								MULTIPLE TREATMENT	
1	8	16	8	20	11	20	.93	.14	.79
2	9	20	8	20	9	20	.14	.00	.14
3	6	16	13	19	8	19	4.05	.02	4.03
4	10	20	6	19	7	19	1.48	.71	.76
5	13	20	6	20	7	20	5.84	3.60	2.23
6	7	20	11	19	13	20	3.93	3.59	.35
7	7	20	9	19	6	20	1.32	.11	1.21

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(1 DEGREE OF FREEDOM) BASED ON THE LOGARITHMS OF THE DOSE LEVELS

WEEK	.03 G/KG N WDI	.03 G/KG N PRG	.8 G/KG N WDI	.8 G/KG N PRG	1.6 G/KG N WDI	1.6 G/KG N PRG	CHISQ (C-1)	CHISQ (1)	ARMTG CHISQ
								SINGLE TREATMENT	
1	3	16	5	16	4	12	.94	.93	.00
2	7	19	5	13	7	19	.01	.00	.01
3	10	20	7	18	9	20	.47	.26	.22
4	4	20	7	17	5	16	1.97	1.32	.65
5	4	19	8	16	8	20	3.32	2.55	.78
6	7	20	6	16	4	17	.86	.23	.63
7	6	20	8	16	9	20	1.67	1.42	.24
8	7	20	6	17	9	20	.53	.25	.28
								MULTIPLE TREATMENT	
1	8	16	8	20	11	20	.93	.00	.93
2	9	20	8	20	9	20	.14	.02	.12
3	6	16	13	19	8	19	4.05	.80	3.25
4	10	20	6	19	7	19	1.48	1.21	.27
5	13	20	6	20	7	20	5.84	5.34	.50
6	7	20	11	19	13	20	3.93	3.92	.02
7	7	20	9	19	6	20	1.32	.01	1.32

ARMITAGE TEST FOR A LINEAR TREND IN PROPORTIONS FOR THE DEATH INDEX
(2 DEGREES OF FREEDOM) BASED ON THE DOSE LEVELS AND INCLUDING THE CONTROL GROUP

	CONTROL		.03 G/KG		.8 G/KG		1.6 G/KG				
WEEK	N WIT	N PRE	N WIT	N PRE	N WIT	N PRE	N WIT	N PRE	CHISQ (2df)	CHISQ (1)	ARMTG CHISQ
							SINGLE TREATMENT				
1	6	15	3	16	5	16	4	12	1.73	.07	1.66
2	7	20	7	19	5	13	7	19	.04	.01	.03
3	14	20	10	20	7	18	9	20	4.24	1.68	2.56
4	9	20	4	20	7	17	5	16	3.26	.00	3.25
5	7	19	4	19	8	16	8	20	3.32	.98	2.34
6	6	20	7	20	6	16	4	17	.90	.28	.62
7	12	20	6	20	8	16	9	20	3.75	.00	3.75
8	9	20	7	20	6	17	9	20	.78	.08	.70
							MULTIPLE TREATMENT				
1	6	15	8	16	8	20	11	20	1.25	.38	.88
2	7	20	9	20	8	20	9	20	.57	.13	.44
3	14	20	6	16	13	19	8	19	6.46	.58	5.88
4	9	20	10	20	6	19	7	19	1.63	.87	.76
5	7	19	13	20	6	20	7	20	6.14	1.84	4.30
6	6	20	7	20	11	19	13	20	6.99	6.42	.56
7	12	20	7	20	9	19	6	20	4.41	1.50	2.90

PROBIT ANALYSIS OF THE PROPORTION OF PREGNANT FEMALES WITH 1 OR MORE DEAD IMPLANTS
PROBIT = A + B(LOG DOSE)

WEEK	B	A	CHISQ	DF
	SINGLE TREATMENT			
1	.270	4.526	.00	1
2	.007	4.679	.01	1
3	-.109	4.817	.22	1
4	.282	4.621	.63	1
5	.381	4.817	.79	1
6	-.111	4.473	.66	1
7	.267	4.902	.25	1
8	.111	4.763	.28	1
	MULTIPLE TREATMENT			
1	.000	4.955	.93	1
2	-.028	4.819	.12	1
3	.210	5.086	3.28	1
4	-.240	4.617	.27	1
5	-.506	4.587	.51	1
6	.435	5.272	.02	1
7	.017	4.684	1.31	1

T-TEST OF THE (TRANSFORMED) NUMBER OF DEAD IMPLANTS.
(DEAD IMPLANTS TAKEN AS A SUBSET OF THE SET OF IMPLANTS)

WEEK	CONTROL			71-7 .03 G/KG					71-7 .8 G/KG					71-7 1.6 G/KG					TEM .2 MG/KG				
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
SINGLE TREATMENT																							
1	15	.51	.28	16	.39	.25	29	1.257	16	.43	.26	29	.831	12	.47	.27	25	.367	20	1.35	.54	33	5.501
2	20	.56	.48	19	.52	.33	37	.366	13	.49	.32	31	.512	19	.61	.42	37	.290	20	2.11	.83	38	7.175
3	20	.67	.35	20	.58	.35	38	.771	18	.55	.51	36	.780	20	.52	.30	38	1.396	20	2.38	.55	38	11.088
4	20	.57	.40	20	.36	.19	38	2.139	17	.50	.33	35	.617	16	.43	.23	34	1.221	20	2.40	.67	38	10.472
5	19	.46	.24	19	.40	.20	36	.781	16	.60	.39	33	1.305	20	.55	.51	37	.685	19	1.09	.65	36	3.981
6	20	.48	.35	20	.45	.26	38	.310	16	.45	.22	34	.364	17	.44	.28	35	.458	20	.51	.23	38	.316
7	20	.67	.40	20	.43	.21	38	2.381	16	.62	.42	34	.381	20	.55	.29	38	1.148	20	.46	.24	38	2.001
8	20	.51	.31	20	.46	.23	38	.603	17	.55	.40	35	.355	20	.61	.44	38	.804	19	.50	.36	37	.070
MULTIPLE TREATMENT																							
1	15	.51	.28	16	.75	.55	29	1.533	20	.52	.34	33	.139	20	.59	.30	33	.884					
2	20	.56	.48	20	.71	.61	38	.862	20	.48	.25	38	.711	20	.63	.47	38	.418					
3	20	.67	.35	16	.48	.31	34	1.634	19	.61	.25	37	.579	19	.62	.55	37	.315					
4	20	.57	.40	20	.59	.42	38	.164	19	.42	.24	37	1.385	19	.53	.34	37	.314					
5	19	.46	.24	20	.60	.25	37	1.787	20	.49	.30	37	.385	20	.46	.25	37	.027					
6	20	.48	.35	20	.45	.25	38	.331	19	.62	.35	37	1.188	20	.71	.40	38	1.899					
7	20	.67	.40	20	.51	.31	38	1.472	19	.52	.27	37	1.400	20	.46	.25	38	2.032					

CONTROL GROUP ANOVA FOR THE NUMBER OF PREGNANT FEMALES

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	1.250	9	.139	2.500	10	.250	3.750	19	.556
2	0.000	9	0.000	0.000	10	0.000	0.000	19	I
3	0.000	9	0.000	0.000	10	0.000	0.000	19	I
4	0.000	9	0.000	0.000	10	0.000	0.000	19	I
5	.450	9	.050	.500	10	.050	.950	19	1.000
6	0.000	9	0.000	0.000	10	0.000	0.000	19	I
7	0.000	9	0.000	0.000	10	0.000	0.000	19	I
8	0.000	9	0.000	0.000	10	0.000	0.000	19	I
				MULTIPLE TREATMENT					
1	1.250	9	.139	2.500	10	.250	3.750	19	.556
2	0.000	9	0.000	0.000	10	0.000	0.000	19	I
3	0.000	9	0.000	0.000	10	0.000	0.000	19	I
4	0.000	9	0.000	0.000	10	0.000	0.000	19	I
5	.450	9	.050	.500	10	.050	.950	19	1.000
6	0.000	9	0.000	0.000	10	0.000	0.000	19	I
7	0.000	9	0.000	0.000	10	0.000	0.000	19	I

CONTROL GROUP ANOVA FOR THE NUMBER OF IMPLANTATIONS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	150.000	9	16.667	34.000	5	6.800	184.000	14	2.451
2	91.200	9	10.133	145.000	10	14.500	236.200	19	.699
3	27.250	9	3.028	38.500	10	3.850	65.750	19	.786
4	44.200	9	4.911	39.000	10	3.900	83.200	19	1.259
5	33.328	9	3.703	20.500	9	2.278	53.828	18	1.626
6	33.050	9	3.672	89.500	10	8.950	122.550	19	.410
7	57.250	9	6.361	26.500	10	2.650	83.750	19	2.400
8	62.000	9	6.889	50.000	10	5.000	112.000	19	1.378
				MULTIPLE TREATMENT					
1	150.000	9	16.667	34.000	5	6.800	184.000	14	2.451
2	91.200	9	10.133	145.000	10	14.500	236.200	19	.699
3	27.250	9	3.028	38.500	10	3.850	65.750	19	.786
4	44.200	9	4.911	39.000	10	3.900	83.200	19	1.259
5	33.328	9	3.703	20.500	9	2.278	53.828	18	1.626
6	33.050	9	3.672	89.500	10	8.950	122.550	19	.410
7	57.250	9	6.361	26.500	10	2.650	83.750	19	2.400

CONTROL GROUP ANOVA FOR THE PRE-IMPLANTATION LOSS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	120.837	9	13.426	38.500	5	7.700	159.337	14	1.744
2	68.200	9	7.578	83.000	10	8.300	151.200	19	.913
3	12.050	9	1.339	14.500	10	1.450	26.550	19	.923
4	23.050	9	2.561	45.500	10	4.550	68.550	19	.563
5	35.687	9	3.965	68.500	9	7.611	104.187	18	.521
6	40.450	9	4.494	46.500	10	4.650	86.950	19	.967
7	30.050	9	3.339	48.500	10	4.850	78.550	19	.688
8	24.450	9	2.717	34.500	10	3.450	58.950	19	.787
				MULTIPLE TREATMENT					
1	120.837	9	13.426	38.500	5	7.700	159.337	14	1.744
2	68.200	9	7.578	83.000	10	8.300	151.200	19	.913
3	12.050	9	1.339	14.500	10	1.450	26.550	19	.923
4	23.050	9	2.561	45.500	10	4.550	68.550	19	.563
5	35.687	9	3.965	68.500	9	7.611	104.187	18	.521
6	40.450	9	4.494	46.500	10	4.650	86.950	19	.967
7	30.050	9	3.339	48.500	10	4.850	78.550	19	.688

CONTROL GROUP ANOVA FOR THE NUMBER OF DEAD IMPLANTS PER PREGNANT FEMALE

WEEK	BETWEEN MALES SUMSQ	DF	MEANSQ	WITHIN MALES SUMSQ	DF	MEANSQ	TOTAL SUMSQ	DF	F
				SINGLE TREATMENT					
1	6.137	9	.682	5.500	5	1.100	11.637	14	.620
2	21.250	9	2.361	20.500	10	2.050	41.750	19	1.152
3	18.250	9	2.028	29.500	10	2.950	47.750	19	.687
4	18.450	9	2.050	28.500	10	2.850	46.950	19	.719
5	3.248	9	.361	5.500	9	.611	8.748	18	.590
6	27.050	9	3.006	5.500	10	.550	32.550	19	5.465
7	34.250	9	3.806	21.500	10	2.150	55.750	19	1.770
8	3.800	9	.422	9.000	10	.900	12.800	19	.469
				MULTIPLE TREATMENT					
1	6.137	9	.682	5.500	5	1.100	11.637	14	.620
2	21.250	9	2.361	20.500	10	2.050	41.750	19	1.152
3	18.250	9	2.028	29.500	10	2.950	47.750	19	.687
4	18.450	9	2.050	28.500	10	2.850	46.950	19	.719
5	3.248	9	.361	5.500	9	.611	8.748	18	.590
6	27.050	9	3.006	5.500	10	.550	32.550	19	5.465
7	34.250	9	3.806	21.500	10	2.150	55.750	19	1.770

CONTROL GROUP ANOVA FOR THE RATIO OF DEAD IMPLANTS TO TOTAL IMPLANTS PER PREGNANT FEMALE

	BETWEEN MALES			WITHIN MALES			TOTAL		
WEEK	SUMSQ	DF	MEANSQ	SUMSQ	DF	MEANSQ	SUMSQ	DF	F
				SINGLE TREATMENT					
1	.041	9	.005	.026	5	.005	.067	14	.878
2	.337	9	.037	.392	10	.039	.729	19	.956
3	.129	9	.014	.208	10	.021	.337	19	.690
4	.134	9	.015	.212	10	.021	.345	19	.701
5	.021	9	.002	.038	9	.004	.060	18	.556
6	.220	9	.024	.033	10	.003	.252	19	7.501
7	.267	9	.030	.177	10	.018	.443	19	1.678
8	.058	9	.006	.117	10	.012	.175	19	.551
				MULTIPLE TREATMENT					
1	.041	9	.005	.026	5	.005	.067	14	.878
2	.337	9	.037	.392	10	.039	.729	19	.956
3	.129	9	.014	.208	10	.021	.337	19	.690
4	.134	9	.015	.212	10	.021	.345	19	.701
5	.021	9	.002	.038	9	.004	.060	18	.556
6	.220	9	.024	.033	10	.003	.252	19	7.501
7	.267	9	.030	.177	10	.018	.443	19	1.678

T-TEST OF THE NUMBER OF CORPORA LUTEA IN PREGNANT FEMALES.

WEEK	CONTROL			71-7 .03 G/KG				71-7 .8 G/KG				71-7 1.6 G/KG				TEM .2 MG/KG			
	N PRG	MEAN	STD DEV	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T	N PRG	MEAN	STD DEV	DF	T
										SINGLE TREATMENT													
1	15	13.87	1.30	16	13.94	1.34	29	.149	16	13.62	2.03	29	.392	12	12.83	1.27	25	2.073	20	13.50	1.40	33	.791
2	20	13.10	2.13	19	12.89	1.56	37	.342	13	13.23	1.48	31	.193	19	12.68	1.45	37	.709	20	11.90	1.52	38	2.055
3	20	13.60	1.43	20	13.70	1.72	38	.200	18	13.78	1.52	36	.372	20	14.05	1.50	38	.970	20	13.00	1.62	38	1.241
4	20	13.95	1.67	20	13.85	1.35	38	.208	17	13.82	1.47	35	.243	16	13.25	1.95	34	1.161	20	13.40	2.56	38	.804
5	19	13.05	2.82	19	12.32	1.70	36	.976	16	13.00	1.32	33	.069	20	12.60	2.46	37	.535	19	12.05	2.25	36	1.209
6	20	12.90	1.77	20	12.65	1.50	38	.482	16	13.37	1.93	34	.768	17	12.53	1.55	35	.671	20	12.25	1.29	38	1.324
7	20	12.90	1.83	20	12.85	1.35	38	.098	16	13.56	1.31	34	1.216	20	13.30	1.63	38	.730	20	13.45	1.39	38	1.068
8	20	12.95	1.70	20	12.40	1.39	38	1.119	17	12.06	1.68	35	1.599	20	12.00	2.10	38	1.571	19	13.79	1.81	37	1.492
										MULTIPLE TREATMENT													
1	15	13.87	1.30	16	13.62	2.16	29	.375	20	13.10	1.25	33	1.762	20	14.40	2.33	33	.797					
2	20	13.10	2.13	20	13.25	1.62	38	.251	20	13.25	1.59	38	.253	20	14.05	1.54	38	1.620					
3	20	13.60	1.43	16	13.50	1.79	34	.187	19	13.16	1.46	37	.955	19	13.26	1.94	37	.620					
4	20	13.95	1.67	20	12.10	2.65	38	2.639	19	12.79	1.55	37	2.248	19	13.68	2.73	37	.369					
5	19	13.05	2.82	20	12.80	1.77	37	.337	20	12.55	2.04	37	.641	20	13.10	1.80	37	.063					
6	20	12.90	1.77	20	13.10	1.37	38	.399	19	13.74	1.91	37	1.418	20	12.75	2.05	38	.248					
7	20	12.90	1.83	20	13.00	2.32	38	.151	19	12.42	1.46	37	.899	20	12.95	1.67	38	.090					